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Abstract: 
Parasitic worms and molecules derived from them drive Th2/Treg immune responses in 
mammalian hosts and have powerful anti-inflammatory properties which are shown to 
have therapeutic effects on inflammatory diseases. Using products derived from the 
helminth parasites Fasciola hepatica and Ascaris lumbricoides we investigated the 
mechanism by which these responses are induced. Dendritic cells (DC’s) play a crucial 
role in linking the innate to adaptive arms of the immune system and directing the 
subsequent immune responses. Here, we report that Fasciola hepatica tegumental 
antigens (FhTeg) can suppress DC maturation and function. While FhTeg alone did not 
induce cytokine production or cell surface marker expression on DCs, it can maintain 
the DCs in an immature state, suppressing their function to Toll-Like-Receptor (TLR) 
stimulation and impairing the subsequent development of adaptive immunity. 
Furthermore, we selected recombinant forms of two major F. hepatica secreted 
molecules, the protease cathepsin L (rFhCL1) and anti-oxidant, sigma class glutathione 
S-transferase (rFhGST-si), to examine their interactions with DCs. Despite enzymatic 
and functional differences between these antigens they both induced IL-6, IL-12p40 and 
chemokine secretion from DCs in a TLR4 dependent manner. While neither helminth 
enzyme induced Th2/Treg immune responses both could instruct DCs that suppress IL-
17 secretion in vivo. This study also demonstrates that another helminth-derived 
heterogeneous extract, Ascaris lumbricoides pseudocoelomic fluid (AlPCF), induced 
partial maturated of DCs as characterised by the increased production of IL-6, IL-12p40 
and MIP-2. These DCs were capable of inducing Th2 responses. Overall the data 
suggests that helminth parasites secrete multiple molecules each possessing a unique 
mechanism of modulation, which can either suppress inflammatory Th1/Th17 responses 
or induce/permit the uninhibited development of modified Th2 responses. 
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Chapter 1: General Introduction 
Helminth parasites infect 3 billion people worldwide (Hotez et al., 2008) and while 
associated with a low mortality rate, if one considers the high number of infections, they 
still cause millions of deaths worldwide (Hotez et al., 2008, Pullan and Brooker, 2008). 
Helminth infections are associated with a polarised T helper 2 (Th2)/T regulatory cell 
(Treg) host response and it is well documented that such polarisation leaves the host 
more susceptible to bystander infections (Maizels and Yazdanbakhsh, 2003). This 
bystander effect has been demonstrated by the ability of helminths to suppress hosts 
protective Th1 responses to bacterial (Brady et al., 1999, Sacco et al., 2002) viral 
(Wolday et al., 2002) and protozoa (Hartgers and Yazdanbakhsh, 2006) pathogens.  
Current knowledge of the mechanism by which helminths influence host 
immune responses is limited, particularly their role in driving adaptive immunity 
(Maizels et al., 2004). Since dendritic cells (DCs) are crucial for bridging innate and 
adaptive immunity by controlling the initiation and differentiation of T helper cells 
(Banchereau and Steinman, 1998), there is a growing interest in understanding and 
defining the interactions between helminths and DCs (MacDonald and Maizels, 2008). 
Since helminth-derived molecules have been shown to mimic the immune response to 
helminth infections, the focus has turned to understanding the mechanisms of innate 
recognition of helminth antigens, particularly by DCs. In this thesis the interactions 
between molecules derived from Fasciola hepatica and Ascaris lumbricoides with DCs 
is studied. 
 
1.6. What are parasitic helminths 
The term ‘helminth’ is use to describe a group of wide ranging parasitic worm-like 
organisms mainly belonging to the phylum’s Platyhelminthes (flatworms) and 
Nematoda (round worms) (Roberts, 1996). Helminths are estimated to infect upwards of 
3 billion people worldwide (Hotez et al., 2008). While ostensibly associated with high 
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morbidity and low mortality, helminth infections are still a causative effect of millions 
of deaths worldwide mainly in developing countries (Hotez et al., 2008, Pullan and 
Brooker, 2008). Trematodes, commonly referred to as “flukes”, are a class within the 
phylum Platyhelminthes and contain the family Fasciolidae, which are large, leaf 
shaped parasites of mammals causing Fascioliasis (Dalton, 1999). Parasitical nematodes 
on the other hand conform to a slender cylindrical shape with bilaterally symmetrical, 
tapering at either end and are often referred to as “round worms” (Bradley and Jackson, 
2004). Parasitical nematodes are usually small but some species can grow above 40 cm 
in length (Taylor, 2007). The following section gives a brief introduction and 
background to the trematode F. hepatica and the nematode A. Lumbricoides, as these 
parasitic helminths are the origin of the antigens of study in this thesis. 
 
1.6.1. Helminth infections and life cycle  
Fascioliasis is an important public health problem with increasingly prevalence in 
humans (WHO, 1995, Mas-Coma, 1999). Estimates of  2.4 - 17 million people are 
infected worldwide (Mas-Coma et al., 2005). The adult F. hepatica occupies the liver 
and bile duct of the host and has a life span of 9 to 13.5 years (Behm and Sangster, 
1999). In both human and animals, pathogenesis is related to parasitic load (Mas-Coma 
et al., 2005). F. hepatica is also of major veterinary importance, causing economic 
losses of up to €2 billion globally due to infection of domestic animals such as cattle 
and sheep (Taylor, 2007). Two hosts are needed for the completion of F. hepatica’s life 
cycle (Fig. 1.1). The intermediate hosts are predominantly freshwater snail species of 
the family Lymnaeidae (Gastropoda: Basommatophora) (Andrews, 1999, Taylor, 2007). 
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Figure 1.1: The life cycle of Fasciola hepatica. Immature eggs are discharged in the 
biliary ducts and in the stool .  Eggs become embryonated in water , eggs release 
miracidia , which invade a suitable snail intermediate host . In the snail the parasites 
undergo several developmental stages (sporocysts , rediae , and cercariae ).  The 
cercariae are released from the snail  and encyst as metacercariae on aquatic 
vegetation or other surfaces.  Mammals acquire the infection by eating vegetation 
containing metacercariae. Humans can become infected by ingesting metacercariae-
containing freshwater plants, especially watercress . After ingestion, the metacercariae 
excyst in the duodenum  and migrate through the intestinal wall, the peritoneal cavity, 
and the liver parenchyma into the biliary ducts, where they develop into adults .  In 
humans, maturation from metacercariae into adult flukes takes approximately 3 to 4 
months. The adult flukes reside in the large biliary ducts of the mammalian host.  F. 
hepatica infect various animal species, mostly herbivores (Andrews, 1999, Taylor, 
2007).  
 
 
Nematodes are the most abundant parasitic worms on the planet (Bradley and Jackson, 
2004) infecting almost a quarter of the worlds population. The nematode A. 
lumbricoides is of major medical importance infecting 1.5 billion people worldwide 
(Harnett and Harnett, 2008). At heavier loads symptoms include abdominal pains, 
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diarrhea, malnutrition, obstruct of the intestines or bile ducts. Migrating larvae can also 
cause pneumonitis and eosinophilia (Baron, 1996). Adult worms primarily infect the 
gastrointestinal tract. From here larval worms released from eggs penetrate the wall of 
the duodenum enter the bloodstream and migrate to the lungs were they invade the 
pulmonary tissues and alveoli before being coughed up and swallowed, to return to the 
the small intestine where they mature to adults (Wossene et al., 2002). Unlike F. 
hepatica, A. lumbricoides has direct life cycle (Baron, 1996, Das et al., 2007) meaning 
there is no intermediate host  (Fig. 1.2).  
 
 
 
 
Figure 1.2: Life cycle of A. lumbricoides. Adult worms occupy the small intestines of 
the host. The females produce eggs that are excreted with faeces were the infective 
larvae develop. Infection occurs by the accidental ingestion of mature infective larvae 
typically in food or on fingers. After oral ingestion by the host, the eggs reach the 
intestine and hatch. The hatched larvae then migrate through the intestinal wall where 
they migrate thought several organs and tissues before returning to the intestine as adult 
worms (Das et al., 2007). 
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1.6.2. Characteristics of helminth infections 
Epidemiological studies show that effective immunity against helminth infections is 
highly dependent upon the hosts ability to mount an adaptive immune response, 
characterised by a CD4+ T helper (Th) type 2 response (Maizels and Yazdanbakhsh, 
2003). Most helminths are too large to be ingested by phagocytes, so the anti-worm 
response induced by Th2 cells is mediated by the production of immunoglobulin E 
(IgE) antibodies and the activation of eosinophils (Anthony et al., 2007). Th2 responses 
are primarily achieved by high levels of the cytokine IL-4 and low levels of interferon 
(IFN)-γ. Other Th2 related cytokines, including IL-5, IL-9, IL-13 and IL-21 are also 
highly produced (Maizels et al., 1993). In combination with a Th2 cell responses 
helminth infections are also associated with skewing of the host immune response 
towards a T regulatory cell (Treg) response (Diaz and Allen, 2007). This dominant 
Th2/Treg cell profile induced by helminths is sometimes called a “modified Th2” 
response (Maizels and Yazdanbakhsh, 2003). 
 During helminth infection CD4+ Th2 plasma cells (B-lymphocytes) switch to 
secreting IgE (Hagan et al., 1991). IgE antibodies mediate the activation of eosinophils. 
IgE antibodies bind to the surface of helminths allowing eosinophils to attach through 
Fcε receptors (Hogan et al., 2008). Eosinophils can then locate and kill helminth 
parasites by the secretion of granule enzymes (degranulation) (Rothenberg and Hogan, 
2006). In a similar way, IgE initiated immune responses also recruit other effector cells 
such as mast cells and basophils for the eradication of helminth parasites (Wedemeyer 
et al., 2000).  In addition, alternatively activated macrophages (AAMΦ) have also been 
implicated with the promoting of Th2 responses and suppressing Th1-driven 
inflammatory pathology during helminth infections (Kreider et al., 2007). Therefore, 
Th2/Treg associated cytokines, IgE antibodies and eosinophilia are the hallmarks of the 
immune response to helminth infection (Maizels et al., 2004).  
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1.6.3. Helminths and concurrent/bystander infections 
There is strong evidence that concurrent helminth infections and helminth co-infections 
with protozoa, bacterial and viral diseases are common in developing countries (Petney 
and Andrews, 1998). As has been noted, helminth infections are synonymous with 
inducing a polarised Th2/Treg host response (See section 1.1.2). It has been well 
documented that such polarisation can facilitate host hyporesponsiveness to co-
infections by suppressing Th1-Th17 responses or by inducing anti-inflammatory 
responses (van Riet et al., 2007). Co-infection with helminths and malaria, often 
observed due to the prevalence of both in tropical areas, best highlights this down 
regulation of pro-inflammatory responses (Hartgers and Yazdanbakhsh, 2006). 
Epidemiological studies show that helminth co-infection can increase the incidence of 
Plasmodium falciparum malaria infection (Nacher et al., 2002, Spiegel et al., 2003). In 
a murine model of infection with the blood-stage malaria parasite Plasmodium 
chabaudi, protective immunity which is associated with Th1 immune responses is 
impaired by concurrent gastrointestinal nematode Heligmosomoides polygyrus infection 
(Su et al., 2005). Whilst there are some incidences of improved malaria protection 
(Nacher et al., 2000),  the majority of studies point to the detrimental effect of helminth 
infections on malaria outcome (Druilhe et al., 2005, Hartgers and Yazdanbakhsh, 2006). 
Other murine models and human studies highlight the ability of helminth co-
infections to suppress protective Th1 responses against bacterial respiratory infections 
such as with Mycobacterium avium (Sacco et al., 2002) or Bordetella pertussis (Brady 
et al., 1999). Although there are few epidemiological studies on the effects of helminth-
tuberculosis co-infections, one study has shown that helminth induced Th2 responses in 
patients with newly diagnosed Mycobacterium tuberculosis (MTB) help favour a 
persistent MTB infection (Resende Co et al., 2007). F. hepatica infection has also been 
shown to have down regulatory effects on Mycobacterium bovis BCG-specific immune 
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responses in cattle (Flynn et al., 2007). In vitro studies also indicate that helminths can 
suppress the immune response to mycobacterial infections (Talaat et al., 2006). 
Helminth infections may also impair immunological responses to viral 
pathogens (Kamal and El Sayed Khalifa, 2006). Humans with acute or chronic hepatitis 
C virus (HCV) and schistosomiasis co-infection cannot generate an efficient, broad 
HCV-specific Th1 response, which might play a role in the persistence and severity of 
HCV infection (Kamal et al., 2001). Similarly, helminth induced modified Th2 
responses can accelerate the progression of human immunodeficiency virus (HIV) 
infection in people co-infected with helminths and the virus (Wolday et al., 2002). 
While cells from persons with helminth infections are more susceptible to HIV infection 
than cells from persons without helminth infection (Gopinath et al., 2000). In addition, 
helminth infections may also be detrimental for effective vaccination programs. Many 
modern vaccines are designed to induce a Th1 response for optimal efficiency, and Th2 
responses induced by helminths can reduce vaccine effectiveness (van Riet et al., 2007, 
Helmby, 2009). In humans, A. lumbricoides infection can impair effectiveness of an oral 
cholera vaccine (Cooper et al., 2002), while in a mouse model of Schistosoma mansoni 
infection, the protective efficacy of BCG vaccination against MTB is reduced (Elias et 
al., 2005).  
 Overall, helminth co-infections studies are characterised by a  downregulation of  
pro-inflammatory responses, leading to the exacerbation of concurrent infections 
(Maizels et al., 2004). Conversely, a reduction in pro-inflammatory responses may also 
be beneficial to the host in situations of atopy, allergy or autoimmune disease (Flohr et 
al., 2009). Similarly strong evidence also exists that helminth infections reduced host 
reactivity to bystander allergens (Elliott et al., 2007). For example, epidemiological 
studies have shown that allergic diseases are rare in areas with high helminth exposure, 
but high in urban/industrialised countries where helminth infections are low (Fallon and 
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Mangan, 2007). This observation has been explained by a decline in infections during 
childhood (Yazdanbakhsh et al., 2002), particularly the lack of exposure to helminth 
infections in developed countries (Dunne and Cooke, 2005). It has been dubbed the 
‘Hygiene Hypothesis’ (Strachan, 1989, Smits and Yazdanbakhsh, 2007). By inducing a 
modified Th2 response, helminths infections may co-opt host regulatory cells to control 
the magnitude and phenotype of Th effector cell populations, possibly through the 
promotion of immunosuppressive cytokines (Diaz and Allen, 2007, Maizels and 
Yazdanbakhsh, 2008). Therefore evidence exists that under some conditions helminth 
parasites may be therapeutically beneficially (Zaccone et al., 2006, Erb, 2009, McKay, 
2009). Some animal and human models support the use helminths as therapeutic agents 
in ameliorating autoimmune and atopic disorders such as inflammatory bowel diseases 
(IBDs) (Weinstock and Elliott, 2009) and Crohn’s disease (Croese et al., 2006).  
 
1.7. Helminths and adaptive immune responses 
Activation of PRRs, displayed on antigen presenting cells (APCs), by PAMPs initiates 
the development of adaptive immune responses (Pasare and Medzhitov, 2004, Iwasaki 
and Medzhitov, 2004). Following interaction with APCs, naïve CD4+ T cells receive 
signals through their T-cell receptors (TCRs) that recognise peptide antigens presented 
to them on major histocompatibility complex (MHC) II complexes in conjunction with 
co-stimulatory receptors signals, that initiate differentiation towards functionally 
distinct CD4+ T helper (Th) cell subtypes (Kapsenberg, 2003). In 1986 Mosmann and 
Coffman reported two Th cell subsets; Th1 and Th2 cells (Mosmann et al., 1986), that 
could be distinguished from each other by the signature cytokines that the differentiated 
cells secreted. 
At present, linage commitment is defined by the cytokines; IFN-γ, IL-4 and IL-17 
for Th1, Th2 and Th17 cells respectively (Korn et al., 2009). Th1 cells direct the 
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elimination of intracellular pathogens, viruses, tumours and some bacteria (Trinchieri, 
2003); Th17 cells promote resistance to extracellular bacteria and fungi; and Th2 cells 
are important for humoral immunity and the control of helminth infections (Anthony et 
al., 2007). Excessive or detrimental (e.g., autoimmune) responses by these effector T 
cells are controlled by regulatory T cells (de Jong et al., 2005).  
 Instructions for the development of adaptive immune responses, specifically the 
control and initiation of differentiation of T helper cells, are largely orchestrated by DCs 
(Banchereau et al., 2000, Banchereau and Steinman, 1998). Therefore, variations in DC 
maturation status, in conjunction with the cytokine environment, can influence the 
subsequent polarisation of T helper cell responses, and that this alteration can be at the 
point of DC activation (Pulendran, 2005, de Jong et al., 2002). The most important Th1 
polarizing cytokine is IL-12 (bioactive IL-12p70). Transforming growth factor (TGF)-
beta and IL-6 acting in concert induce differentiation of mouse naive T cells into the 
Th17 lineage (Ouyang et al., 2008).  
But much less is known about the mechanisms that result in Th2-cell-inducing 
DCs (Kapsenberg, 2003). Both IL-4 and IL-10 from DCs have been identified as 
possible polarizing candidates for Th2-driving, but both IL-4- (MacDonald and Pearce, 
2002) and IL-10-deficient (Perona-Wright et al., 2006a) DCs can still drive Th2 
responses. Therefore without any obvious candidates or mechanisms, a number of 
hypotheses have been put forward to explain Th2 induction by DCs.  These fall into 
three groups; (A) the default mechanism, (B) the inhibition mechanism or (C) the 
alternative pathway hypothesis  (MacDonald and Maizels, 2008).  
Firstly, the maturation or default model proposes that unless triggers for Th1 
responses are received by the DC (i.e. high IL-12 (Kalinski et al., 1999)) the T cell will 
automatically ‘default’ into a phenotype that will initial Th2 responses (Trinchieri, 
2003). Examples of helminth-derived molecules can be used to highlight each 
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hypothesis. The best example of this model is the ability of S. mansoni egg antigen 
(SEA) to induce Th2-cell-inducing DCs (MacDonald et al., 2001, de Jong et al., 2002, 
Agrawal et al., 2003) in a absence of overt DC activation. The type of DC induced by 
SEA is sometimes called a DC 2 phenotype (see section 1.4). Similar results have been 
observed for the filarial nematode Acanthocheilonema viteae secreted ES 62 kDa 
glycoprotein (ES-62) product (Whelan et al., 2000), S. mansoni derived Lyso- 
phosphorylcholine (PC) (van der Kleij et al., 2002), N. brasiliensis excretory/secretory 
antigens (NES) (Balic et al., 2004), Schistosoma larvae products (0-3hRP) (Jenkins and 
Mountford, 2005), E. granulosus antigen B (AgB) and sheep hydatid fluid (SHF) 
(Rigano et al., 2007) and the glycoconjugate lacto-N-fucopentaose III (LNFPIII) 
derived from S. mansoni (Thomas et al., 2003).  
The second model is a system of competition and inhibition, in which activated 
signalling pathways may intersect and inhibit one another (Kapsenberg, 2003). The best 
examples of this include helminth products that block or suppress the production of key 
Th1 polarising cytokines, such as IL-12. Lipopolysaccharide (LPS) induced IL-12 from 
DCs can be suppressed by pre-treatment with SEA (Jankovic et al., 2004, Cervi et al., 
2004, Kane et al., 2004, van Liempt et al., 2007), NES (Balic et al., 2004) or E. 
granulosus  AgB (Rigano et al., 2007). DC pre-treatment with SEA has also been 
shown to modulate LPS induced gene expression (Kane et al., 2004).  
The last hypothesis conceives alternative pathways associated with the 
activation of DCs through specific signals that induce specific Th responses (Reis e 
Sousa, 2006). In this model various PAMPs can be theorized to be either Th1 or Th2 
stimuli, linked to distinct sets of PRRs, such as C-type lectin receptors (CTLs) 
(MacDonald and Maizels, 2008). For example, toll-like receptors (TLR) 4 binding LPS 
have been shown to activate DC to prime for Th1-type responses (MacDonald et al., 
2001) as compared to CTL binding SEA products that prime Th2-type responses (van 
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Liempt et al., 2007). As can be seen by the overlapping diversity of the helminth-
derived products in the varying circumstances highlighted in each scenario, the 
possibility arises that no single mechanism fully explains the mechanisms of Th2 
induction by DCs. This bring forth the possibility that a combination of some or all the 
possible mechanisms is the most likely determinate of Th2 induction by DCs 
(MacDonald and Maizels, 2008).  
 
1.8. Helminths and innate immune responses 
While anti-helminth immune responses are mainly characterised by Th2/Treg cells, the 
innate arm of the immune system plays two very important roles in frontline host 
defence against helminths (Janeway and Medzhitov, 2002). Firstly, the innate system 
reduces infection through mechanisms such as physical barriers (Male et al., 2006).  
Secondly, the innate system plays a crucial role in pathogen detection (Kawai and 
Akira, 2009). This is achieved through a limited number of germ-line encoded 
receptors; the PRRs (Mogensen, 2009). PRRs mainly recognise PAMPs produced by 
pathogens and that are not naturally found on host cells or tissues (Medzhitov and 
Janeway, 2000). The best characterised family PRRs are the TLRs (Medzhitov, 2001, 
Takeda and Akira, 2005, West et al., 2006). There are 13 known mammalian TLRs, 10 
in humans and 13 in mice (Kumagai et al., 2008). TLRs are expressed mostly by APCs; 
including macrophages and B lymphocytes, but most importantly DCs (McGettrick and 
O'Neill, 2007) (see section 1.5). Along with TLRs other PRRs also play important roles 
in innate PAMPs recognition. C-type lectin receptors (CLRs) are transmembrane lectins 
(sugar-binding proteins) that in contrast to TLRs, recognize carbohydrate glycan 
structures present on the pathogens (Geijtenbeek et al., 2004).  
 Helminth-derived molecules are recognised by the host in an effort to generate 
an immune response to eliminate the parasite. But the current knowledge how helminths 
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are recognised by the innate immune is limited by the few PRR ligands of parasite 
origin that had been identified (McGuinness et al., 2003, Zaccone et al., 2006). In a 
number of cases recognition of helminth-derived molecules has been demonstrated to be 
dependent various TLRs, including TLR2, 3 and most prominently TLR4 (Table. 1). 
The best described helminth-derived product is  A. viteae ES-62, which is recognised by 
DCs in a TLR4 dependent manner (Goodridge et al., 2001, Goodridge et al., 2005). 
Similarly, LNFPIII is also recognised in a TLR4 dependent fashion (Perona-Wright et 
al., 2006b). Studies on knockout and mutant mice have shown Schistosoma larval 
preparation (0-3hRP) to be partially dependent on TLR4 (Jenkins et al., 2005). While 
Schistosomal derived lipids (lyso-PS) (van der Kleij et al., 2002) and dsRNA from 
schistosomal eggs (Aksoy et al., 2005) bind TLR2  and TLR3 respectively. 
 CTL receptors are also important for the recognition of helminth products (van 
Kooyk and Rabinovich, 2008). The CTL receptors DC-SIGN (van Die et al., 2003), 
MGL and MR (van Liempt et al., 2007) have all be implicated in SEA recognition, 
while TLR2 nor TLR4 play a role (Kane et al., 2008). Similarly, MBL has been shown 
to be involved in the detection of  Trichinella spiralis ES products (TsES)  (Gruden-
Movsesijan et al., 2003). There is also a wide range of helminth-derived products with 
immunological properties to which no recognition mechanism has yet been attributed 
(Harnett and Harnett, 2008, Johnston et al., 2009) (Table 1). At the signalling level, 
many of the helminth-derived molecules in Table 1 have been associated with the 
activation of a number of pathways. Ligand binding of PRRs such as TLRs activate 
signal transduction pathways that initiated gene expression (Mogensen, 2009). 
Structurally, TLR proteins possess a extracellular domain made up mainly of leucine-
rich repeats, a single transmembrane segment and a intracellular (cytoplasmic) domain 
called TIR (Toll/interleukin-1 (IL-1) receptor) (Jin and Lee, 2008). 
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 Worm product Species or origin PRR(s) Activation status Th Reference 
Heterogeneous      
SEA Schistosoma mansoni DC-SIGN, MGL, 
MR, L-SIGN 
DC↔(Y) Th2 (van Die et al., 2003), (van Liempt et al., 2007),  
(Meyer et al., 2007) 
0-3hRP Schistosoma mansoni TLR4 DC/MΦ Th2 (Jenkins et al., 2005) 
NES Nippostrongylus brasiliensis ND DC Th2 (Balic et al., 2004). 
HpES Heligmosomoides polygyrus ND DC↔(Y) Th2/Treg (Segura et al., 2007) 
TsES Trichinella spiralis MBL DC Th2/Treg (Gruden-Movsesijan et al., 2003), (Ilic et al., 2008) 
TsMLCr Trichinella spiralis MR DC↔ Th2/Treg (Gruden-Movsesijan and Milosavljevic Lj, 2006), (Ilic et al., 2008) 
PCF Ascaris suum ND DC↔(Y) ND (McConchie et al., 2006) 
PI Ascaris suum ND DC↔ (Y) ND (Silva et al., 2006) 
Defined      
ES-62 Acanthocheilonema viteae TLR4 DC(Y)/MC(Y)/MΦ Th2 (Goodridge et al., 2005), (Whelan et al., 2000) 
LNFPIII Schistosoma. mansoni TLR4 DC Th2 (Thomas et al., 2003) 
AgB Echinococcus granulosa ND DC Th2 (Rigano et al., 2007) 
lyso-PS Schistosoma. Mansoni TLR2 DC Th2/Treg (van der Kleij et al., 2002) 
Egg-derived dsRNA Schistosoma. mansoni TLR3 DC ND (Aksoy et al., 2005).  
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PC-glycosphingolipids Ascaris suum ND DC/MΦ (Y) ND (Kean et al., 2006), (Deehan et al., 2002) 
Heterogeneous      
NaES Necator americanus ND NKc ND (Hsieh et al., 2004), (Teixeira-Carvalho et al., 2008) 
BES Brugia malayi ND AAMΦ ND (Allen and MacDonald, 1998) 
FhES Fasciola hepatica ND Eo, AAMΦ(Y) ND (Serradell et al., 2007), (Flynn and Mulcahy, 2008) 
DiAg Dirofilaria immitis ND B cell Th2 (Tezuka et al., 2003) 
AsES Ascaris suum ND MΦ ND (Andrade et al., 2005) 
Defined      
FhTPx Fasciola hepatica ND AAMΦ ND (Donnelly et al., 2005) 
FhPrx  Fasciola hepatica ND AAMΦ Th2 (Donnelly et al., 2008) 
SmPrx Schistosoma mansoni ND AAMΦ Th2 (Donnelly et al., 2008) 
Sm16 Schistosoma mansoni ND HPBM↔ (Y) ND (Brannstrom et al., 2009) 
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Alpha-1/Omega 1 Schistosoma mansoni ND Basophil Th2 (Cass et al., 2007), (Schramm et al., 2007) 
 
Table 1.1: Helminth-derived products; a full list of helminth-derived immunomodulators documented and DC interaction, plus a selection of molecules of interest. Abbreviations: ND, Not 
determined; TLR, Toll-like receptor; PS, phosphatidylserine; SEA, water-soluble egg antigen; HPBM, Human peripheral blood mononuclear; GST, glutathione-S transferase; PC, phosphorylcholine; 
TPX, thioredoxin peroxidase; 0-3hRP, Schistosoma larvae derived products; NES, N. brasiliensis excretory/secretory antigens; HpES, H. polygyrus ES antigens; TsES, T. spiralis ES antigens; TsMLCr, 
T. spiralis crude muscle larvae antigen; PCF, pseudocoelomic fluid; PI, high-molecular-weight components; LNFPIII, lacto-N-fucopentaose III; AgB, antigen B; NaES, N. americanus ES antigens; 
BES, B. malayi ES antigens; FhES, F. hepatica ES antigens; DiAg, Dirofilaria immitis polyproteins; AsES, A. suum excretory/secretory antigens; Prx, peroxiredoxin; Sm16, Alpha-1 and Omega 1 is a 
non-acronymic designation. ; partial DC activation (Dowling et al., 2008).; ↔, no change, , suppression,   induction; (Y), suppression of secondary activation; DC, dendritic cell; MΦ, 
macrophage; MC, mast cell, NKc, natural killer cell; AAMΦ, alternatively activated macrophage; Eo, eosinophil. 
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Adapter molecules binding to the intracellular TIR domain can initiate the 
transductional signalling (Akira and Takeda, 2004, O'Neill, 2006). There are five TIR 
domain-containing adaptor proteins involved in signalling by TLRs. They are known as 
MyD88 (myeloid differentiation primary-response gene 88), MAL (MyD88-adaptor-
like protein), TRIF (TIR-domain-containing adapter-inducing interferon-β), TRAM 
(TRIF-related adaptor molecule) and SARM (Sterile alpha and HEAT/Armadillo motif) 
(O'Neill and Bowie, 2007). MyD88  is the key signalling adaptor for all TLRs with the 
exception of TLR3 and some TLR4 signals. Its main role is the activation of nuclear 
factor kappa B (NF-κB) (Kenny and O'Neill, 2008). NF-κB transcription factors are a 
family of DNA-binding proteins are most the important signal transducers (Hayden and 
Ghosh, 2008). NF-κB is expressed in all cell types has multiple critical roles in the 
regulation the large number of genes that involved in multiple stages of immune 
responses, including DC activation (Li and Verma, 2002). The mammalian NF-κB 
family of transcription factors consists of five members; p50 (NF-vB1), p52 (NF-κB2), 
p65 (RelA), c-Rel, and RelB. IκB family proteins, of which there are several, bind and 
sequester NF-κB in the cytoplasm (Beinke and Ley, 2004, Sun and Ley, 2008). 
Consequently, inhibitory NF-κB (IκB) degradation must occur for NF-κB to be 
translocated into the nucleus to function. (Hayden and Ghosh, 2004). 
Limited data is available on the signal transduction pathways induced by many 
helminth-derived molecules but NF-κB activation is a common trait of Th2 inducing 
DCs, suggesting its importance (Perrigoue et al., 2008). While LPS induces the 
persistent activation of NF-κB, LNFPIII can induce rapid but transient NF-κB nuclear 
translocation and activity in the nucleus (Thomas et al., 2005). E. granulosus AgB 
(Rigano et al., 2007) can activated NF-κB in stimulated DC, while there is also 
evidence that SEA pulsed DCs may activate NF-κB1 and not NF-κB2 (Artis et al., 
2005). 
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 MAPKs (mitogen-activated protein kinases) and IRFs (interferon regulatory 
factors) work in conjunction with NF-κB to initiate the regulation and termination of 
immune responses (Krishna and Narang, 2008, Tamura et al., 2008). The MAPK 
signalling pathways are among the most ancient signal transduction pathways and are 
highly evolutionary conserved intracellular signalling enzymes that are activated in 
response to infectious agents and innate stimulators (Dong et al., 2002, Zhang and 
Dong, 2005). They play an important role in immune responses. There are three main 
families of MAPKs in mammals: p38 MAPK (p38), extracellular signal-regulated 
kinases (ERKs) and the c-Jun NH2-terminal kinases (JNKs) (Nakahara et al., 2006, 
Dowling et al., 2008).  LNFPIII, which has already been discussed above, also has the 
ability to phosphorylate ERK. Likewise, SEA can induce the phosphorylation of ERK 
and p38 but not JNK (Perona-Wright et al., 2006b). While ES-62 suppresses activation 
of p38 and JNK, induces ERK dependent inhibition of IL-12 production (Goodridge et 
al., 2003).  
Many IRF members play central roles in the cellular differentiation of 
hematopoietic cells and in the regulation of gene expression in response to pathogen-
derived danger signals (Tamura et al., 2008). IRF family members are important in two 
innate signal transduction pathways; TLR signalling and the regulation of DC 
development (Honda and Taniguchi, 2006). A total of nine members have been 
identified in humans and mice (Mamane et al., 1999, Taniguchi et al., 2001). There is 
no current knowledge as to the role of IRF family transcription factors in signal 
transduction following DC activation by helminth parasite molecules.  
 
1.9. Helminths and DCs 
As mentioned earlier DCs are crucial for bridging innate and adaptive immune 
responses to infection, specifically the control and initiation of the differentiation of T 
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helper cells (Banchereau et al., 2000, Banchereau and Steinman, 1998). But our 
knowledge of how helminths are recognised by DCs is limited and until relatively 
recently few PRR ligands of parasite origin had been identified (Zaccone et al., 2006). 
DCs where discovered and identified in the early 1970’s by Steinman et al. (Steinman 
and Cohn, 1973, Steinman and Cohn, 1974, Steinman et al., 1974, Steinman et al., 
1975) and shown to be seeded throughout the peripheral tissues. A heterogeneous 
population of bone-marrow derived cells, the main function of DCs is to continuously 
sample their local environment for pathogen antigens (Sher et al., 2003). These are then 
processed and presented as antigenic fragments on MHC class I or II molecules to 
regulate naïve T cells with TCR specificity for the MHC:peptide complex, leading to 
the initialisation and determination of adaptive immune responses (Banchereau and 
Steinman, 1998, Wu and Liu, 2007). There are two main categories of DCs: 
conventional (myeloid) DCs (cDCs) and plasmacytoid (lymphoid) DCs (pDCs) 
((Shortman and Liu, 2002, Villadangos and Schnorrer, 2007). All cDCs lineages 
express high levels of CD11c, which is considered a definitive pan marker (Villadangos 
and Heath, 2005). cDCs can be divided two into categories, and further subdivided into 
five subset DC populations (Bonasio and von Andrian, 2006); characterised by their 
path taking to access the lymph organs (i.e. conform or not to Langerhans cell 
paradigm) and their varying cell surface marker expression profiles (Randolph et al., 
2008).  
 Before encountering PAMPs DCs exist in an ‘immature’ phenotype. Immature 
DCs (iDCs) are characterised by low expression of the co-stimulatory molecules such as 
CD80, CD86 and CD40 and low MHC expression (Banchereau and Steinman, 1998, 
Banchereau et al., 2000). DCs stimulated with PAMPs such as LPS take up a “classical” 
activation status, defined by the elevated expression of cell surface co-stimulatory 
markers, MHC and the secretion various cytokines (Kapsenberg, 2003, Dowling et al., 
   17 
2008). Signalling thought NF-κB and MAPK pathways are highly involved in the 
initiation of this DC activation (Nakahara et al., 2006, Dowling et al., 2008). 
 Helminth-matured DCs can be often characterised by lack many of these 
classical maturation markers which are often absent or expressed at low levels or by the 
secretion of a select panel of cytokines such as IL-12p40 (Johnston et al., 2009). While 
helminths-matured DCs are classed as being less phenotypically mature they are still 
capable of priming naïve T-cells to activate Th2/Tregs associated with helminth 
infection (Maizels et al., 2004) (See section 1.2).  
 Helminth modulation of DC phenotype is most likely through the release of 
soluble mediators from various life stages of the parasites. Therefore some of the best 
characterised helminth-matured DCs involve heterogeneous mixes of soluble 
preparation from whole or partial parasites. There have been a number of independent 
studies on SEA-DC interactions. In all cases DCs pulsed with SEA do not show an 
increase in expression of co-stimulatory molecules or cytokines, indicating that no 
conventional maturation was induced (MacDonald et al., 2001, Kane et al., 2004, van 
Liempt et al., 2007). Furthermore in all cases SEA-matured DCs are hyporesponsive to 
subsequent TLR activation. In one case SEA was shown to suppress LPS-induced 
activation of murine DCs, including MHC class II, co-stimulatory molecule expression, 
and IL-12 production (Kane et al., 2004). In another study, SEA could suppress both 
polyinosinsic:cytidylic acid (poly-(I:C)) and LPS induced DCs maturation, as indicated 
by a decrease in co-stimulatory molecule expression and production of IL-12, IL-6 and 
tumor necrosis factor (TNF)-α (van Liempt et al., 2007). In addition, SEA suppressed 
Th1 responses induced by the poly-(I:C)-pulsed DCs, and skewed LPS-induced mixed 
responses towards a Th2 response (van Liempt et al., 2007). SEA is also of particular 
interest since it fails to activate DCs yet these antigens are capable of driving Th2 
immune responses (See Table 1).  
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From the same species but different life stage, Schistosoma larvae derived 
products (0-3hRP) can to induce partial maturation of DCs (Jenkins and Mountford, 
2005). These DCs are characterised by low IL-6 and IL-12p40, partial costimulatory 
marker expression and when co-cultured with naive T-cells in vitro or injected into mice 
can polarise T-cell responses towards a Th2 phenotype. 0-3hRP could also stimulate IL-
6, IL-10 and IL-12p40 from macrophages, where the secretion of IL-12p40 and IL-10 
are reduced in TLR4 knockout and mutant mice. However in that study the secretion of 
IL-6 was not dependent upon TLR4 suggesting that other TLRs are involved (Jenkins et 
al., 2005).  
Similarly, NES have been shown to induce partial maturation of DCs 
characterised by IL-6, IL-12p40, partial costimulatory marker expression and to have 
Th2 priming abilities (Balic et al., 2004). Another study has shown that the 
gastrointestinal nematode Heligmosomoides polygyrus-ES products alone failed to 
induce DC activation, but further had the ability to impair DC function and suppressed 
both Th1 and Th2 adaptive immune responses (Segura et al., 2007). The same DCs 
promoted the differentiation of T-cells with a regulatory phenotype and an ability to 
suppress effector CD4+ cell proliferation and cytokine secretion. TsES but not TsMLCr 
could partially up regulate DC costimulatory molecules; both T. spiralis preparations 
increased amounts of secreted IL-10 and decreased amounts of IL-12p70. TsES and 
TsMLCr primed DC could also instruct the in vitro production of IL-4 by T cells 
purified from of T. spiralis infected rats, indicating a polarization to a modified Th2 
response (Ilic et al., 2008). While neither pseudocoelomic fluid (PCF) (McConchie et 
al., 2006) or high-molecular-weight components (PI) (Silva et al., 2006) of A. suum did 
not activate DCs, both could suppress costimulatory molecule expression and cytokine 
production in response to third party antigens. 
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 While the above mentioned preparations are heterogeneous mixes of molecules, 
the goal remains to identify the exact antigens from these preparations that interact with 
DCs (Hewitson et al., 2009). The best characterised such case is the PC-containing 
single filarial nematode-secreted product ES-62, (Goodridge et al., 2001, Goodridge et 
al., 2005) which induces the low level production of IL-12p40, TNF-α and IL-6 from 
DCs in a TLR4 dependent manner. Pre-treatment of DCs and macrophage with ES-62 
also inhibits their ability to produce LPS induced IL-12 (Goodridge et al., 2003). 
LNFPIII derived from S. mansoni acts in a TLR4 dependent fashion to partially up-
regulate costimulatory molecule expression on DCs which can then drive Th2 immune 
responses (Thomas et al., 2003). Similarly, purified antigens from Echinococcus 
granulosa (Rigano et al., 2007) partially activate DCs that can subsequently prime Th2 
immune responses.  
Schistosome lyso-PS can condition DCs to secrete IL-10 in a TLR2 dependent 
manner, thus swaying the immune system response towards a modified Th2 form (van 
der Kleij et al., 2002). While dsRNA from schistosomal eggs can activate TLR3 in DCs 
to produce IL-12p40 and TNF-α (Aksoy et al., 2005). In the same way, the PC 
containing native glycophingolipid from A. suum have been shown to increase DC and 
macrophage co-stimulatory molecule expression and secretion of IL-12p40 and TNF-α. 
On the other hand, pre-treatment can suppress LPS induced IL-12p70 in both cells 
(Kean et al., 2006). 
 
1.10. Project background 
In this study we set out to understand how helminth parasites instruct DCs to induce 
Th2 responses in their hosts. The main focus of this thesis is to understand the 
immunomodulatory properties of F. hepatica and A. lumbricoides derived molecules 
with a focus on their ability to modulate immature DCs and subsequent adaptive 
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immunity. Understanding the immunomodulatory properties of F. hepatica and A. 
lumbricoides derived molecules may also lead to the development of improved vaccines 
and/or novel therapeutics to treat autoimmune and atopic disorders (Carvalho et al., 
2009). 
 
1.10.1. F. hepatica tegument (FhTeg) 
The tegumental coat of F. hepatica is a metabolically active layer that is in intimate 
contact with the host tissues and body fluids (Threadgold, 1976). It is here that much of 
the immune interplay between the fluke and host takes place. The tegument is shed 
every 2 to 3 hrs during the course of infection, thus representing a constant source of 
antigen in direct contact with the host's immune cells. The tegument has a number of 
functions, which includes protection against the host immune response. Studies have 
shown that by shedding its tegument, the fluke can also shed immune complexes that 
have formed on the surface, thereby evading a damaging immune response, and the shed 
antigen acts as a decoy "mopping up" host immune cells (Mulcahy, 1999, Halton, 2004). 
While a number of studies have investigated the proteome (Morphew et al., 2007) and 
the secretome (Robinson et al., 2009) of F. hepatica, none have exclusively examined 
the tegument. Only one study has attributed any immunomodulatory properties of the F. 
hepatica tegument (Trudgett et al., 2003). Synthetically produced short peptides, with 
sequences homologous to tegumental proteins, were incubated with rat peritoneal mast 
cells resulting in their degranulation.  
 
1.10.2. F. hepatica excretory/secretory antigens (FhES) 
ES products from adult F. hepatica (FhES) have been shown to contain carbohydrate 
components that are cytotoxic to eosinophils (Serradell et al., 2007, Serradell et al., 
2009). Whereas in vitro treatment of bovine macrophages with FhES products inhibited 
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IFN-γ and NO production in response to bacterial products and skewed the macrophage 
population towards an AAM phenotype (Flynn and Mulcahy, 2008) (Table 1.1). During 
all developmental stages, F. hepatica secretes an abundance proteases and antioxidant 
molecules that are critical to the survival of the parasite within the host. Fasciola 
cathepsin L proteases (CLs) and glutathione S-transferases (GSTs) are families of 
proteases and antioxidant respectively and are of particular interest in helminth biology. 
Both CLs and GSTs are dominant molecules in FhES, with both found in relatively 
large abundance (Jefferies et al., 2001). Both the GST superfamily and cathepsins have 
been extensively studied as potential vaccine candidates against F. hepatica (Hillyer, 
2005, McManus and Dalton, 2006).  
 
1.10.3. F. hepatica-derived glutathione transferases (FhGSTs)  
GSTs are an ancient protein superfamily with multiple roles in all eukaryotic organisms, 
but within parasites represent the main detoxification mechanism of hydrophobic and 
electrophilic compounds. GSTs are a versatile enzyme superfamily whose main role is 
to inactivate a wide range of exogenous/endogenous toxic molecules enzymes in 
helminths and to turn them into water-soluble compounds (Torres-Rivera and Landa, 
2008). GSTs are one of many antioxidant molecules secreted by F. hepatica, including 
peroxiredoxin and thioredoxin. GSTs are very versatile enzymes and apart from their 
major role as detoxification enzymes are also involved in a number of functions 
including the metabolism of drugs, pesticides and other xenobiotics, signal modulation, 
transport of molecules and may have a function in prostaglandin and steroid hormone 
synthesis (Hayes et al., 2005). GSTs feature extensively in the secretome of F. hepatica, 
and can be found in ES products but also associated with the tegument (Robinson et al., 
2009). They account to up too 4% of the total soluble protein in F. hepatica (Chemale et 
al., 2006).  
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 GSTs can be grouped in three subfamilies according to their cellular location: 
mitochondrial GSTs; microsomal (membrane-bound) GSTs; and cytosolic GSTs 
(cGSTs) (Frova, 2006). The soluble or cGSTs are the most numerous and well 
described group and are subdivided into several classes. The group members are have 
ubiquitous classes and can occur in any organism including the mu (M), alpha (A), pi 
(P), theta (T), sigma (S), zeta (Z) and omega (O) classes. The main cGSTs classes 
identified in parasites, including F. hepatica, are M, P and S, along with some in the A 
and O classes (Torres-Rivera and Landa, 2008). While there are few instances in the 
current literature of helminth-derived GSTs exerting immunomodulatory properties, 
there are some examples of related proteins (Ouaissi et al., 2002). One, a structurally 
related molecule to GST derived from FhES, could inhibition of NO production from rat 
peritoneal macrophages and T cell proliferation in vitro (Cervi et al., 1999).  
 
1.10.4. F. hepatica-derived cathepsin L (FhCLs) 
F. hepatica expresses papain-like cysteine peptidases termed cathepsins (Smith et al., 
1993b). Cathepsins are expressed by all organisms from bacteria to mammals, but 
helminth parasites have exploited cathepsins to perform a wide range of functions that 
enable them to reside in their mammalian hosts. Cathepsins are involved in a variety of 
pathogen-specific functions which enhance virulence, including modulation or 
suppression of host immune defences by cleaving immunoglobulin (Smith et al., 
1993a), altering the activity of immune effector cells, penetration migration through 
host tissues, and catabolism of host proteins to peptides and amino acids  (Robinson et 
al., 2008). Fasciola cathepsins have varying but overlapping substrate specificities. The 
family can be grouped into five distinct genetically similar groups named FhCL1-5. 
FhCL1, FhCL2 and FhCL5 are required for liver penetration and tissue and blood 
feeding.  
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 Experiments using purified native enzymes demonstrated that FhCL1 and 
FhCL2 can degrade haemoglobin, immunoglobulin, and interstitial matrix proteins 
(Morphew et al., 2007). Helminth cathepsins are predominantly associated with the 
cells lining the gut lumen and reproductive structures, the sites at which rapid protein 
degradation and synthesis takes place. F. hepatica cathepsins are synthesized within the 
gastrodermal epithelial cells of the parasite and are stored in specialized secretory 
vesicles as inactive zymogens (Collins et al., 2004). Cathepsins make up a large 
proportion of the total transcriptome of many trematode parasites (Robinson et al., 
2009), and nearly 15% of the transcripts derived from adult F. hepatica. Mature F. 
hepaticas only secrete cathepsin L cysteine proteases, highlighting the importance of 
these molecules in the parasite pathology (Dalton et al., 2003). The importance of 
FhCL1 and FhCL2 in F. hepatica survival and adaptation can be shown by the fact that 
FhCL1 and FhCL2 are by far the most predominantly expressed cathepsins by adult 
parasites and can account for approximately 67% and 28% of total secreted cathepsin Ls 
respectively (Stack et al., 2008). F. hepatica CL has also been shown to suppresses 
Bordetella pertussis-specific IFN-γ production in vivo (O'Neill et al., 2001).  
 
1.10.5. A. Lumbricoides-derived pseudocoelomic fluid (PCF) 
Antigens derived from A. lumbricoides and A. suum, which infect humans and pigs 
respectively, have been of growing interest due to the potential immunosuppressive 
effects of ascarids on their hosts (Johnston et al., 2009). Previous studies have mainly 
focused on A. Suum-derived antigens (Table 1.1). A. Suum ES (Andrade et al., 2005) 
and lipid products (Kean et al., 2006) have been shown to trigger in vitro nitric oxide 
from macrophage. While both PCF (McConchie et al., 2006) and PI (Silva et al., 2006) 
derived from A. suum can suppress DCs responses to secondary antigens. Also, various 
A. Suum products can alter expression of allergic diseases (Rocha et al., 2008, Araujo et 
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al., 2008, Lima et al., 2002, Itami et al., 2005, Matera et al., 2008). But our 
understanding of the interaction of A. lumbricoides antigens on DCs function is limited. 
 
1.10.6. Aim of thesis 
The aims of the thesis were to:  
A) Study the ability of F. hepatica tegumental antigen to suppress DC maturation and 
function.  
 
B) Investigate the ability of F. hepatica-derived enzymes to induce and/or modulate DC 
maturation and alter T helper cell priming ability in vivo.  
 
C) Examine the capacity of an A. lumbricoides extract to induce and/or modulate DC 
maturation and alter T helper cell priming ability in vivo.  
 
 
 
 
 
 
 
 
 
 
 
 
 
   25 
Chapter 2: Materials and Methods 
2.5 Materials 
2.5.1 Reagents  
Table 2.1 list of reagents used in methods 
Product  Catalog # Company 
Compressed industrial air  --- BOC Gases Ireland, Dublin 12, Ireland. 
Compressed carbon dioxide (CO2) 
industrial  
40-VK BOC Gases Ireland, Dublin 12, Ireland. 
Medical oxygen --- BOC Gases Ireland, Dublin 12, Ireland. 
Halotane --- BOC Gases Ireland, Dublin 12, Ireland. 
C57BL/6j mice, female --- Harlan UK Limited,  Oxfordshire,  UK 
Balb/cj mice, female --- Harlan UK Limited,  Oxfordshire,  UK 
CeH/HeN --- Harlan UK Limited,  Oxfordshire,  UK 
CeH/HeJ --- Harlan UK Limited,  Oxfordshire,  UK 
DO11.10 mice, female 003303 The Jackson Lab, ME, USA 
Balb/cj mice, female 000651 The Jackson Lab, ME, USA 
RPMI 1640 medium 31870-025 GIBCO BRL, Paisley, Scotland 
Foetal calf serum (FCS) 10270-106 GIBCO BRL, Paisley, Scotland 
Sterile phosphate saline buffer (PBS) 14190-094 GIBCO BRL, Paisley, Scotland 
L-glutamine 25030-024 GIBCO BRL, Paisley, Scotland 
Penicillin-streptomycin 15070-063 GIBCO BRL, Paisley, Scotland 
Mouse CD40 (PE) 553791 Becton Dickinson, Oxford, England 
Mouse CD80 (PE) 553769 Becton Dickinson, Oxford, England 
Mouse CD86 (FITC) 553691 Becton Dickinson, Oxford, England 
PE Rat IgG2a κ Isotype Control (For 
CD40) 
553930 Becton Dickinson, Oxford, England 
PE Hamster IgG2 κ Isotype Control 
(For CD86) 
550085 Becton Dickinson, Oxford, England 
FITC Rat IgG2a, κ Isotype Control 
(For CD80) 
553929 Becton Dickinson, Oxford, England 
Mouse CD4 (FITC) 553650/ 
553651 
Becton Dickinson, Oxford, England 
Mouse CD3 (PerCP) 553067 Becton Dickinson, Oxford, England 
Mouse CD3 (PE) 555275 Becton Dickinson, Oxford, England 
Mouse CD11c (APC) 550261 Becton Dickinson, Oxford, England 
Mouse CD25 (PE) 553075 Becton Dickinson, Oxford, England 
Hamster Anti-Mouse CD11c (PE-
Cy5.5) 
MCD11c18 Caltag-Medsystems Ltd, Buckingham, 
UK.  
PE-Cy5.5 Hamster IgG Isotype 
Control (For CD11c) 
HM18 Caltag-Medsystems Ltd, Buckingham, 
UK.  
Hamster Anti-Mouse CD11c (APC) MCD11c05 Caltag-Medsystems Ltd, Buckingham, 
UK.  
CD28 553297 Becton Dickinson, Oxford, England 
CTLA-4  553720 Becton Dickinson, Oxford, England 
Mouse IL-5 ELISA Set 555236 Becton Dickinson, Oxford, England 
Mouse IL-10 ELISA Set 555252 Becton Dickinson, Oxford, England 
Mouse IL-12 (p70) ELISA Set 555256 Becton Dickinson, Oxford, England 
Mouse TNF-α ELISA Set 555268 Becton Dickinson, Oxford, England 
Mouse IL-6 ELISA Set 555240 Becton Dickinson, Oxford, England 
Mouse IL-12 (p40) ELISA Set 555165 Becton Dickinson, Oxford, England 
Mouse IL-23 (p19/p40) ELISA Ready-
SET-Go 
88-7234 eBioscience Ltd, Hatfield, UK 
Mouse IFN-γ DuoSet ELISA kit DY485 R&D Systems Europe Ltd., Oxon, UK 
   26 
Mouse IL-4 DuoSet ELISA kit DY404 R&D Systems Europe Ltd., Oxon, UK 
Mouse IL-10 DuoSet ELISA kit DY417 R&D Systems Europe Ltd., Oxon, UK 
Mouse IL-17 DuoSetELISA kit DY421 R&D Systems Europe Ltd., Oxon, UK 
Mouse MIP-1α DuoSet ELISA kit DY450 R&D Systems Europe Ltd., Oxon, UK 
Mouse MIP-2 DuoSet ELISA kit DY452 R&D Systems Europe Ltd., Oxon, UK 
Mouse MCP DuoSet ELISA kit DY479 R&D Systems Europe Ltd., Oxon, UK 
Prostaglandin E2 ELISA Kit 514010 Cayman Chemicals, MI, USA 
Griess reagent system (Nitric oxide) G2930 Promega, Madison, USA 
Pipette Tips-Eppendorf (200µl) 70.760.001/7
0.760.002 
Sarstedt, Wexford, Ireland 
Pipette Tips-Eppendorf (1000µl) 70.762 Sarstedt, Wexford, Ireland 
96-well plate (flat bottom) 82.1581 Sarstedt, Wexford, Ireland 
96-well plate (round bottom) 82.1582 Sarstedt, Wexford, Ireland 
Sterile 24-well plate (round bottom) 83.1836 Sarstedt, Wexford, Ireland 
Sterile petri dishes (92/16mm) 82.1472.001 Sarstedt, Wexford, Ireland 
Sterile 10 ml pipettes 86.1245.001 Sarstedt, Wexford, Ireland 
Sterile 25 ml pipettes 86.1685.001 Sarstedt, Wexford, Ireland 
Sterile 1.5 ml micro tubes  72.690.001 Sarstedt, Wexford, Ireland 
Sterile 5 ml tubes  62.558.201 Sarstedt, Wexford, Ireland 
Sterile 15 ml centrifuge tubes  62.554.002/6
2.554.502 
Sarstedt, Wexford, Ireland 
Sterile 50 ml centrifuge tubes  62.559.001 Sarstedt, Wexford, Ireland 
Sterile 3.5 ml transfer pipettes 86.1171/86.1
171 
Sarstedt, Wexford, Ireland 
Filtropur S 0.2µm 83.1826.001 Sarstedt, Wexford, Ireland 
Sterile Nunc F96 MicroWell™ Plates 137101 Nunc, Roskilde, Denmark 
Sterile 6-well plate (round bottom) 83.1839 Sarstedt, Wexford, Ireland 
tissue culture flask (75cm2) 83.1813.002 Sarstedt, Wexford, Ireland 
Finnpipette® Multistepper® pipette 
tips 
Z353507 Sigma-Aldrich, Dublin 24, Ireland 
Corning Costar High Binding Capacity 
96-well plate (flat bottom)  
44-2504 eBioscience Ltd, Hatfield, UK 
Sterile Nunclon Surface 12-well plate 
(flat bottom)  
1-50628A  Nunc, Roskilde, Denmark 
FluoroNunc 96 Well Black Plates F96 
MaxiSorp 
4-37111A Nunc, Roskilde, Denmark 
Sterile tissue culture plate 35mm plate 
(flat bottom)  
1-50318A  Nunc, Roskilde, Denmark 
40mm cell strainer 352340 Unitech/BD, Dublin 24, Ireland 
70mm cell strainer 352350 Unitech/BD, Dublin 24, Ireland 
19G needles  301500 Unitech/BD, Dublin 24, Ireland 
25G needles  300600 Unitech/BD, Dublin 24, Ireland 
27G needles  300635 Unitech/BD, Dublin 24, Ireland 
1 ml syringes 300013 Unitech/BD, Dublin 24, Ireland 
10 ml syringes ASY225-
40BX 
Lennox Ltd, Dublin 12, Ireland 
Parafilm-M ASE165-15 Lennox Ltd, Dublin 12, Ireland 
FACS tubes 352054 Unitech/BD, Dublin 24, Ireland 
FACS flow sheath 342003 Becton Dickinson, Oxford, England 
FACS clean 340345 Becton Dickinson, Oxford, England 
FACS rinse 340346 Becton Dickinson, Oxford, England 
The CellTiter 96® AQueous Cell 
Proliferation Assay (MTS based) 
G3582 Promega, Madison, USA 
Cell Growth Determination Kit (MTT 
based) 
CGB-1 Sigma-Aldrich, Dublin 24, Ireland 
Annexin V-FITC apoptosis detection 
kit I 
556547 BD pharmingen, Oxford, England 
Dialysis tubing  D-9777 Sigma-Aldrich, Dublin 24, Ireland 
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Hydrogen peroxide 30% (H2O2) H1009 Sigma-Aldrich, Dublin 24, Ireland 
Trizma® hydrochloride 
(NH2C(CH2OH)3 · HCl) 
T5941 Sigma-Aldrich, Dublin 24, Ireland 
Calcium chloride (CaCl2) 383147 Sigma-Aldrich, Dublin 24, Ireland 
Glycine (NH2CH2COOH) G8898 Sigma-Aldrich, Dublin 24, Ireland 
Sulfuric acid (H2SO4) 435589 Sigma-Aldrich, Dublin 24, Ireland 
Phenylmethylsulfonyl fluoride (PMSF) 
(C7H7FO2S) 
78830 Sigma-Aldrich, Dublin 24, Ireland 
HEPES (C8H18N2O4S) H3375 Sigma-Aldrich, Dublin 24, Ireland 
Triton® X-114 (non-ionic detergent) 93421 Sigma-Aldrich, Dublin 24, Ireland 
Chloroform (CHCl3) C2432 Sigma-Aldrich, Dublin 24, Ireland 
Sodium dodecyl sulphate (SDS) L4390 Sigma-Aldrich, Dublin 24, Ireland 
DMSO (Dimethyl sulfoxide) 
((CH3)2SO) 
D2650 Sigma-Aldrich, Dublin 24, Ireland 
TRI Reagent® T9424 Sigma-Aldrich, Dublin 24, Ireland 
Sodium hydroxide (NaOH) S5881 Sigma-Aldrich, Dublin 24, Ireland 
Sodium chloride (NaCl) 71378 Sigma-Aldrich, Dublin 24, Ireland 
Sodium phosphate dibasic (NaH2PO4) S9763 Sigma-Aldrich, Dublin 24, Ireland 
Ethanol absolute (CH3CH2OH) E7023 Sigma-Aldrich, Dublin 24, Ireland 
Tetramethylbenzidine (TMB ) 
dihydrochloride (tablets) 
T3405 Sigma-Aldrich, Dublin 24, Ireland 
Paraformaldehyde (PFA) P6148 Sigma-Aldrich, Dublin 24, Ireland 
Temed T9281 Sigma-Aldrich, Dublin 24, Ireland 
Methanol (CH3OH) 179337 Sigma-Aldrich, Dublin 24, Ireland 
Hydrochloric acid (HCL) 07102 Sigma-Aldrich, Dublin 24, Ireland 
Phorbal myristate acetate (PMA) P8139 Sigma-Aldrich, Dublin 24, Ireland 
Bovine serum albumin (BSA) A7906 Sigma-Aldrich, Dublin 24, Ireland 
Skim Milk Powder 70166 Sigma-Aldrich, Dublin 24, Ireland 
Trypan Blue solution (sterile-filtered, 
cell culture tested) 
T8154 Sigma-Aldrich, Dublin 24, Ireland 
Phosphate-Citrate Buffer with Sodium 
Perborate (for ELISA) 
P4922 Sigma-Aldrich, Dublin 24, Ireland 
Acetone (CH3COCH3) 27023 AGB Scientific/VWR Int. Limited, Dublin 
15, Ireland 
PyroGene® Recombinant Factor C 
Endotoxin Detection System 
50-658U Lonza, Walkersville, MD, USA 
X-ray developer Solution 120100 Fuji photo film Co Ltd, Toyko, Japan  
X-ray fixer Solution 120204 Fuji photo film Co Ltd, Toyko, Japan  
X-ray starter Solution 120401 Fuji photo film Co Ltd, Toyko, Japan  
Fuji medical X-ray film (18x24cm) 100 NIF Fuji photo film Co Ltd, Toyko, Japan  
c-Jun N-terminal kinase (JNK) 
inhibitor 
420116 Calbiochem, La Jolla, CA, USA 
p38 MAP kinase inhibitor S7067 Sigma-Aldrich, Dublin 24, Ireland 
extracellular signal-regulated kinase 
(ERK) inhibitor 
U0126 Sigma-Aldrich, Dublin 24, Ireland 
CytoSelect 96-well Phagocytosis 
Assay, Colorimetric (RBC) 
CBA-220 Cell Biolabs Inc., CA, USA 
Sheep Red Blood Cells (Suspended 
100%) 
0855876 Innovative Reseach, MI, USA 
Triton® X-114 93421 Sigma-Aldrich, Dublin 24, Ireland 
Tween® 20, Molecular Grade H5151 Promega, Madison, USA 
Coverslips  MLS17-20 Lennox Ltd, Dublin 12, Ireland 
Cellulose Acetate Membrane Filters 11104-047N Sartorius, Goettingen, Germany 
OVA Peptide (323-339, 
ISQAVHAAHAEINEAGR) 
RP10610 GenScript Corp., NJ, USA 
Extracti-Gel D detergent removing gel  20208 Pierce, Rockford, IL, USA 
Recombinant mouse GM-CSF 415-ML-050 R&D Systems Europe Ltd., Oxon, UK 
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Microcon-YM-30 Filter Unit, 30 kDa 42409/42422 Millipore, MA, USA 
Purified anti-mouse CD3 553057 BD pharmingen, Oxford, England 
Nonident® P40 substitute detergent 74385 Sigma-Aldrich, Dublin 24, Ireland 
[3H] thymidine  TRA310 GE Healthcare UK Ltd., 
Buckinghamshire, UK 
Mouse CpG ODN 1826 tlrl-modn InvivoGen, CA, USA 
Flagellin (S. thyphimurium) tlrl-stfla InvivoGen, CA, USA 
Peptidoglycan (PGN) (Staphylococcus 
aureus) 
tlrl-pgnsa InvivoGen, CA, USA 
Poly (I:C) (polyinosinsic:cytidylic acid) tlrl-pic InvivoGen, CA, USA 
Lipopolysaccharide (LPS) (E. coli, 
Serotype R515) 
ALX-581-007 Alexis Biochemicals, Lausanne, 
Switzerland 
Zymosan A (Saccharomyces 
cerevisiae) 
Z4250 Sigma-Aldrich, Dublin 24, Ireland 
Anti-mouse CD40/TNFRSF5 Antibody MAB440 R&D Systems Europe Ltd., Oxon, UK 
RIPA Buffer R0278 Sigma-Aldrich, Dublin 24, Ireland 
Protease Inhibitor Cocktail P8340 Sigma-Aldrich, Dublin 24, Ireland 
Phosphatase Inhibitor Cocktail 1 P2850 Sigma-Aldrich, Dublin 24, Ireland 
Phosphatase Inhibitor Cocktail 2 P5726 Sigma-Aldrich, Dublin 24, Ireland 
Bicinchoninic acid (BCA) reagent A 23228 Promega, Madison, USA 
Bicinchoninic acid (BCA) reagent B 23224 Promega, Madison, USA 
Precision Plus Protein All Blue 
Standards 
161-0373 Biorad, Hercules, USA 
ImmobilonTM chemiluminescent HRP 
substrate 
WBKLS0050 Millipore, MA, USA 
Immobilon®-P Polyvinylidene 
Difluoride (DVDF) membranes 
P2938 Sigma-Aldrich, Dublin 24, Ireland 
Whatman 3MM Chromatography 
Paper 20X20CM 
3030/861 Lennox Ltd, Dublin 12, Ireland 
Phospho-SAPK/JNK (Thr183/Tyr185) 
Rabbit mAb 
4668 Cell Signaling Technology Inc., MA, 
USA 
Phospho-p38 MAPK (Thr180/Tyr182) 
Antibody 
9211 Cell Signaling Technology Inc., MA, 
USA 
Phospho-NF-κB p65 (Ser276) 
Antibody 
3037 Cell Signaling Technology Inc., MA, 
USA 
Phospho-p44/42 MAPK (Erk1/2) 
(Thr202/Tyr204) 
4370 Cell Signaling Technology Inc., MA, 
USA 
Anti-rabbit IgG, HRP-linked Antibody 7074 Cell Signaling Technology Inc., MA, 
USA 
p44/42 MAPK (total Erk1/2) Antibody 9102 Cell Signaling Technology Inc., MA, 
USA 
IRF-5 Antibody 3257 Cell Signaling Technology Inc., MA, 
USA 
 
2.6 Solutions and Media  
2.6.1 Solutions  
10X Phosphate buffered saline (PBS)  
400g NaCl 
10g KCl 
58g Na2HPO4 
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10g KH2PO4  
Solution adjusted to pH 7.3 with HCL or NaOH and brought to 1 L with dH2O. Stored 
at room temperature. 1X PBS was prepared by diluting 10X PBS at a ratio of 1:9 with 
dH2O. 
 
Citric acid buffer 
2.941g Citric Acid 
Citric acid buffer and adjusted to pH 5.5 with HCL or NaOH made up to 100mls with 
dH2O. Stored at room temperature.   
 
TMB substrate solution  
9.8ml Citric Acid buffer 
2mg TMB 
200µl DMSO 
3µl H2O2 
2mg TMB powder added to 200µl DMSO. TMB/DMSO solution added to 9.8mls citric 
acid buffer make TMB Substrate Solution. Hydrogen peroxide added and TMB/DMSO 
solution added just before use.  
 
10X electrophoresis buffer 
250 mM tris  
1.92 M glycine  
1% SDS 
Solution adjusted to pH 8.3 with HCL and stored at room temperature. 1X 
electrophoresis buffer was prepared by diluting 10X electrophoresis buffer at a ratio of 
1:9 with dH2O. 
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5X SDS-PAGE reducing buffer 
0.625 M tris/HCl pH 6.8   
50% glycerol 
10% SDS 
0.1% bromophenol blue  
5% 2-mercaptoethanol  
 
FACS Buffer (PBA) 
100mls PBS  
2mls (2%) FCS  
0.05 g (0.05%) NaH3 
 
Fixation buffer: 1% paraformaldehyde (PFA) 
Paraformaldehyde: 1.0g  (1%) 
Make up to 1000 ml with dH2O, at 70oC. Stored at 4oC 
 
0.2 M Sodium phosphate ELISA buffer 
11.8g Na2HPO4 
16.1g NaH2PO4 
Solution adjusted to pH 6.5 with HCL or NaOH and brought to 1 L with dH2O. Stored 
at 4oC.  
 
0.1 M Sodium carbonate ELISA buffer 
7.3g NaHCO3 
1.59g Na2CO3 
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Solution adjusted to pH 9.5 with HCL or NaOH and brought to 1 L with dH2O. Stored 
at 4oC.  
 
0.1 M Ammonium bicarbonate buffer 
7.906g Ammonium bicarbonate. 
Solution brought to 1 L with dH2O. Stored at 4oC.  
 
Western Blot Transfer Buffer (one blot) 
Tris: 0.9g  (25mM) 
Glycine: 4.5g  (200mM) 
Methanol: 60ml  (20%) 
Make up to 300 ml with dH2O 
 
Western Blot 10X Running Buffer 
Tris: 30g (250mM) 
Glycine: 144g (1920mM) 
SDS: 10g 
Make up to 1L with dH2O, pH 8.3.  Store at RT. 1X was prepared by diluting 10X 
Running Buffer at a ratio of 1:9 with dH2O. 
 
Western Blot Blocking Buffer 
Marvel 5g (5%) (0.75g in 15mls; 1.5g in 30mls) 
Make up to 100ml with PBS. 
 
Western Blot Antibody Buffer 
5% blocking buffer with 0.05% Tween-20 (50µl) 
0.75g in 15mls, 7.5µl Tween-20. 
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2.6.2 Media 
Complete RPMI (cRPMI) 5%:  
RPMI 1640 medium with 5% (or 2% for FhCL1 antigens) heat inactivated FCS (30 
mins at 60oC), 0.05 mM 2-ME, 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-
glutamine and 50µM 2-mercaptoethanol (All products supplied by Invitrogen-Gibco). 
 
2.7 Equipment  
Table 2.2: list of equipment used in methods 
Equipment Catalog # Company 
Stirred ultra-filtration cell model 8220 5123 Millipore 
Merit water still, 240V W4000 Lennox Ltd, Dublin 12, Ireland 
HiPrep 26/60 Sephacryl S-200 HR gel filtration 
column 
17-1195-
01 
Amersham Biosciences Limited,  
Amersham, UK 
Perista pump  SJ-1211 
ATTO Bio-Instrument, Bunkyo, 
Tokyo 
BioCollector Fraction Collector AC-5750 
ATTO Bio-Instrument, Bunkyo, 
Tokyo 
Microcentrifuge Benchtop model 4214 
Medical Supply Co Ltd., Dublin 
15, Ireland 
Stuart Scientific Combined Incubator and Orbital 
Shaker S150 
Medical Supply Co Ltd., Dublin 
15, Ireland 
Lightwave Diode Array UV/Vis Spectrophotometer S2000 
Medical Supply Co Ltd., Dublin 
15, Ireland 
Bloch Heater - BBA series - Grant Boekel  
Medical Supply Co Ltd., Dublin 
15, Ireland 
Analogue Stirred Water Baths NE4-22T  
AGB Scientific/VWR Int. Limited, 
Dublin 15, Ireland 
Consort nv electrophoresis power supply E844 Belgium 
Dual Mini Slab Kit-gel electrophoresis apparatus  AE-6450 
ATTO Bio-Instrument, Bunkyo, 
Tokyo 
Hemacytometer, Neubauer, Double cell --- 
Medical Supply Co Ltd., Dublin 
15, Ireland 
Tecan Genios Microplate Reader --- 
Tecan Group Ltd., Männedorf, 
Switzerland 
Tecan Safire2 UV-VIS-IR and fluorescence plate 
reader --- 
Tecan Group Ltd., Männedorf, 
Switzerland 
Thermo / Forma Scientific CO2 Water Jacketed 
Incubator 
Model 
3111 
Medical Supply Co Ltd., Dublin 
15, Ireland 
Leica Inverted microscope DMIL 
Leica Microsystems, Wetzlar, 
Germany 
SIGMA 4K15 Benchtop Refrigerated Centrifuge 10740 Sigma Laboratory Centrifuges 
BIOQUELL Microflow Class II ABS Cabinet ABS1200F 
AGB Scientific/VWR Int. Limited, 
Dublin 15, Ireland 
FACSCalibur flow cytometer  --- 
Becton Dickinson, Oxford, 
England 
Flowjo software --- Tree Star, Inc, Ashland, OR, USA 
BD CellQuest™ Pro software --- 
Becton Dickinson, Oxford, 
England 
ENDNOTE --- ISI ResearchSoft, Berkeley, USA 
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GeneGenius Gel Documentation and Analysis 
System --- Syngene, Cambridge, UK 
Fuji medical film processor   FPM 100A 
Fuji photo film Co Ltd, Toyko, 
Japan  
Fuji film cassette (18x24cm) EC-DW 
Fuji photo film Co Ltd, Toyko, 
Japan  
Vortex mixer 
TT52-
9008200 
Lennox Laboratory Supplies Ltd, 
Dublin 12, Ireland. 
 
2.8 Methods  
2.4.21 In-vitro cultivation of parasites and preparation of F. hepatica excretory-
secretory (FhES) and tegumental coat (FhTeg) 
Adult F. Hepatica worms were collected from infected cattle from a local abattoir. 
Excretion-secretion (FhES) products were collected from live F. Hepatica. Briefly, F. 
Hepatica worms were washed three times in sterile PBS. 20-25 worms were placed in 
40 mls cRPMI at 37oC and 5% CO2 for 24h. This culture medium was removed and 
designated FhES. FhES extracts were clarified by centrifugation at 14,000 x g for 30 
mins at 4oC (to remove any shed eggs). F. Hepatica tegument (FhTeg) was obtained by 
washing 20-25 worms F. hepatica adult worms (live) in sterile PBS twice and then 
incubating them in 1% Nonidet P-40 detergent (NP-40 (Sigma-Aldrich), in PBS) for 30 
min at 4oC with gentle shaking. Supernatant was collected and FhTeg were clarified by 
centrifugation at 14,000 x g for 30 mins at 4oC (to remove any shed eggs). NP-40 was 
removed from FhTeg preparation using an Extracti-Gel D detergent-removing gel 
column (Pierce) (Hillyer, 1980). The FhTeg preparation was then and dialysis against 
sterile PBS overnight.  
Both FhTeg and FhES were filter concentrated using a stirred ultra-filtration cell 
(Millipore) and compressed air. Briefly, Ultra-filtration membranes (Millipore) were 
first prepared by washing in sterile dH2O for 90 min in agitated petri dish. dH2O was 
changed every 30 mins and the membrane inverted. Each membrane was stored 
overnight in 10% ethanol/sterile dH2O and washed in dH2O for 30 mins in an agitated 
petri dish before use. Either FhTeg or FhES were added to the stirred ultra-filtration cell 
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under 25 psi of compressed air, with samples kept on ice at all times. Once 
concentrated, FhTeg and FhES were stored at -20oC. Protein concentrations were 
measured using the BCA protein assay kit (Pierce) (see 2.4.3) and endotoxin levels were 
assessed using the Pyrogene® endotoxin detection system (Cambrex) (see 2.4.4). Both 
FhES and FhTeg gave endotoxin levels similar to background control levels and to 
complete RPMI 1640 medium so was taken to be endotoxin-free.  
 
2.4.22 Recombinant protein production and native Ascaris antigen isolation 
Active and variant inactive F. hepatica cathepsin L antigen rFhCL1 and rvFhCL1 
(accession No. AAB41670), respectively and F. hepatica GST sigma and mu class 
(rFhGST-si (accessions No. ABI79450) and rFhGST-mu (accession No. ACF59730)) 
were prepared in Pichia pastoris and Escherichia coli recombinant expression systems 
as previously described in the laboratories of Professors John Dalton and Peter Brophy 
(Roche et al., 1999, LaCourse et al., 2009), respectively. A. lumbricoides extracts was 
prepared by obtaining adult worms (female) from ascaris infected individuals. Worms 
were washed with sterile PBS and a sterile needed was injected into the pseudocoelom 
of the worm to remove A. lumbricoides pseudocoelomic fluid (AlPCF). PCF is a 
metabolically active fluid that maintains hemostatic pressure in the worm and provides 
precursor molecules for membrane and cuticular synthesis and heme containing proteins 
for oxidative metabolism  (Kennedy and Qureshi, 1986). Protein concentrations were 
measured using the BCA protein assay kit (Pierce) (see 2.4.3) and endotoxin levels were 
assessed using the Pyrogene® endotoxin detection system (Cambrex) (see 2.4.4). 
AlPCF tested negative for endotoxin levels since levels were similar to background 
control levels and to complete RPMI 1640 medium so was taken to be endotoxin-free.  
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2.4.23 Determination of Protein concentration 
Determination of protein concentrations was done using the bicinchoninic acid (BCA) 
protein assay in a clear 96-well micro-titre plate. Standards were prepared using in 0.25 
mg/ml increment between 0 and 2.0 mg/ml with bovine serum albumin (BSA) in an 
appropriate buffer. Samples or BCA standards were pipetted in 10µl aliquots in 
duplicate or triplicate into a clear 96-well micro-titre plate. BCA working reagent was 
prepared by mixing BCA Reagent A: BCA Reagent B in the ratio 50:1. 200µl BCA 
working reagent was then added to all standard and sample wells. Plates were covered 
and incubate at 37oC for 30 mins, and absorbance was read at 562nm in a micro-titre 
plate reader. Duplicate or triplicate values were averaged and standard curves were 
generated and protein concentrations determined using Microsoft Excel software.  
 
2.4.24 Endotoxin detection assay 
Endotoxin levels were assessed using the Pyrogene® endotoxin detection system 
(Cambrex) which utilizes recombinant Factor C (rFC), an endotoxin sensitive protein, 
which is activated by endotoxin binding. When activated by endotoxin binding, 
recombinant Factor C acts upon a fluorogenic substrate in the assay mixture to produce 
a fluorescent signal in proportion to the endotoxin concentration in the sample. 
Reactions were run in steile 96-well microplate fluorescent plates (Nunc F96 
MicroWell™ Plates). Samples were plated in triplicate in the presence of rFC and the 
fluorogenic substrate. Fluorescence was measured in a fluorescent microplate reader 
(Tecan Safire2) at time zero and then measured again after one-hour incubation at 37oC. 
Excitation/emission wavelengths of 380/440 nm were used. The log net fluorescence is 
proportional to the log endotoxin concentration and is linear in the 0.01-10 EU/ml 
range.  
 
   36 
2.4.25 Endotoxin removal procedure 
Removal of detectable endotoxin was preformed by phase separation using Triton X-
114 detergent (Aida and Pabst, 1990). This phase separation technique provides a rapid 
and gentle method for removing endotoxin from protein solutions. Since both rFhGST-
si and rFhGST-mu were prepared in E. coli recombinant expression systems (see 
section see 2.4.2), each were treated to remove any detectable endotoxin. Briefly, 
protein solutions containing endotoxin were treated with 1% Triton X-114, vortexed 
vigorously and placed on ice for 5 mins. The solutions were vortexed again and warmed 
to 37oC for 5 mins then 56oC for 1 further min in a water bath. Two separation phases 
are subsequently formed; an endotoxin-Triton X-114 containing pellet and an 
endotoxin-detergent free supernatant. The Triton X-114 phase, containing the 
endotoxin, can be further clarified by is precipitated by brief centrifugation (approx 10 
sec) in a micro centrifuge. Normally, phase separation can lead to a 1000-fold reduction 
of endotoxin levels in contaminated preparations. It has been reported that proteins 
treated by this procedure retained normal functions and that complete removal of 
endotoxin can be achieved by repetition of phase separation. All antigens that gave 
endotoxin levels similar to background control levels and to cRPMI 1640 medium as 
tested in the Pyrogene® endotoxin detection system (see 2.4.5) were taken to be 
endotoxin-free.  
 
2.4.26 Isolation and culture of murine bone marrow derived DCs (BMDCs) 
Mice were killed by cervical dislocation. Bone marrow-derived immature DCs were 
prepared by culturing bone marrow cells, isolated from the femurs and tibia of mice 
using sterile surgical equipment, 70% alcohol to sterilise the dissection area and 
performed in a microflow class II cabinet (AGB). Cells were re-suspended in cRPMI 
1640 with recombinant mouse GM-CSF (20 ng/ml; R&D Systems Ltd, UK) and were 
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cultured in humidified incubator at 37oC and 5% CO2 in sterile petri dishes (92/16mm, 
Sarstedt). On days 3 fresh medium with GM-CSF (20 ng/ml) was added to the cells. On 
day 6 of culture half of total volume of supernatant was carefully removed without 
disturbing the cell monolayer and replaced with fresh cRPMI medium containing GM-
CSF (20 ng/ml). On day 8, cells were collected by removing adherent cells with gentle 
“scrapping” with a sterile 1 ml syringe butt, counted (see section 2.4.14) and used for 
assays (Lutz et al., 1999). DC purity was >90% positive for expression of the pan 
marker CD11c (APC) (Caltag Laboratories). Appropriately labelled isotype-matched 
antibodies were used as controls. Acquisition was performed using a fluorescence-
activated cell sorter (FACS) Calibur flow cytometer (BD Biosciences), and analysis of 
results performed using FlowJo software (Tree Star) (see section 2.4.23). 
 
2.4.27 Determination of cell yield  
Trypan blue stains can be used in dye exclusion procedures for viable cell counting. 
Viable cells do not take up the dye whereas non-viable cells do. A Neubauer 
haemocytometer slide and an inverted microscope (Leica) were used to determine the 
number of cells harvested. Cell to be counted were added to a cell suspensions usually 
at a dilution factor = 3, containing Trypan Blue (Sigma-Aldrich) and allowed to stand 
for 5-10 mins. With a cover-slip in place the cell suspension in Trypan were pipetted 
onto the slide beneath the cover slip ensuring that the solution covered the entire surface 
of the counting chamber/grid. The microscopic slide contains a grid etched on its 
surface. The volume of a solution in any give part of the grid can be calculated from the 
area of the grid and the height between the grid and the cover-slip. Each square of the 
haemocytometer, with cover-slip in place, represents a total volume of 0.1 mm3 or 10-4 
cm3. This is the conversion factor for the haemocytometer. Since 1 cm3 is 
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approximately 1 ml, the subsequent cell concentration/ml (and total cell number) can be 
determined using the following calculations: 
 
Cell No. = 
(Volume (mls)) x (average count) x (dilution factor) x 104 [chamber conversion factor] 
Example: 
(10mls) x (45 cells) x (3) x (104) = 13.5 x 106 cells/ml 
 
2.4.28 Determination of cell viability and apoptosis: MTT, MTS and annxein 
The CellTiter 96 AQueous Non-Reactive Cell Proliferation Assay (the key component; 3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4 sulfophenyl)-2H-
tetrazolium, inner salt or MTS) (Promega) and the Cell Growth Determination Kit (the 
key component; 3-[4,5 dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide or 
MTT) (Sigma) were used to determine cells viability of DCs in vitro. MTS and MTT 
are bio-reduced by cells into a formazan product that is soluble in tissue culture 
medium, and that can be read at an absorbance of 490 nm and 562 nm respectively. The 
conversion of MTS and MTT into aqueous, soluble formazan is accomplished by 
dehydrogenase enzymes found in metabolically active cells. The quantity of formazan 
product as measured by absorbance is directly proportional to the number of living cells 
in culture. Briefly, for the MTS assay cells were plated on sterile 96 well plates at a 
density of 10,000 cells/well in 200 µl cRPMI. For the MTT assay cells were plated on 
96 well plates at a density of 200,000 cells/well in 200µl cRPMI. Cells were treated 
with antigens and TLR ligands as in section 2.4.10 and were incubated for a further 18 
hours 37oC and 5% CO2 in a humidified incubator. For the MTS assay, MTS solution 
was added (40 µl/well) and cells were incubated for 3 further hours at 37oC and 5% CO2 
and the absorbance of 490nm measured with a microplate reader (Genios, Tecan). For 
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the MTT assay, MTT solution was added (22 µl/well) and cells were incubated for 3 
hours in a humidified incubator at 37oC and 5% CO2. Culture medium was carefully 
removed as not to disturb cells and 200 µl MTT solvent was added to each well and 
pipette multiple times to dissolve MTT formazan crystals. The absorbance at 562 nm 
was measured with a microplate reader. Duplicate or triplicate values were averaged, 
standard curves were generated and protein concentrations determined using Microsoft 
Excel software.  
Similarly, cell viability was also measured using the Annexin V-FITC apoptosis 
detection kit I (BD Biosciences).  Briefly, 1 x 106 cells/ml were seeded into a 24-well 
plate and treated with respective antigens and each TLR ligand, either separately or 
together, or medium alone.  Cells were harvested 24 h later, washed twice in cold PBS 
and incubated in binding buffer (0.1 M Hepes/NaOH, 1.4 M NaCl, 25mM CaCl2) with 
Annexin V-FITC and propidium iodide (PI) for 15 min. Following addition of more 
binding buffer, cells were immediately analysed by flow cytometry. 
 
2.4.29 Preparation of MAPK inhibitions studies and use in cell cultures  
For MAPK inhibition studies, highly selective cell permeable inhibitors were used to 
block the functions of p38, JNK and ERK MAPKs. DCs where incubated with 
commercially available inhibitors at 20 µM/ml; c-Jun N-terminal kinase (JNK) 
(420116) (Calbiochem, La Jolla, CA, USA), P38 (S7067) and extracellular signal-
regulated kinase (ERK) (U0126) (both Sigma-Aldrich) for 1h before addition of 
stimulus (Dowling et al., 2008). Eighteen hours after TLR ligand activation, 
supernatants were removed for quantification of cytokine and nitrite levels, and FACS 
analysis was performed to determine cell surface marker expression. JNK inhibitor was 
dissolved in sterile PBS (Invitrogen) and stored at -20oC in the dark. ERK and P38 
inhibitor were dissolved in sterile DMSO (Sigma-Aldrich) and stored at 4oC in the dark.  
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2.4.30 In vitro DCs TLR and non-TLR -ligand activation 
DCs were usually seeded into 24-well plates (Nunc) at 1x106/ml in complete RPMI 
1640 plus 5 ng/ml GM-CSF. The cells were treated with the respective antigens (FhTeg, 
FhES, rFhGST-si, rFhCL1 or AlPCF) typically at 10 µg/ml for 2.5 h prior to stimulation 
with LPS (Escherichia coli 0111:B4, Alexis and Sigma Aldrich; 100 ng/ml), zymosan 
A (Saccharomyces cerevisiae; 5 µg/ml), PGN (Staphylococcus aureus peptidoglycan; 5 
µg/ml), poly (I:C) (polyinosinsic:cytidylic acid, synthetic analogue of double stranded 
RNA 2.5 µg/ml), flagellin (Salmonella. typhimurium 0.5 µg/ml), CpG (stimulatory 
oligonucleotide (ODN) 1826 5 µg/ml) (Invivogen, France) or anti-CD40 Ligand (clone  
1C10; R&D Systems) for 18 h. In time course experiments, DCs were treated with 
respective antigens 2.5 h before, at the same time as, or 2.5 h after LPS stimulation.  
Control cells were treated with medium, respective antigens or TLR ligands alone. For 
dose response experiments DCs were usually treated with antigens at concentration of 
15-1 µg/ml for 2.5 hours before stimulation with ligands for a further 18 h. For all 
experiments control DC’s were treated with medium, respective antigens or the 
respective agonist alone.   
 
2.4.31 ELISA (enzyme linked immunosorbent assay) 
ELISAs are used to quantify cytokine levels in a given liquid solution such as culture 
medium or serum. The principles of ELISAs are as follows. A monoclonal Capture 
antibody (mAb) specific for the cytokine of interest is bound to a 96 well plate by 
incubation overnight (usually at 4oC) at a defined concentration in a buffer such as PBS. 
Excess or unbound antibodies are removed by washing with an appropriate buffer such 
as 1x PBS with 0.05% Tween-20, BCA or FCS blocking buffers added prevents non-
specific binding, washed again before the addition of samples and known standards 
(usually for 2 h at room temperature). The plate are washed again to remove unbound 
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cytokine and a biotinylated detection mAb specific for the cytokine of interest in the 
presence of streptavidin horseradish peroxidase (HRP) usually for 2 h at RT. 
Streptavidin has high binding affinity for biotin and catalyses the oxidation of 
tetramethylbenzidine (TMB). After washing again TMB is added which forms a blue 
colour that increases intensity in coloration with the level of captured cytokine. The 
reaction is stopped by the addition sulfuric acid and absorbance read at 450 nm. To 
calculate concentrations Absorbance reading at 450 nm of unknown samples can be 
plotted against the optical density (OD) absorbance readings of known standard curve 
(Male et al., 2006).  
Supernatant sample from cell cultures were collected at set time points as 
outlined in section 2.4.16 and cytokine, chemokines and prostaglandin production was 
measured by commercially available ELISA kits. Supernatants were tested for IL-6, IL-
10, IL-12p40, IL-12p70, IL-23, TNF-α, IL-4, IL-5, IL-17 and IFN-γ levels with BD 
OptEIA™ ELISA sets; (BD Biosciences) and Duoset™ ELISA kits (R&D systems). 
Production of MIP-1α and MIP-2 Duoset™ ELISA kits (R&D systems). Prostaglandin 
E2 (PGE2) and levels were also measured by ELISA (Cayman Chemical EIA Kits, 
USA).  
 
2.4.32 Nitric oxide assay 
Nitric oxide levels were detected using the Griess Reagent System (Promega). Nitric 
oxide (NO) is an important physiological messenger and effector molecule in 
immunoloigical systems (Bredt and Snyder, 1994). The Griess Reagent System is based 
on the chemical reaction detect NO2- by its use of sulfanilamide solution and N-1-
napthylethylenediamine dihydrochloride (NED) under acidic (phosphoric acid) 
conditions. Sulfanilamide and NED were added sequentially each for 5-10 minutes and 
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the sample the absorbance of 565 nm measured with a microplate reader (Genios, 
Tecan). 
 
2.4.33 TLR screening: InvivoGen 
This method is based on TLR-induced activation of the transcription factor NF-κB in 
HEK293 clones and takes advantage of the fact that TLR ligands are typically 
recognized by a single TLR. Ag-induced stimulation of TLRs 2-9 (see table 2.3) was 
tested in HEK-293 cells expressing a given TLR protein as well as a reporter gene 
driven by NF-κB promoter (InvivoGen). Each 293-TLR cell line was induced with a 
known specific ligand as a positive control, and a recombinant HEK-293 cell line for 
the reporter gene only was used as a negative control. TLR activation is represented as 
activity of the secreted alkaline phosphatase in arbitrary units read at an optical density 
of 650nm. TNF-α was used to stimulate HEK-293 cells as a non-TLR ligand positive 
control (TLR-). Respective antigens were added at same concentrations as reported in 
section 2.4.16.  
TLR  Ligands  Concentration 
TLR2  PAM2 10 ng /ml 
TLR3  Poly(I:C)  25 µg/ml 
TLR4  E.coli K12 LPS  100 ng/ml 
TLR5  S. typhimurium flagellin  1 µg/ml 
TLR7  Imidazoquinoline/R848 3 µg/ml 
TLR8  Imidazoquinoline/R848 10 µg/ml 
TLR9  CpG ODN 2006  10 µg/ml 
 
Table 2.3: TLR positive control ligands used during TLR screening. (InvivoGen). 
http://www.invivogen.com/family.php?ID=175&ID_cat=10&ID_sscat=94  
 
2.4.34 Flow cytometry  
Expression of cell surface markers on cells was quantified by four-colour flow 
cytometry. Briefly, adherent cells were recovered from culture plates or flasks after 
supernatant removal and gentle “scrapping” with a sterile 1 ml syringe butt and re-
suspended in PBA (1X sterile PBS, 2% FCS and 0.02% sodium azide). FCS prevents 
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non-specific binding of fluorescently conjugated antibodies while the sodium azide 
minimises their endocytosis by the cells. Where suspension cells were used, they were 
taken direct from culture and buffer exchanged into PBA. Cell suspensions in PBA were 
transferred to 5ml FACS tube and centrifuged at 300 x g for 5 mins at 4oC with an 
acceleration speed of 5 x g and a deceleration speed of 3 x g. Centrifugation adheres the 
cells to the bottom of the FACS tube allowing the supernatant to be carefully removed 
from each FACS tube without disturbing the cell pellet. Typically, 2.5 µl fluorescently 
conjugated antibody (BD Biosciences and Caltag) specific for the protein of interest 
usually, was added to each FACS tubes containing a cells of interest. 100 µl PBA was 
added, the cells re-suspended by voxtexing and the subsequent cell suspension 
incubated for 30 mins at 4oC in the dark. Cells were washed in 2 ml PBA and 
centrifuged as outlined above and supernatant again carefully removed from each FACS 
tube as not to disturb the cell pellet. Finally, cells were fixed with 1-5% 
paraformaldehyde (PFA) solution in FACS flow sheath for a minimum of 10 mins and 
acquired with in 24 hrs. 
DCs and T cells were tested for various cell surface markers as outlined in 
section 2.1.1. Multiple fluorescently conjugated antibodies were used in tandem 
ensuring that their flourochromes differed. All antibodies were used at suppliers 
recommended concentrations, incubation lengths and temperatures (which can vary 
from product to product according to manufacturer’s specifications). Unlabelled cells or 
appropriately labelled isotype-matched antibodies were used as controls for all 
experiments. Surface marker expression was analysed on a FACSCalibur flow 
cytometer using CellQuest (BD Biosciences) and FlowJo Software (Tree Star). 
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2.4.35 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was performed based on a previously established method (Laemmli, 1970) 
and carried out using the mini-gel system (ATTO Bio-Instrument). Plates were first 
arranged in the relevant casting rig and the system was checked for leaks. Based on the 
molecular weight range of proteins within FhTeg 12% acrylamide resolving gels 
(10kDa-200kDa) were used.  For all cases western blots 10% resolving gels (20kDa-
300kDa) were used. Resolving gels were prepared based on the recipes given in table 
2.4 TEMED and 10% ammonium persulphate were added last just prior to pouring to 
prevent the gel polymerisation before being poured. The resolving gel was poured in a 
way to leave room for the stacking gel and topped with isopropanol to ensure a flat 
surface, prevent drying and air bubbles forming. The resolving gel was let set for 
between 5-30 mins.  
5% stacking gel were prepared based on the recipes given in table 2.1. Once 
again, TEMED and 10% ammonium persulphate were added last just prior to pouring to 
prevent the gel solidifying before being poured. Once the resolving gel had 
polymerised, the isopropanol was decanted from the gels. The stacking gel was then 
poured into place quickly followed by the placing of the appropriate spacer combs to 
form the loading wells and the stacking gel was allowed to polymerise for between 5-30 
mins. The combs were then removed from the gels and the gels transferred from the 
casting rig to the electrophoresis chamber. The chamber was then filled with 1X 
electrophoresis buffer (see 2.2.1). For protein sample with sufficiently high 
concentrations, such as FhTeg, sample preparation was preformed by mixing 20 µl of 
neat sample stock with 5 µl 5X SDS-PAGE reducing buffer. This 25µl mixture was 
boiled for 2 mins on a heading plate. Prepared samples, usually 12.5 µl aliquots (10µg) 
and 10 µl aliquots standards (Precision Plus Protein™ Standards; Bio-Rad) were loaded 
onto wells of the gel. For protein samples with low concentrations such as those form 
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protein extrations, samples were concentrated by incubation for 2 h at -20oC in acetone 
at a 1:5 dilution. After 2 h samples were centrifuged at 8,000 x g for 10 mins to pellet 
the proteins and the acetone supernatant discarded. Protein samples (10 µg for pNF-
κBp65, and 40 µg for all others signal transduction proteins) were loaded with pre-
stained protein markers into wells as above. Electrophoresis was performed between 
150 V and 200 V for 60-90 mins or until samples began to run off end of gel. Gels were 
carefully removed from electrophoresis chamber and casting rig, washed in H2O and the 
5% stacking gel was cut away and discarded.  
 
No. of Resolving Gel 15ml - 2 Atto Mini-Gels 7.5ml - 1 Atto Mini-Gels Stacking  ( 2 gels)  
Resolving Gel % Acrylamide 10% 12% 10% 12% 5% 
40% Acrylamide/Bisacrylamide 3.75ml 4.5ml 1.875ml 2.25ml 0.625ml 
1M Tris/HCl pH 8.8 5.6ml 5.6ml 2.8ml 2.8ml --- 
1M Tris/HCl pH 6.8 --- --- --- --- 0.625ml 
dH2O 5.4ml 4.65ml 2.7ml 2.325ml 3.625ml 
10% SDS 150µl 150µl 75µl 75µl 50µl 
10% APS 75µl 75µl 37.5µl 37.5µl 50µl 
TEMED 25µl 25µl 12.5µl 12.5µl 25µl 
 
Table 2.4: Components of SDS-PAGE gels. Resolving and stacking gels, with 
preparation volumes for one and four gels (ATTO Bio-Instrument Mini-Gels).  
 
2.4.36 Protein extraction and western blot analysis (Immunoblots) 
Total protein was extracted from cell lysates using RIPA buffer (containing 50mM Tris-
HCl, 150mM NaCl, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl 
sulphate, and protease and phosphatase inhibitor cocktails, pH 8.0 (Sigma-Aldrich)). 
Cells were incubated in the extraction buffer on ice for 5 min before being centrifuged 
at 8,000 x g for 10 min at 4oC.  Supernatants were transferred to clean tubes, and protein 
concentrations were determined using the BCA protein assay kit (Pierce) (see 2.4.3). 
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Where necessary, protein samples were concentrated by incubation for 2 h at -20oC in 
acetone at a 1:5 dilution. Protein samples (10-40 µg) and pre-stained protein markers 
(Precision Plus Protein™ Standards; Bio-Rad) were separated by SDS-PAGE (10% 
resolving gel) (section 2.4.15) and blotted onto 0.45 µM Immobilon™-P polyvinylidene 
difluoride membrane (Sigma-Aldrich). Membranes were blocked for 1 h at room 
temperature in 5% nonfat dried milk in PBS, and incubated overnight at 4oC with the 
respective antibody selective for the protein of interest (see table 2.1). Membranes were 
washed in PBS with 0.05% Tween-20 (PBS-T) and incubated for 1 h at room 
temperature with peroxide-conjugated anti-rabbit IgG (Sigma-Aldrich; 1:2000). After 
further washing, proteins were visualized with SuperSignal West Pico 
chemiluminescent substrate (Pierce) or Immobilon™ chemiluminescent HRP substrate, 
exposed to film for 1-30 mins, and processed using an FPM 100A Processor (FujiFilm). 
Protein bands were quantified using the GeneSnap acquisition and GeneTools analysis 
software (GeneGenius Gel Documentation and Analysis System; Syngene).  
 
2.4.37 Phagocytosis assay 
The phagocytic ability of DCs was measured using the CytoSelect™ 96-well 
Phagocytosis Assay (Cell Biolabs Inc.). Briefly, DCs from C57BL/6 mice were plated 
at 0.5 x 106/ml in complete RPMI and incubated overnight at 37oC to allow adherence 
to plate. On day two, DCs were treated with antigens (FhTeg, rFhGST-si, rFhCL1 or 
AlPCF; all 10 µg/ml) or TLR ligands (LPS (100 ng/ml) or zymosan A (5 µg/ml)) alone, 
or with each antigen and TLR ligands at the same time, for 2.5hrs before the addition of 
sheep erythrocytes opsonised by IgG at a ratio of 50:1 (Innovative Reseach). 
Supernatants were aspirated after 1h and adherent cells washed with sterile PBS to 
remove non-phagocytosed erythrocytes. Adherent DCs were then lysed, substrate 
solution added and the amount of engulfed erythrocytes determined by colorimetric 
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assay at absorbance of 610nm and quantified by a 2 fold serial dilution standard curve 
of lysed erythrocytes. Negative control cells where treated with 2 µM Cytochalasin D to 
block phagocytosis.  
 
2.4.38 In vivo T-cell priming assay 
For assays of in vivo T-cell priming, DCs isolated from BALB/c mice (as per 2.4.11) 
were stimulated in vitro with medium or one of each antigens; FhTeg, rFhGST-si, 
rFhCL1 or AlPCF; (all 10µg/ml) in the presence of ovalbumin (OVA) peptide (323-
ISQAVHAAHAEINEAGR-329; 100 nM; GenScript Corp.). After 24 h, the cells were 
washed with sterile endotoxin free PBS and DCs (3 x 105) were delivered over the 
sternum of naive DO11.10 mice under halothane anaesthesia by subcutaneous injection. 
After 7 days, mice were killed by cervical dislocation, skin draining lymph nodes and 
spleens were removed and a single cell suspension of cells plated with medium, OVA 
peptide (100-1000 nM) or with PMA (25 ng/ml; Sigma-Aldrich) and anti-CD3ε 
monoclonal antibody (1 µg/ml; clone 145-2C11; BD Biosciences). After 72 h 
incubation period at 370C and 5% CO2, supernatants were removed for measurement of 
IL-4, IL-5, IFN-γ, IL-17 and IL-10 by commercial assay (R&D Systems). Flow 
cytometry analysis of CD4, CD28 and T-lymphocyte-associated antigen 4 (CTLA-4) 
(BD Biosciences) expression and sdLN cells was done as described above.  
 
2.4.39 T-cell Proliferation assay 
Lymph node cells were prepared as described above and plated on 96 well plates. After 
72 h 1 µCi of [3H] thymidine was added per well. After four additional hours cells were 
harvested onto filter plates and [3H] thymidine uptake determined via a liquid 
scintillation counter (NUI Maynooth). 
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2.4.40 Statistics 
All data were analysed for normality prior to statistical testing.  Where multiple group 
comparisons were made, data were analysed using one-way ANOVA. For comparisons 
between two groups, the Student’s t test was used or non parametric Mann-Whitey U 
test was used analysis used for analysis when two experimental samples were 
compared. In all tests, p < 0.05 was deemed significant. 
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Chapter 3: FhTeg suppresses DC maturation and function 
3.1. Introduction 
Controlling immune pathology, in particular inflammatory responses, prolongs parasitic 
worm’s survival within the host and thus increases its chances of completing its life 
cycle. Helminths classically induce highly polarized Th2 and T-regulatory immune 
responses, correlating with chronic infection in the host but with little associated 
immune pathology (Maizels and Yazdanbakhsh, 2003). Fasciola infection (O'Neill et 
al., 2000) and Fasciola-derived antigens (O'Neill et al., 2001) have also been shown to 
suppress antigen-specific Th1 immune responses both in vitro and in-vivo, or modulate 
the function of innate immune cells by inducing alternative activation of macrophages 
(AAMø) (Donnelly et al., 2005). But in contrast to bacteria and viruses, little is known 
about how helminths induce DC maturation. A limited number of studies demonstrate 
that helminths can induce a less phenotypically mature DC that differs predominantly 
by their activation status, which lacks many of the classical maturation markers such as 
co-stimulatory molecules (CD80, CD86, MHC II, CD40) and pro-inflammatory 
cytokines (IL-12p70 and TNFα) (MacDonald and Maizels, 2008). However, the effect 
of Fasciola antigens on DC function has yet to be determined. 
In this study, we have isolated the tegumental coat from F. hepatica and are the 
first to investigate the effects of F. hepatica tegumental antigen on DC maturation and 
function. Preliminary studies on the immunomodulatory properties of FhTeg had taken 
place. Since parasitic helminth infections have been reported to ameliorate symptoms of 
pro-inflammatory diseases (Elliott et al., 2003, La Flamme et al., 2003, Elliott et al., 
2004, Summers et al., 2005), it was we assessed whether FhTeg could suppress pro-
inflammatory cytokine production in vivo using a model of septic shock. Intraperitoneal 
(i.p.) injection of LPS alone induced significantly higher levels of serum IFN-γ Injection 
of FhTeg alone induced similar cytokine responses to PBS. But injection of mice with 
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FhTeg either 2.5h prior to, or after, LPS injection resulted in significantly reduced 
serum levels of IFN-γ and IL-12p70 but not serum levels of IL-12p40. Therefore, it was 
shown that FhTeg could suppresses pro-inflammatory cytokines in vivo in a model of 
septic shock (Hamilton et al., 2009). TLR activation is associated with inflammatory 
disorders such as inflammatory bowel disease and septic shock (Abreu and Arditi, 
2004), thus mechanisms of suppressing TLR maturation of DCs may lead to the 
development of potential therapeutics (Kobayashi et al., 2003, Daubeuf et al., 2007). It 
was subsequently been shown that LPS-stimulated DC activation could also be 
modulated by FhTeg. Treatment of LPS-stimulated DCs with FhTeg resulted in the 
reduced cytokine production of IL-12p70 IL-10, TNF-a, NO in addition to the reduced 
expression of IL-12p35 RNA. Levels of supernatant IL-12p40, IL-6 and IL-23 were 
unaffected. FhTeg was also shown to down regulate the LPS-stimulated cell surface co-
stimulatory molecules CD40, CD80 and CD86 as well as MHC II. Similar to the 
suppression of pro-inflammatory cytokines in vivo in a model of septic shock this 
modulation was found to not to be dependent of time of exposure. Finally, the 
modulatory effects of FhTeg were shown to work independently of TLR4, since the 
suppressive effects outlined above was still evident in TLR4KO or C3H/HeJ (defective 
LPS response) mice. It was also shown that FhTeg did not interfere with DC cell growth 
or viability.  
Since DCs are a good source of IL-12p70 and critical in driving adaptive 
immunity, a complete comparative analysis of the DC phenotypes induce by a range of 
TLR ligands was preformed (Dowling et al., 2008). Given that FhES has been shown to 
have immunomodulatory properties (see Table 1.1), and studies of the proteome 
(Morphew et al., 2007) and the secretome (Robinson et al., 2009) of F. hepatica have 
highlighted some similarities, we firstly compared the ability of FhTeg and FhES to 
modulate cytokine production in DCs matured with a range of TLR ligands. We further 
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investigated the effect of FhTeg on DC cell surface marker expression, its ability to bind 
PRRs and modulate signal transduction pathways. Lastly, the effect of FhTeg on DC 
function was characterised by its ability to alter their phagocytic and T cells priming 
capacity.  
 
3.2. Results 
3.2.1. FhTeg does not reduce DC viability or proliferation  
DC viability and proliferation was assessed after FhTeg, FhES and TLR-ligand 
stimulation. Cell viability was measured using the CellTiter 96 AQueous Non-Reactive 
Cell Proliferation assay (MTS; Promega) and cell growth/proliferation was measured 
using the Cell Growth Determination Kit (MTT; Sigma). MTS is bio-reduced by cells 
into a formazan product that is soluble in tissue colour medium, and that can be read at 
an absorbance of 490nm for the MTS assay and 562nm for the MTT assay. Absorbance 
is proportional to formazan, with is proportional to viable living cells (MTS assay) or 
cell growth (MTT assay). Blank wells containing no cells were used to determine 
background and each absorbance result was divided by the absorbance of the negative 
control cells (medium only) to determine the relative cell viability. Cell viability and 
proliferation was determined for FhTeg and FhES treated DCs alone and after 
stimulation with multiple TLR agonists. FhTeg or FhES did not affect cell viability for 
any ligands (see Fig. 3.1).  
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Figure 3.1: FhTeg does not affect cell viability and cell growth. (A) MTS and (B) 
MTT assays preformed on DCs from C57BL/6 mice shows FhTeg has no affect cell 
viability and cell growth of dendritic cells at a concentration of 10 µg/ml. DCs were 
treated with FhTeg (10 µg/ml) for 2.5 hours before stimulation with zymosan A (Zym, 
5µg/ml), PGN (5 µg/ml), flagellin (Flag, 0.5 µg/ml), poly (I:C) (2.5 µg/ml), or CpG-
ODN1826 (2.5 µg/ml) in the presence or absence of FhTeg (10 µg/ml), added 2.5h 
before TLR stimulation, or with medium alone as a control. Data are the mean values of 
3 individual wells (±SEM), and a representative of at least 2 individual experiments. 
NS; not significant.  
 
3.2.2. FhTeg not FhES suppresses cytokines in TLR-stimulated DCs 
The effect of FhTeg and FhES on cytokine production of DC stimulated with multiple 
agonists was investigated. The 11 known TLRs can be and placed into groups according 
to the ligands they recognise (O'Neill, 2006). Five TLR agonists where chosen which 
broadly represent each group and which are triggered by a distinct set of microbial 
components. These include a variety of microbe-derived molecules including gram-
positive and negative bacteria, fungi and viruses, all of which have been shown to 
unregulated cytokine production and cell surface marker expression. TLR3 is triggered 
by Poly (I:C), a synthetic analogue of double-stranded RNA (Tsujimoto et al., 2006); 
Flagellin, which is a major component of flagellar filament, activates TLR5 (Agrawal et 
al., 2003). TLR9 is trigger by the synthetic oligonucleotide CpG (ODN 1826) that 
contains unmethylated CpG dinucleotides (Napolitani et al., 2005); and  Peptidoglycan 
(PGN), major surface component of gram-positive bacteria activates TLR2 (Michelsen 
et al., 2001). Finally, Zymosan A from Saccharomyces cerevisiae binds TLR2/6 (Dillon 
NS NS
(A) (B)
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et al., 2006). The concentrations of TLR ligands were determined by previous published 
data, manufacturer’s recommendations and by in vitro test in our laboratory. The 
concentration employed were as follows: Poly (I:C) -100 µg/ml, Flagellin -0.5 µg/ml, 
CpG (ODN 1826) -2.5 µg/ml, PGN -5 µg/ml (all from Invivogen) and Zymosan A from 
S. cerevisiae -5 µg/ml (Sigma-Aldrich). 
DCs were treated with FhTeg or FhES (both 10 µg/ml) 2.5 h before stimulating 
DCs with each TLR ligand. As controls DCs were also treated with medium (negative), 
FhTeg (negative), FhES (negative) or each TLR-Ligand alone (positive controls). Cells 
were incubated for a further 18 hours and culture supernatant where assayed for 
cytokine production by ELISA and nitrite was measured using Griess reagent system. 
Medium, FhTeg or FhES alone did not induce any of the cytokines tested, therefore are 
not shown. FhTeg significantly inhibited the production of IL-6, IL-10, IL12p70, TNF-α 
and nitrite in zymosan-stimulated DCs (see Fig. 3.2). PGN induced IL-6, IL-12p40, 
IL12p70, TNF-α and nitrite were suppressed after FhTeg treatment. FhTeg did not 
influence cytokine secretion in response to flagellin. Low cytokines levels were induced 
in response to flagellin, which may be explained by the fact that murine BMDC have 
previously been shown to express much lower levels of TLR5 (10 fold less) compared 
to splenic DCs (Didierlaurent et al., 2004). Poly (I:C) did not induce all cytokines but 
suppression in response to FhTeg was seen for IL-6 and nitrite. CpG induce all 
cytokines but suppression in response to FhTeg was observed for IL-10, IL-12p70 and 
nitrite. FhES, apart from a limited suppressive affect on PGN-induced TNF-α, did not 
suppress any cytokines induced by any of the 5 TLR ligands (see Fig. 3.3). Thus, only 
FhTeg has the ability to suppress the production of multiple cytokines induce by various 
TLR ligands with the greatest down regulation seen for IL-6, IL-10, IL-12p70 and 
nitrite from DCs. 
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Figure 3.2: FhTeg targets multiple TLR pathways in DCs. DCs from C57BL/6 mice 
were cultured with zymosan A (Zym, 5µg/ml), PGN (5 µg/ml), flagellin (Flag, 0.5 
µg/ml), poly (I:C) (2.5 µg/ml), or CpG-ODN1826 (2.5 µg/ml) in the presence or 
absence of FhTeg (10 µg/ml), added 2.5h before TLR stimulation, or with medium 
alone as a control. Supernatants were harvested 18 h after TLR-ligand stimulation and 
IL-12p70, IL-10, TNF-α, IL-12p40 and IL-6 were measured using sandwich ELISA, 
and nitrite was measured using medium Griess reagent. Data are the mean values 
(±SEM) of at least 3 individual experiments. ***, p < 0.001. **, p < 0.01. *, p < 0.1 
compared with TLR-ligand stimulated only group. 
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Figure 3.3: Cytokine production of stimulated DCs is unaffected by FhES. DCs 
from C57BL/6 mice were cultured as in Fig 3.2 in the presence or absence of FhES (10 
µg/ml), added 2.5h before TLR stimulation, or with medium alone as a control. 
Supernatants were harvested 18 h after TLR-ligand stimulation and IL-12p70, IL-10, 
TNF-α, IL-12p40 and IL-6 were measured using sandwich ELISA, and nitrite was 
measured using medium Griess reagent. Data are the mean values (±SEM) of at least 2 
individual experiments.  *, p < 0.1 compared with TLR-ligand stimulated only group. 
 
3.2.3. FhTeg suppresses costimulatory marker expression 
The effect of FhTeg on cell surface expression of DC stimulated with various TLR 
ligands was investigated. We have previously established that expression of all three 
costimulatory marker; CD40, CD80 and CD86 are significantly up regulated by all 5 
TLR ligands tested (Dowling et al., 2008). DCs were treated with TLR ligands in the 
presence or absence of FhTeg as in Fig 3.2, and flow cytometric analysis was 
preformed. Pre treatment at 2.5 hr with FhTeg was shown to suppress increased the 
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expression all three markers in response to TLR ligand DC activation, except for 
zymosan induced CD40 and CD80 (Fig. 3.4).  
 
 
Figure 3.4: FhTeg suppresses co stimulatory marker expression in TLR stimulated 
DCs. DCs from C57BL/6 mice were matured with TLR-ligands as in Fig. 3.2 and cell 
surface expression of CD40, CD80 and CD86 were measured by flow cytometry after 
18h. DCs cultured in medium alone and gated on a live CD11c+ population were used as 
controls. Data are the mean values (±SEM) of 3 independent experiments. ***, p < 
0.001. **, p < 0.01. *, p < 0.1 compared with TLR-ligand stimulated only group. 
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3.2.4.  FhTeg suppression of DC TLR activation can be time dependent or time 
independent  
As shown previously, FhTeg suppression of LPS-stimulated DC maturation was 
independent of time of exposure. To investigate if this was the same for all TLR 
ligands, DCs were treated with FhTeg (10 µg/ml) for 2.5 hours before, at same time as, 
or 2.5 hours after stimulation with the previously stated panel of TLR-ligands. DCs 
were incubated for a further 18 hours from time of DC stimulation and culture 
supernatants where assayed for cytokine production by ELISA and nitrite was measured 
using medium and Griess Reagent (Fig. 3.5). FhTeg suppressed cytokine production of 
zymosan stimulated DCs when added simultaneously (0hr) or after zymosan (+2.5 hrs). 
The greatest suppression is seen at -2.5 hrs and suppression decreases inversely in line 
with time after DC zymosan stimulation. This trend is largely followed for poly (I:C) 
and CpG, with the greatest cytokine suppression observed with FhTeg treatment at -
2.5hrs before stimulation and the least suppression with FhTeg treatment +2.5hrs after 
stimulation. Therefore, FhTeg suppression of cytokines induced by these ligands shows 
a dependence on time of exposure. The suppression of PGN induced cytokines on the 
other hand is time independent in all cases (Fig. 3.5).  
 Again, the cell surface expressions of co-stimulatory molecules CD40, CD80 
and CD86 were measured by flow cytometry, with FhTeg down regulating cell surface 
expression of CD40, CD80 and CD86 for all time points measured. In line with the 
suppression seen for the cytokine results, the greatest down regulation of co-stimulatory 
markers was observed at -2.5 hrs (Fig. 3.6). Once more as with cytokine production, 
down regulation of co-stimulatory markers decreases inversely with time to DC 
stimulation. Therefore, addition of FhTeg at +2.5 hrs had the least effect of decreasing 
co-stimulatory marker expression, which indicates that the suppressive effects of FhTeg 
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are time dependent in some instances. Medium or FhTeg alone did not induce any 
effects on DCs (data not shown). 
 
 
 
 
Figure 3.5: FhTeg inhibits TLR-induced DC cytokine production in a time 
dependent or independent manner. DCs from C57BL/6 mice were matured as in Fig. 
3.2. DCs were also treated with FhTeg (10 µg/ml) 2.5 hours before, same time as, or 2.5 
hours after TLR-ligand stimulation. Data are the mean values of 3 individual wells 
(±SEM), and a representative of at least 2 individual experiments.  ***, p < 0.001. **, p 
< 0.01. *, p < 0.05 compared with TLR-stimulated group. 
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Figure 3.6: FhTeg inhibits TLR-induced DC surface marker expression in a time 
dependent or independent manner. Cell surface expression of CD40, CD80 and 
CD86 were measured by flow cytometry on TLR-stimulated DCs for 18h or medium 
alone. DCs from C57BL/6 mice were treated as in (Fig 3.5), and are gated on a live 
CD11c+ population. Data are the mean values of 3 individual wells (±SEM), and a 
representative of at least 2 individual experiments. 
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3.2.5.  FhTeg reduces DC phagocytotic ability 
Phagocytosis is an integral part of DC biology, and like macrophages and neutrophils, 
DCs are considered professional phagocytes. However, DCs are distinguished from 
these cells in that their primary function is not to destroy phagocytised particles but 
rather to present them to naive T cells thus initiating adaptive immune responses 
(Savina and Amigorena, 2007). The phagocytic ability of DCs was measured using the 
CytoSelect™ 96-well Phagocytosis Assay (Cell Biolabs Inc.). Briefly, DCs from 
C57BL/6 mice were plated at 0.5 x 106/ml in complete RPMI and incubated overnight 
at 37oC to allow adherence to plate. DCs were then treated with FhTeg (10 µg/ml), LPS 
(100 ng/ml) or zymosan A (5 µg/ml) alone, or with FhTeg and LPS or FhTeg and 
zymosan at the same time, for 2.5 h before the addition of sheep erythrocytes opsonised 
by IgG at a ratio of 50:1. Supernatants were aspirated after 1 h and adherent cells 
washed with sterile PBS to remove non-phagocytosed erythrocytes. Adherent DCs were 
then lysed, substrate solution added and the amount of engulfed erythrocytes determined 
by colorimetric assay at absorbance of 610nm. Negative control cells where treated with 
2µM Cytochalasin D to block phagocytosis. 
Both LPS- and zymosan-stimulated DCs showed a significant increase (p ≤ 
0.01) in engulfed erythrocytes compared with medium controls (Fig. 3.7). To determine 
whether FhTeg was interfering with phagocytic ability, DCs were cultured with 
medium, LPS or zymosan in the presence or absence of FhTeg prior to exposure to 
opsonised erythrocytes. Results demonstrate that incubation with FhTeg alone did not 
induce phagocytosis of RBCs by DCs (Fig. 3.7). Furthermore, incubation with FhTeg 
significantly suppressed the phagocytic ability of DCs in response to both LPS and 
zymosan (Fig.. 3.7; p ≤ 0.01). 
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Figure 3.7: Exposure of TLR ligand-activated DCs to FhTeg significantly reduces 
their ability to phagocytose erythrocytes. DCs from C57BL/6 mice mice were 
cultured with medium only, FhTeg (10 µg/ml), LPS (100 ng/ml) or zymosan A (5 
µg/ml) for 2.5hrs before the addition of opsonised sheep erythrocytes to DCs at a ratio 
of 50:1. After 1 hr phagocytosis was stopped, cells washed to remove non-opsinised 
erythrocytes, lysed and amount of engulfed erythrocytes determined by colorimetric 
assay. Negative control cells where treated with 2µM Cytochalasin D to block 
phagocytosis (data not shown). Data are the mean values (±SEM) of at least 3 
individual experiments. **, p ≤ 0.01 compared to non-FhTeg treated control group. ++, 
p ≤ 0.01 compared to  medium control group. 
 
 
3.2.6. FhTeg and NF-κB signalling 
3.2.6.1. FhTeg does not activate the transcription factor NF-κB in DCs by TLRs 
The transcription factor NF-κB, is commonly referred to as the master switch for the 
immune system (Hayden and Ghosh, 2008). NF-κB is expressed in all cell types has 
multiple critical roles in the regulation the large number of genes that involved in 
multiple stages of immune responses, including innate immune cell activation, 
inflammation, lymphocyte activation and DC maturation (Li and Verma, 2002). The 
mammalian NF-κB family of transcription factors consists of five members; with p65 
being one of the most important. With the exception of TLR3 all TLRs work through 
the MyD88 adapter to activate NF-κB and MAP kinases (O'Neill, 2006). FhTeg 
mediated activation of the transcription factor NF-κB was investigated in HEK-293 
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cells which functionally express TLR proteins. FhTeg failed to induce NF-κB when 
exposed to a panel of TLR expressing cell lines.  
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Figure 3.8: FhTeg does not induce activation of TLR-2, 3, 4, 5, 7, 8 and 9, as tested 
in HEK-293 cell line expression one of each TLR. The HEK-293 cells functionally 
express a given TLR protein as well as a reporter gene driven by NF-κB promoter 
which controls secretion of alkaline phosphatase. TLR activity results are given as 
optical density (OD). Screening was performed in duplicate by challenging the TLR 
clones with 10µg/ml FhTeg and comparing its ability to induce alkaline phosphatase 
activity to that of negative controls (non-induced TLR clones) and positive controls 
(TLR-induced TLR clones). The ligands used for each HEK-293-TLR cell line positive 
controls were: PAM2 (10 ng/ml) for TLR-2, Poly I:C (100 ng/ml) for TLR-3, LPS K12 
(100 ng/ml) for TLR-4, Flagellin (1 µg/ml) for TLR-5, R848 (10 µg/ml) for both TLR-7 
and  TLR-8, ODN 2006 (10 µg/ml) and  ODN 1826 (10 µg/ml) for TLR-9. An HEK293 
cell line expressing only the receptor gene was used as a control (TNF-α is a NF-κB 
activator) (InvivoGen). NI; not induced.  
 
 
3.2.6.2.  FhTeg suppresses NF-κBp65 activation  
The transcription factor NF-κB is primarily associated with TLR activation and is 
associated with regulating the expression of a large number of genes associated with 
pro-inflammatory processes and Th1 immune responses. The active nuclear form of the 
NF-κB transcription factor complex is composed of two DNA binding subunits, p65 and 
p50, both of which are critical for DNA binding (Hayden and Ghosh, 2008). Here, we 
investigated if FhTeg could modulate NF-κBp65 expression in resting DCs and in DCs 
matured with LPS. FhTeg alone did not significant increase in NF-κBp65 at any time 
point tested (data not shown). As anticipated, treatment of DCs with LPS led to a 
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significant increase in NF-κBp65 at 15 min which gradually decreased over time (Fig. 
3.9 A, representative blot). However, densitometric analysis on blots revealed that this 
was only significant at 15 min (Fig. 3.9 B; p ≤ 0.01). Pre-treatment of DCs with FhTeg 
suppressed LPS-induced NF-κBp65 at all time points but suppression was only 
significant at 15 min (Fig. 3.9 A and 3.9 B; p ≤ 0.01). 
 
 
 
Figure 3.9: FhTeg suppresses NF-κBp65 activation. DCs from C57BL/6 mice were 
treated with FhTeg (10 µg/ml) or medium 2.5 h prior to stimulation with LPS (100 
ng/ml) for 18 h. Control DCs were treated with FhTeg or medium alone. (A) Cells were 
harvested 0 to 2 h after LPS stimulation, and NF-κBp65 was determined in whole-cell 
lysates by Western blot analysis. A representative blot is shown. The cells were treated 
with medium (lane 1), FhTeg (lane 2), LPS for 15 min (lane 3), FhTeg plus LPS for 15 
min (lane 4), LPS for 30 min (lane 5), FhTeg plus LPS for 30 min (lane 6), LPS for 1 h 
(lane 7), and FhTeg plus LPS for 1 h (lane 8). (B) Densitometric analysis was 
performed on all immunoblots, and NF-κBp65 was expressed in arbitrary units as a 
percentage increase over the group treated with medium only (control) group. Values 
that were significantly different (P ≤ 0.01) from the value for the LPS-treated group are 
indicated (**). Values that were significantly different (P ≤ 0.01) from the value for the 
group treated with medium (control) are indicated (++). 
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3.2.7. No uniform suppression of MAPKs by FhTeg 
Since the suppressive effects of FhTeg are not mediated through TLR4 binding we 
investigated whether it is targeting a common component of TLR pathways, such as the 
MAPKs. To address this question, DCs were treated with MAPK inhibitors specific for 
ERK, p38 and JNK following exposure to FhTeg but prior to stimulation with 5 TLR 
ligands. Although specific MAPK inhibitors abrogated the FhTeg-mediated suppression 
for a limited number of cytokines, the effect was not uniform (Table 3.1 (a), (b), (c)). 
Furthermore, no abrogation of the suppressive effect of FhTeg on cell surface marker 
expression was detected following the use of inhibitor for ERK, JNK or p38 (Table 3.2).
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Ligand  IL-6 (ng/ml) IL-10 (pg/ml) IL-12p40 (ng/ml) IL-12p70 (ng/ml) TNF-α (ng/ml) Nitrite (µM/ml) 
(a) The effect of JNK inhibitor on cytokine production from TLR ligand-matured DCs 
PGN  
 
19.5 ± 0.3 
6.6 ± 1.4*** 
 
5.9 ± 0.2 
3.1 ± 0.3 
 
47.0 ± 3.1 
25.3 ± 1.1*** 
 
14.9 ± 4.0 
11.6 ± 2.4 
15.8 ± 0.4 
19.6 ± 0.2*** 
 
17.9 ± 0.3 
14.4 ± 0.5 
0.5 ± 0.0 
0.4 ± 0.0*** 
 
0.1 ± 0.0 
0.0 ± 0.0 
1.8 ± 0.0 
1.9 ± 0.1 
 
0.1 ± 0.0 
0.1 ± 0.0 
10.1 ± 0.1 
7.0 ± 0.0*** 
 
1.3 ± 0.1 
1.6 ± 0.1 
Zymosan  
 
15.3 ± 0.1 
14.7 ± 0.4 
 
10.5 ± 0.3 
12.5 ± 1.3 
 
336.1 ± 7.7 
285.8 ± 0.7*** 
 
72.7 ± 3.5 
80.1 ± 2.4 
15.7 ± 0.1 
14.8 ± 0.3*** 
 
13.9 ± 0.1 
11.5 ± 0.1 
0.2 ± 0.0 
0.2 ± 0.0 
 
0.0 ± 0.0 
0.1 ± 0.0 
6.0 ± 0.1 
8.6 ± 0.1*** 
 
2.5 ± 0.1 
7.1 ± 0.1 
15.4  ± 0.2 
9.7  ± 0.0*** 
 
6.5 ± 0.1 
3.6 ± 0.1 
Poly (I:C)  
 
7.3 ± 0.2 
6.4 ± 0.1*** 
 
4.3 ± 0.1 
4.6 ± 0.1 
 
- 10.9 ± 0.1 
8.3 ± 0.2*** 
 
9.7 ± 0.2 
7.8 ± 0.2 
- 0.2 ± 0.0 
0.1 ± 0.0*** 
 
0.1 ± 0.0 
0.1 ± 0.0 
5.0 ± 0.1 
6.9 ± 0.1*** 
 
3.4 ± 0.0 
4.6 ± 0.0 
Flagellin  
 
3.5 ± 0.1 
2.9 ± 0.2** 
 
1.4 ± 0.1 
0.3 ± 0.2 
 
- 5.2 ± 0.1 
7.8 ± 0.1*** 
 
4.5 ± 0.2 
5.9 ± 0.2 
- - - 
CpG  
 
22.5 ± 0.4 
6.8 ± 0.5*** 
 
19.4 ± 0.4 
7.0 ± 1.5 
786.0 ± 13.1 
887.2 ± 34.6*** 
 
195.3 ± 1.6 
270.7 ± 7.8 
12.1 ± 0.2 
11.0 ± 0.4** 
 
11.3 ± 0.3 
10.5 ± 0.3 
3.1 ± 0.0 
3.4 ± 0.1*** 
 
1.9 ± 0.0 
2.8 ± 0.0 
6.4 ± 0.1 
7.2 ± 0.1*** 
 
6.0 ± 0.1 
8.6 ± 0.1 
34.6 ± 0.6 
33.2 ± 0.1** 
 
20.3 ± 0.2 
24.2 ± 0.1 
 
Table 3.1 (a): The effect of JNK inhibitors on cytokine production by DCs induced with a panel TLR ligands with or without FhTeg. DCs from C57BL/6 
mice were stimulated with TLR ligand for 18h, with inhibitors added 90 mins before stimulation, FhTeg 2.5 h after and cytokines were measured in supernatants 
using sandwich ELISA, and nitrite was measured using medium Griess Reagent. Data are the mean values (±SEM) of at least 3 individual experiments. ***, p < 
0.001. **, p < 0.01 compared with TLR ligand stimulated group. Top group: TLR Ligand (top) / TLR Ligand + MAPK Inhibitor (bottom). Bottom group: FhTeg + 
TLR Ligand (top) / FhTeg + TLR Ligand + MAPK Inhibitor (bottom).  
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Ligand IL-6 (ng/ml) IL-10 (pg/ml) IL-12p40 (ng/ml) IL-12p70 (ng/ml) TNF-α (ng/ml) Nitrite (µM/ml) 
(b) The effect of ERK inhibitor on cytokine production from TLR ligand-matured DCs 
PGN  
 
13.9 ± 0.4 
8.9 ± 0.5*** 
 
8.6 ± 0.3 
1.4 ± 0.1 
 
55.3 ± 1.9 
11.9 ± 1.4*** 
 
22.8 ± 1.3 
12.5 ± 2.1 
29.0 ± 0.8 
32.7 ± 1.0*** 
 
37.8 ± 2.0 
13.6 ± 0.2 
1.4 ± 0.1 
0.6 ± 0.0*** 
 
0.0 ± 0.1 
0.8 ± 0.1 
1.4 ± 0.1 
0.0 ± 0.0*** 
 
0.0 ± 0.0 
0.0 ± 0.0 
18.1 ± 0.2 
2.9 ± 0.5*** 
 
4.0 ± 0.1 
1.4 ± 0.0 
Zymosan  
 
15.6 ± 0.3 
7.8 ± 0.2*** 
 
11.7 ± 0.4 
4.3 ± 0.1 
 
334.7 ± 9.9 
34.0 ± 1.2*** 
 
112.5 ± 4.0 
28.9 ± 3.4 
10.5 ± 0.5 
10.1 ± 0.3 
 
11.4 ± 0.3 
7.2 ± 0.0 
0.3 ± 0.0 
0.0 ± 0.0*** 
 
0.1 ± 0.0 
0.0 ± 0.0 
3.6 ± 0.2 
0.1 ± 0.0*** 
 
2.7 ± 0.0 
0.1 ± 0.1 
23.0  ± 0.2 
3.7  ± 0.1*** 
 
12.3 ± 0.1 
2.0 ± 0.3 
Poly (I:C)  
 
7.3 ± 0.5 
2.2 ± 0.1*** 
 
5.7 ± 0.3 
1.9 ± 0.1 
 
- 28.3 ± 0.4 
5.0 ± 0.0*** 
 
24.4 ± 0.1 
3.5 ± 0.0 
- 0.3 ± 0.0 
0.0 ± 0.0*** 
 
0.2 ± 0.0 
0.0 ± 0.0 
9.6 ± 0.1 
1.1 ± 0.0*** 
 
6.4 ± 0.2 
1.6 ± 0.5 
Flagellin  
 
0.3 ± 0.0 
0.0 ± 0.0*** 
 
0.4 ± 0.0 
0.0 ± 0.0 
 
- 5.8 ± 0.1 
2.4 ± 0.1*** 
 
8.5 ± 0.1 
2.6 ± 0.1 
0.2 ± 0.2 
1.7 ± 0.1*** 
 
0.6 ± 0.1 
0.5 ± 0.0 
- - 
CpG  
 
13.2 ± 0.2 
12.6 ± 0.4 
 
13.1 ± 0.4 
7.8 ± 0.1 
479.6 ± 8.2 
11.0 ± 0.8*** 
 
183.2 ± 3.6 
9.6 ± 1.5 
24.2 ± 0.2 
16.8 ± 0.6*** 
 
24.7 ± 0.7 
25.4 ± 0.2 
5.4 ± 0.2 
1.1 ± 0.1*** 
 
3.8 ± 0.3 
0.9 ± 0.1 
4.3 ± 0.1 
0.0 ± 0.0*** 
 
4.4 ± 0.1 
0.1 ± 0.0 
42.8 ± 0.4 
8.1 ± 0.1*** 
 
28.9 ± 0.2 
3.1 ± 0.1 
 
Table 3.1 (b): The effect of ERK inhibitors on cytokine production by DCs induced with a panel TLR ligands with or without FhTeg. DCs from C57BL/6 
mice were stimulated with TLR ligand for 18h, with inhibitors added 90 mins before stimulation, FhTeg 2.5 h after and cytokines were measured in supernatants 
using sandwich ELISA, and nitrite was measured using medium Griess Reagent. Data are the mean values (±SEM) of at least 3 individual experiments. ***, p < 
0.001. **, p < 0.01 compared with TLR ligand stimulated group. Top group: TLR Ligand (top) / TLR Ligand + MAPK Inhibitor (bottom). Bottom group: FhTeg + 
TLR Ligand (top) / FhTeg + TLR Ligand + MAPK Inhibitor (bottom).  
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Ligand IL-6 (ng/ml) IL-10 (pg/ml) IL-12p40 (ng/ml) IL-12p70 (ng/ml) TNF-α (ng/ml) Nitrite (µM/ml) 
(c) The effect of p38 inhibitor on cytokine production from TLR ligand-matured DCs 
PGN  
 
13.9 ± 0.4 
0.1 ± 0.0*** 
 
8.6 ± 0.3 
0.2 ± 0.0 
55.3 ± 1.9 
15.1 ± 0.7*** 
 
22.8 ± 1.3 
18.6 ± 1.5 
29.0 ± 0.8 
16.8 ± 0.6*** 
 
37.8 ± 2.0 
8.3 ± 0.3 
1.4 ± 0.1 
0.0 ± 0.2*** 
 
0.0 ± 0.1 
0.0 ± 0.6 
1.4 ± 0.1 
0.0 ± 0.0*** 
 
0.0 ± 0.0 
0.0 ± 0.0 
18.1 ± 0.2 
0.7 ± 0.1*** 
 
4.0 ± 0.1 
0.6 ± 0.1 
 
Zymosan  
 
17.6 ± 0.2 
0.6 ± 0.0*** 
 
12.3 ± 0.3 
0.4 ± 0.0 
739.1 ± 20.7 
34.3 ± 3.4*** 
 
139.0 ± 5.3  
31.5 ± 9.6 
17.9 ± 0.4 
12.9 ± 0.2*** 
 
16.5 ± 0.3 
2.7 ± 0.1 
0.2 ± 0.0 
0.0 ± 0.0*** 
 
0.1 ± 0.0 
0.0 ± 0.0 
3.5 ± 0.1 
0.0 ± 0.0*** 
 
2.3 ± 0.2 
0.0 ± 0.0 
19.4 ± 0.3 
1.4 ± 0.0*** 
 
8.5 ± 0.1 
0.5 ± 0.1 
 
Poly (I:C)  
 
7.3 ± 0.5 
1.3 ± 0.0*** 
 
5.7 ± 0.3 
0.7 ± 0.0 
- 28.3 ± 0.4 
12.8 ± 0.3*** 
 
24.4 ± 0.1 
2.2 ± 0.1 
0.0 ± 0.2 
0.3 ± 0.1** 
 
0.4 ± 0.2 
0.0 ± 0.1 
0.3 ± 0.0 
0.0 ± 0.0*** 
 
0.2 ± 0.0 
0.0 ± 0.0 
9.6 ± 0.1 
2.1 ± 0.0*** 
 
6.4 ± 0.2 
0.6 ± 0.2 
Flagellin  
 
0.3 ± 0.2 
0.0 ± 0.0*** 
 
0.4 ± 0.0 
0.0 ± 0.0 
- 5.8 ± 0.1 
4.5 ± 0.1*** 
 
8.5 ± 0.1 
3.4 ± 0.1 
 
- - - 
CpG  
 
13.2 ± 0.2 
3.6 ± 0.2*** 
 
13.1 ± 0.4 
1.1 ± 0.1 
479.6 ± 8.2 
13.1 ± 3.1*** 
 
183.2 ± 3.6 
14.1 ± 3.3 
24.2 ± 0.2 
23.8 ± 0.4 
 
24.7 ± 0.7 
30.0 ± 0.1 
5.4 ± 0.2 
0.0 ± 0.1*** 
 
3.8 ± 0.3 
0.0 ± 0.3 
4.3 ± 0.1 
0.0 ± 0.0*** 
 
4.4 ± 0.1 
0.1 ± 0.0 
42.8 ± 0.4 
12.9 ± 0.1*** 
 
28.9 ± 0.2 
1.3 ± 0.0 
 
 
Table 3.1 (c): The effect of p38 inhibitors on cytokine production by DCs induced with a panel TLR ligands with or without FhTeg. DCs from C57BL/6 mice 
were stimulated with TLR ligand for 18h, with inhibitors added 90 mins before stimulation, FhTeg 2.5 h after and cytokines were measured in supernatants using 
sandwich ELISA, and nitrite was measured using medium Griess Reagent. Data are the mean values (±SEM) of at least 3 individual experiments. ***, p < 0.001. **, 
p < 0.01 compared with TLR ligand stimulated group. Top group: TLR Ligand (top) / TLR Ligand + MAPK Inhibitor (bottom). Bottom group: FhTeg + TLR 
Ligand (top) / FhTeg + TLR Ligand + MAPK Inhibitor (bottom).  
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Ligand  CD40 CD80 CD86 
(a) The effect of JNK inhibitor on mean fluorescence intensity from 
TLR ligand-matured DCs 
PGN  
 
119/98 - ↓ 18% 
49/46 - ↓ 6 % 
355/345 - ↓ 31%  
176/162 - ↓ 8 % 
108/91 - ↓ 23% 
51/39 - ↓ 24 % 
Zymosan  
 
195/130 - ↓ 33% 
114/73 - ↓ 34% 
416/460 - ↑ 11% 
214/255 - ↑ 16% 
118/139 - ↑ 18% 
61/68 - ↑ 10% 
Poly (I:C)  
 
63/77 - ↑ 22% 
40/50 - ↑ 20% 
387/283 - ↓ 27% 
196/164 - ↓ 16% 
142/111 - ↓ 22% 
61/68 - ↑ 12% 
Flagellin  
 
57/58 - ↔ 
24/28 - ↑ 17% 
343/326 - ↓ 27% 
174/140 - ↓ 20% 
91/60 - ↓ 34% 
46/31 - ↓ 33 % 
CpG  
 
139/110 - ↓ 21% 
111/93 - ↓ 16 % 
361/326 - ↓ 10% 
237/234 - ↓ 1% 
96/78 - ↓ 19% 
71/64 - ↓ 10% 
(b) The effect of ERK inhibitor on mean fluorescence intensity from 
TLR ligand-matured DCs 
PGN  
 
134/111 - ↓ 17% 
60/32 - ↓ % 
288/185 - ↓ 36% 
177/87 ↓ 51% 
103/84 - ↓ 18% 
52/45 - ↓ 14% 
Zymosan  
 
230/207 - ↓ 10% 
158/80 - ↓ 49% 
517/341 - ↓ 34% 
365/157 - ↓ 57% 
100/55 - ↓ 45% 
56/17 - ↓ 70% 
Poly (I:C)  
 
129/79 - ↓ 39% 
57/32 - ↓ 44% 
296/170 - ↓ 43% 
176/73 - ↓ 59% 
125/102 - ↓ 18% 
77/54 - ↓ 30% 
Flagellin  
 
45/38 - ↓ 23% 
27/22 - ↓ 19% 
245/175 - ↓ 29% 
148/79 - ↓ 47% 
63/59 - ↓ 6% 
36/38 - ↑ 6% ¥ 
CpG  
 
179/137 - ↓ 23% 
136/78 - ↓ 43% 
251/218 - ↓ 13% 
184/151 - ↓ 18% 
76/75 - ↔  
62/53 - ↓ 15% 
(c) The effect of p38 inhibitor on mean fluorescence intensity from 
TLR ligand-matured DCs 
PGN  
 
136/137 - ↓ 72% 
60/19 - ↓ 68% 
288/126 - ↓ 64% 
177/100 - ↓ 44% 
103/39 - ↓ 61% 
51/28 - ↓ 45% 
Zymosan  
 
120/127 - ↑ 6% 
86/62 - ↓ 28% 
342/239 - ↓ 30% 
297/196 - ↓ 34% 
80/60 - ↓ 25% 
47/25 - ↓ 47% 
Poly (I:C)  
 
134/37 - ↓ 72% 
57/20 - ↓ 65% 
296/156 - ↓ 47% 
176/84 - ↓ 52% 
128/80 - ↓ 36% 
77/37 - ↓ 52% 
Flagellin  
 
45/31 - ↓ 31% 
27/17 - ↓ 37% 
245/126 - ↓ 49% 
148/93 - ↓ 37% 
63/38 - ↓ 40% 
36/29 - ↓ 19% 
CpG  
 
179/56 - ↓ 69% 
136/27 - ↓ 80% 
251/215 - ↓ 13% 
184/120 - ↓ 35% 
76/60 - ↓ 21% 
61/29 - ↓ 52% 
 
Notation:  
TLR Ligand / TLR Ligand + MAPK Inh 
FhTeg + TLR Ligand / FhTeg + TLR Ligand + MAPK Inh 
 
Table 3.2: The effect of MAPK inhibitors on cell surface marker expression by 
DCs induced with a panel TLR ligands with or without FhTeg. DCs from C57BL/6 
mice were stimulated with TLR ligands for 18h; with inhibitors and FhTeg added 90 
mins before and 2.5 h before stimulation respectively. Cell surface expression of CD40, 
CD86, and CD80 were measured by flow cytometry. Data are the mean values (±SEM) 
of at least 3 individual experiments, showing mean fluorescent intensity percentage 
decrease/increase from TLR ligand stimulated DCs. ↓: Significantly down regulated, ↑: 
Significantly up-regulated, ↔: No significant change. Value considered significant 
when p < 0.05 compared to stimulated DCs with no inhibitor.  
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3.2.8. In vivo T-Cell priming  
3.2.8.1. T-cell cytokine profiles and cell proliferation 
Since FhTeg significantly suppressed cytokine production and costimulatory marker 
expression from stimulated DCs, its effects on the ability of differentially activated DCs 
to prime T-cell responses in sdLN was investigated in DO11.10 mice. DCs were 
cultured with OVA peptide in the presence or absence of FhTeg prior to their 
inoculation into naive DO11.10 mice. T-cell priming was measured 7 days later by re-
stimulation of sdLN cells with OVA peptide and PMA/anti-CD3. DCs primed with 
medium induced IFN-γ, IL-10 and IL-4 production from sdLN cells in response to OVA 
stimulation (Fig. 3.10). Although the levels of IL-4 and IL-10 were low in comparison 
to PMA/anti-CD3-stimulated cells, they were comparable to that published in the 
literature (Jenkins and Mountford, 2005). DCs primed with FhTeg induced significantly 
less OVA-specific IFN-γ from sdLN cells than control DCs primed with medium (Fig. 
3.10; p ≤ 0.05) indicating that DCs exposed to FhTeg suppress local Th1 responses in 
vivo. Unlike other helminth antigens such as S. mansoni 0-3hRP (Jenkins and 
Mountford, 2005), in this model system FhTeg did not appear to drive local Th2 
responses, with IL-10 and IL-4 levels from DC-FhTeg recipients similar to those of DC-
Med recipients.  
 Interestingly, sdLN cells from DC-FhTeg recipients, stimulated with PMA/anti-
CD3, produced significantly decreased levels of all cytokines (Fig. 3.10; p ≤ 0.05) when 
compared to cells from DC-medium recipients indicating that FhTeg had a general 
suppressive effect on the non specific T-cell responses. This suppressive effect was also 
observed when we examined proliferation, since sdLN cells from DC-FhTeg recipients 
proliferated significantly less in response to OVA stimulation than cells from DC-Med 
recipients (Fig. 3.10; p ≤ 0.01). However, there was no significant difference in 
proliferation of cells stimulated with PMA/anti-CD3 (Fig. 3.10). 
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Figure 3.10: FhTeg alters the ability of DCs to prime T-cell responses. DCs from 
DO11.10 mice were cultured with OVA (100 nM) in the presence or absence of FhTeg 
(10 µg/ml) overnight at 37°C. Stimulated DCs were thoroughly washed and 
subcutaneously injected over the sternum of naïve DO11.10 mice. After 7 days, sdLN 
cells were removed for re-stimulation in vitro with OVA (500 nM) or with PMA (25 
ng/ml) and anti-CD3 (1 µg/ml). After 72 h, supernatants were analyzed by ELISAs for 
IFN-γ, IL-10, and IL-4. Data are the mean values (±SEM) of three individual wells from 
four individual mice and are representative of three experiments. Values that were 
significantly different (P ≤ 0.01) from the value for the appropriate group of DCs 
treated with medium (DC-Med) are indicated as follows: *, P ≤ 0.05; **, P ≤ 0.01. 
 
 
3.2.8.2.  Flow cytometry analysis 
CD28 and CTLA-4 are related receptors that differentially regulate T-cell activation. 
While CD28 enhances T-cell proliferation and survival, in contrast CTLA-4 inhibits T-
cell responses (Green, 2000). We measured the expression of CD28 and CTLA-4 on 
CD4 positive cells and found that FhTeg did not impact on the expression of these 
molecules (Fig. 3.11). The suppression of cell proliferation or cytokine production can 
therefore not be attributed to changes in the expression of these cell surface markers. 
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Figure. 3.11: The expression levels of CD28 and cytotoxic T-lymphocyte antigen-4 
(CTLA-4) on CD4 T cells is unchanged following OVA antigen specific activation. 
Cells from DO11.10 mice were harvested and analysed by three-colour flow cytometry 
for CD4, CD28 and CTLA-4. (A) The histograms show representative data of the 
surface expression of CD28 and CLTA-4 on CD4+ cells from sdLN after 72 h in vitro 
culture; OVA-med (black line), OVA-OVA (grey line), OVA-FhTeg-med (black dotted 
line) OVA-FhTeg-OVA, (grey dotted line), and isotype controls (solid histogram). (B) 
Combined data from 3 independent experiments showing the mean fluorescent intensity 
(MFI) for surface expression of CD28 and CLTA-4 on CD4+ cells from sdLN after 72 h 
in vitro culture.  
 
3.3. Discussion 
This present study demonstrates the suppressive effect of F. hepatica tegument on DC 
maturation and function. As discussed in the introduction helminth infections are 
associated with a modified Th2 response. Studies have shown that helminth-derived 
antigens, such as the filaria-derived antigen, ES-62, which induces IL-12p40, IL-6, and 
TNF-α production from DCs, can partially induce DC maturation (Goodridge et al., 
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2005) and S. mansoni larva antigen, which can induce low, yet significant, increases in 
IL-12p40 and IL-6 from DCs (Jenkins and Mountford, 2005). Despite the inactivation or 
partial activation of DCs, many helminth-matured DCs are still capable of driving potent 
Th2 immune responses (Jenkins and Mountford, 2005, Whelan et al., 2000).  
 The tegumental coat of F. hepatica is a metabolically active layer that is in 
intimate contact with the host tissues and body fluids. It is here that much of the 
immune interplay between the fluke and host takes place. The tegument is shed every 2 
to 3 h during the course of infection, thus representing a constant source of antigen in 
direct contact with the host's immune cells. Studies have shown that by shedding its 
tegument, the fluke can also shed immune complexes that have formed on the surface, 
thereby evading a damaging immune response, and the shed antigen acts as a decoy 
"mopping up" host immune cells (Halton, 2004, Mulcahy, 1999).  
Previous work had highlighted the modulatory potential of FhTeg. Firstly, the 
role of FhTeg in vivo in a model of septic shock was examined. Mice injected with 
FhTeg either prior to or following LPS exposure demonstrated significantly suppressed 
levels of serum IL-12p70 and IFN-γ, but not IL-12p40 (Hamilton et al., 2009). The 
suppression of proinflammatory cytokines in vivo carries implications for the control of 
concurrent infections with F. hepatica, as studies have shown that it suppresses IFN-γ, 
altering the immune response to tuberculosis (O'Neill et al., 2001) and delaying 
bacterial clearance in concurrent infections with Salmonella enterica serovar Dublin or 
Bordetella pertussis (Aitken et al., 1981, Brady et al., 1999). Secondly, due to their 
central role in priming immune adaptive responses the effect of FhTeg on DCs was 
examined. Previously published studies have demonstrate that exposure of immature 
DCs to helminth-derived antigens failed to induce DC maturation (Balic et al., 2004, 
Perona-Wright et al., 2006b). Similarly, FhTeg alone did not have any effect on DC 
maturation as these cells did not secrete cytokines or increase costimulatory marker 
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expression in response to FhTeg. Also, FhTeg was shown not to affect the viability or 
proliferation of DCs as shown by Annexin staining and MTT/MTS assays. Thirdly, 
FhTeg treated DCs exhibited marked hypo-responsive to LPS stimulation, both in a 
reduction in a selected number of cytokines and a down regulation of costimulatory 
markers.   
 So Could FhTeg interfere with activation of DCs to a wider range of TLR 
ligands? FhTeg was shown to render DCs hyporesponsive to a range of TLR ligands 
with significant decreases in cytokine production of IL-12p70, IL-10, IL-6, TNF-α, and 
nitrite. Similar to FhTeg/LPS-treated DCs there was a decrease in costimulatory marker 
expression (CD80, CD86, and CD40). As with LPS, It was shown that cytokine 
suppression by FhTeg was selective, given that in general IL-12p40 and IL-23 
production were not affected. This was reflected in zymosan treated DCs (data not 
shown). RNA analysis of LPS activated DCs treated with FhTeg showed reduced levels 
of IL-12p35 subunit is down regulated but no the IL-12p40 subunit compared to LPS 
treated controls (Hamilton et al., 2009). This is of interest given that the p40 subunit is 
shared by IL-12 and IL-23 and both cytokines belong to the same family of 
proinflammatory cytokines (Waibler et al., 2007). Also, the timing of exposure of DCs 
to FhTeg did not affect the significant suppressive effects in response to activation to a 
range of TLR ligands. But the suppressive effects of FhTeg on zymosan, CpG and poly-
(I:C)-activated DCs decreased inversely with increasing time after TLR activation. This 
effect was not observed for PGN-induced cytokine production. This indicates that the 
suppression of DC TLR activation by FhTeg is time dependent or time independent 
depending on the TLR ligand. But since suppression always remains significantly 
reduced, the results suggest that FhTeg does not compete with LPS or any other TLR 
ligand tested for binding, and that FhTeg is not exerting its effects through any TLR. 
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 Similarly to FhTeg, FhES failed to induce maturation of DCs. The ability of 
FhES to interfere with TLR activation of DCs was also investigated. Unlike FhTeg, 
FhES had no effect on maturation of cytokine production induced by TLR ligands. Even 
thought FhTeg and FhES have been shown to share commonality in the presence of 
some helminth-derived antigens ( (Robinson et al., 2009) and R. M. Morphew and P. M. 
Brophy, unpublished data), the immunomodulatory property to suppress DC activation 
in response to TLR ligands is unique to FhTeg.  
 The ability of FhTeg to decrease proinflammatory cytokines is in keeping with a 
helminths need to suppress inflammatory processes (Goodridge et al., 2005), and since 
IL-12p70 is an important polarizing cytokine known to drive Th1 differentiation 
(Trinchieri, 2003), this suppression may result in the Th1 suppression observed during 
F. hepatica coinfections. The decrease in IL-10 observed was not anticipated, since this 
cytokine is traditionally associated with an anti-inflammatory or regulatory response 
(Moore et al., 2001). However, recent studies show IL-10 production by Th1 cells, 
emphasizing the versatile role that IL-10 plays during infection (O'Garra and Vieira, 
2007).  
 The MAPK pathway is a highly conserved pathway involved in the initiation of 
DC maturation through all known TLR ligands (Dowling et al., 2008). Activation of the 
three main mammalian groups, JNK, ERK, and p38, culminates in the release of 
cytokines from DCs following the downstream activation of a signalling cascade 
involving adaptor proteins, such as MyD88 and Mal (Nakahara et al., 2006). Helminth-
mediated suppression of cytokine production by antigen-presenting cells has been shown 
to be modulated by MAPK pathways. For example, ES-62-mediated suppression of 
LPS-induced IL-12p40 by macrophages can be reversed with the addition of the ERK 
inhibitor (Goodridge et al., 2003), and S. mansoni egg antigen dramatically reduces 
LPS-stimulated phosphorylation of p38 (Kane et al., 2004). However, in the present 
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study, we have shown that FhTeg does not target these pathways, since MAPK 
pathways are involved in the suppressive effect of only a small number of select 
cytokines. Instead, we found that FhTeg targeted the transcription factor NF-κBp65, one 
of the active subunits of the NF-κB complex involved in NF-κB binding to DNA. This 
effect on downstream signalling events could explain the observed decrease in 
proinflammatory cytokines demonstrated in this study. Activation of NF-κB is also 
inhibited by other parasites, such as Brugia malayi (Semnani et al., 2008) and 
Toxoplasma gondii (Butcher et al., 2001), where NF-κB translocation is blocked from 
entering the nucleus. We have yet to determine whether FhTeg can suppress other 
members of the NF-κB family (such as the p50 subunit) or other transcription factors, 
such as IRF3, which are also activated following LPS stimulation. 
 The effect of FhTeg on DC function was further confirmed by the demonstration 
of reduced phagocytic ability by FhTeg-primed DCs which would impact on the 
development of the adaptive immune response. Adaptive immune responses were then 
investigated by T-cell priming studies. In addition to cytokine production, co-
stimulation is essential for the successful activation and differentiation of naïve CD4+ T 
cells, and similarly, the suppression of costimulatory markers could influence Th1 cell 
differentiation. This was confirmed in the T-cell priming studies, which demonstrated 
that FhTeg-primed DCs significantly suppressed local Th1 immune responses. These 
results indicate that exposure to FhTeg, and the subsequent lack of cytokine production 
and costimulatory molecule expression, can interfere with the function of DCs and their 
ability to prime naïve T cells. Thus, from these results it was hypothesised that that 
FhTeg maintains the DCs in an immature state, impairing their function and ultimately 
modulating the development of adaptive T-cell responses. Our data support previous 
findings which demonstrate that F. hepatica infection and antigens suppress Th1 
immune responses in vivo (Brady et al., 1999, Flynn et al., 2007). Furthermore, the 
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suppression of Th1 responses is likely to be a survival mechanism for the worm, since 
vaccine trials in domestic livestock have shown the importance of inducing strong Th1 
immune responses in the host to protect against challenge infection (Mulcahy et al., 
1998). 
 While the exact mechanism of FhTeg-mediated suppression remains to be 
elucidated, the timing of exposure of DCs to our antigen did not affect the suppressive 
effects, suggesting that it does not compete with LPS for binding and that it is not 
exerting its effects through TLR4 itself. This was confirmed by the fact that FhTeg is 
still effective in DCs from TLR4 mutant and knockout mice (Hamilton et al., 2009). 
Furthermore, FhTeg was able to suppress the effects of all TLR ligands tested (which 
included both MyD88-dependent and -independent pathways), in addition to non-TLR 
ligands. While we would not directly rule out the involvement of other TLRs, it seems 
likely that FhTeg utilizes a pathway common to these receptors, particularly since it did 
not activate HEK-296 cells functionally expressing a range of TLRs.  
 In summary, we report that F. hepatica tegumental antigen modulates DC 
maturation and function, which may go some way to explaining its reported 
immunomodulatory properties in vivo. FhTeg is a heterogeneous group of molecules, 
and preliminary proteomic studies have already pointed to a number of potential 
molecules that can render DCs hyporesponsive. These proteomic studies also show that 
the profile observed for the tegument differs from that of its F. hepatica ES products (R. 
M. Morphew and P. M. Brophy, unpublished data). Although the precise immunological 
scenario is not completely understood it is clear that FhTeg maintains the DCs in an 
immature state, impairing their function and the subsequent development of adaptive 
immunity. We have yet to determine whether FhTeg drives Th2 or T-regulatory immune 
responses, but the effect of FhTeg most closely aligns with the inhibition hypothesis, in 
which activated signalling pathways may intersect and inhibit one another (MacDonald 
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and Maizels, 2008). Given the powerful modulatory effect that FhTeg exhibits, 
understanding its exact mechanisms may lead to the development of novel immune 
therapeutics for the treatment of Th1-mediated inflammatory diseases (Elliott et al., 
2003, Summers et al., 2005). 
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Chapter 4: Major secretory antigens of the helminth Fasciola hepatica activate a 
suppressive DC phenotype that suppresses Th17 cells but fails to activate Th2/Treg 
immune responses.  
4.4. Introduction  
Until relatively recently, few PAMPs of helminth origin have been identified (Zaccone 
et al., 2006) (Table 1.1). For this reason, it is important to investigate the interaction of 
defined helminth-derived molecules with DCs and elucidate the mechanism by which 
they alter DC function. The second reason for the use of defined helminth-derived 
molecules is the diverse range of DC phenotypes and responses that can be induced 
using complex mixtures of helminth antigens. DCs activated by helminths induce a 
modified form of DC maturation, lacking the classical activation markers. In some cases 
these markers can be absent (Kane et al., 2004), but most commonly are expressed at 
low levels (Johnston et al., 2009). Despite the limited maturation, helminth-primed DCs 
can nevertheless activate naïve T-cells (Maizels et al., 2004). DCs exposed to a soluble 
preparation of whole pathogen native antigens such as the Th2-priming Schistosoma 
larval preparation (0-3hRP) (Jenkins et al., 2005, Jenkins and Mountford, 2005) or SEA 
(MacDonald et al., 2001) and either co-cultured with navie T-cells in vitro or injected 
into mice can polarise T-cell responses towards a Th2 phenotype. SEA is of particular 
interest since fail to activate DCs yet these antigens are capable of driving Th2 immune 
responses (Cervi et al., 2004, MacDonald et al., 2001, van Liempt et al., 2007). Similar 
findings have been reported with and excretory/secretory (ES) material from 
Nippostrongylus brasiliensis (Balic et al., 2004). However, Segura et al (2007) found 
that adoptive transfer of DCs treated with ES from Heligmosomoides polygyrus resulted 
in suppression of both Th1 and Th2 responses in recipient mice (Segura et al., 2007). 
The same DCs promoted the differentiation of T-cells with a regulatory phenotype and 
an ability to suppress effector CD4+ cell proliferation and cytokine secretion.  
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While, the above mentions preparations are heterogeneous mixes of molecules, 
the exact antigens from these preparations that interact with DCs have yet to be 
identified. However, single antigens from native helminth preparations have been 
shown to drive similar responses. The single filarial nematode-secreted product ES-62 
from Acanthocheilonema viteae binds to TLR4 inducing low levels of IL-12p40, TNF-α 
and IL-6 from DCs (Goodridge et al., 2001). Similarly, purified antigens from 
Echinococcus granulosa (Rigano et al., 2007) and A. suum (Silva et al., 2006) partially 
activate DCs that can subsequently prime Th2 immune responses. In this study, we 
examined the interactions of recombinant Fasciola cathepsin Ls (CL) and a 
recombinant sigma class glutathione S transferase (GST) with DCs to determine if these 
are novel helminth PAMPs. ES products have been shown to modulate T cell responses 
in mice (Donnelly et al., 2008) and as stated previously, both are major components of 
F. hepatica ES. F. hepatica cathepsins are papain-like cysteine peptidases which 
facilitate the entry into and migration of the parasite through the host tissue, enhance 
virulence and suppress the host immune effector cell responses (Robinson et al., 2008). 
One of the predominant secreted products, a cathepsin L1 cysteine protease (FhCL1), 
suppressed the onset of protective Th1 immune responses in mice to bacterial infections 
and prevented the development of a Th1 response to vaccination (O'Neill et al., 2001, 
Collins et al., 2004). Mature F. hepatica only secrete cathepsin L cysteine proteases, 
highlighting the importance of these molecules in the parasite pathology. Another major 
antigen, comprising 4% of the ES of F. hepatica, is the anti-oxidant glutathione 
transferase (FhGST) (Chemale et al., 2006) which in dimeric form significantly 
inhibited the proliferation of rat spleen cells in response to ConA stimulation in vitro 
(Cervi et al., 1999). GST’s neutralise oxygen radical intermediates released by innate 
immune cells thus protecting the parasite from host immune attack. They can be 
subdivided into seven species independent classes which include the sigma and mu class 
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(Torres-Rivera and Landa, 2008). We investigate the ability of rFhGST-si and rFhCL1 
to induce an innate immune response in comparison with the archetypal TLR ligands 
such as LPS and ability of each in driving the immune responses.  
 
4.5. Results 
4.5.1.  rFhCL1 and rFhGST-si but not rvFhCL1 or rFhGST-mu induced partial 
activation of DCs 
To assess the immunomodulatory properties of the secreted enzymes of F. hepatica, 
functionally active recombinant sigma class GST (rFhGST-si), mu class GST (rFhGST-
mu) and cathepsin L1 (rFhCL1) were synthesized (Collins et al., 2004, LaCourse et al., 
2009). In addition, a conformationally intact proteolytically-inactive variant of 
cathepsin L1 (rvFhCL1), which has the active site cysteine replaced with a glycine, was 
also produced (Collins et al., 2004). All recombinant preparations were deemed to be 
endotoxin free as assessed using the Pyrogene® endotoxin detection system (Cambrex). 
Initially, a series of dose response analyses were completed to determine the optimum 
quantity of recombinant for subsequent analyses. A concentration of 10 µg/ml for each 
antigen was selected since it did not affect DC viability or growth and stimulated 
optimum cellular responses as compared to those induced by the positive control, LPS 
(Fig 4.1 B, C). 
We demonstrated that DCs stimulated with rFhCL1 secreted significant levels of 
IL-12p40 and IL-6 not IL-12p70, TNF-α, nitric oxide, IL-23 or IL-10 (Fig. 4.1 A-C and 
data not shown) compared to unstimulated cells. This activation of DCs was dependent 
upon the dose of rFhCL1 delivered, with increasing doses showing correspondingly 
increased secretion of IL-12p40 and IL-6 (Fig. 4.1 D, E), indicating a requirement for 
enzymatic activity. Consistent with this, was the observation that stimulation of DCs 
with the enzymatically inactive variant rvFhCL1 did not induce the secretion of any 
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cytokines measured (Fig. 4.1 A-C and data not shown). Treatment of DCs with 
rFhGST-si induced an identical cytokine secretion profile to rFhCL1 (Fig 4.1 A-C; p ≤ 
0.001) although the quantity of IL-6 measured was far greater than that seen following 
exposure to rFhCL1. Similar to rFhCL1, the secretion of these cytokines was also dose-
dependent (Fig. 4.1 F, G). However, rFhGST-mu did not induce the secretion of any 
cytokines (Fig. 4.1 A-C and data not shown) suggesting that the enzyme activity 
required for DC activation by Fasciola-GST may be specific to distinct sub-classes.  
Following these results we went on to determined if these enzymes could induce 
elevated expression of co-stimulatory markers CD40, CD86, CD80 and MHC II on 
DCs. Both rFhCL1 and rFhGST-si stimulated a significant increase in CD40 expression 
compared to the isotype control (Fig. 4.1 H). The expression of CD80, CD86 (Fig. 4.1 
H) or MHC II (data not shown) was not altered following exposure to these recombinant 
proteins. Both rvFhCL1 and rFhGST-mu failed to alter the expression levels of all cell 
surface markers measured (data not shown). We have given due consideration to the 
possibility that residual endotoxin (the major component of which is LPS) in the antigen 
preparations contributed to the activation of DCs described here. However, all the data 
indicates that the effects seen are due to the activity of the recombinant proteins and not 
the presence of endotoxin. For example, the phenotype of DC activation described for 
the rFhCL1 and rFh-GST-si is different to that induced by LPS (Fig. 4.1 A-C, H). These 
enzymes were produced from the same expression systems as rvFhCL1 and rFhGST-
mu, respectively, both of which had no measurable effect on the activation status of 
DCs suggesting that any effect seen is unlikely to be due to endotoxin contamination. 
Finally, the effects of the rFhCL1 and rFhGST-si on DC activation were shown to be 
heat labile since they were no longer observed following boiling (Fig. 4.2; p ≤ 0.001) 
which contraindicates the involvement of endotoxin.  
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Figure 4.1: Exposure of DCs to rFhCL1 and rFhGST-si but not rvFhCL1 and 
rFhGST-mu induces partial activation of DCs. (A-C) DCs from C57BL/6 mice were 
cultured with medium (Med), rFhCL1 (10 µg/ml), rvFhCL1 (10 µg/ml), rFhGST-si (10 
µg/ml), rFhGST-mu (10µg/ml) or LPS (100 ng/ml) for 24 h, and the production of IL-
12p40, IL-6 and IL-12p70 in supernatants was determined by ELISA. (D, E) DCs were 
cultured with a range of concentrations of rFhCL1 or (F, G) rFhGST-si for 24h and the 
levels of IL-12p40 and IL-6 measured by ELISA. Data are the mean values (±SEM) of 
at least 3 individual experiments. *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001 compared to 
unstimulated cells (not shown). (H) Cells were harvested and analysed by four-colour 
flow cytometry for CD40, CD80 and CD86. Cells were gated on CD11c+ cells. The 
histogram shows isotype control (filled histogram), unstimulated cells (black line), 
rFhCL1 or rFhGST-si-stimulated cells (grey line) and LPS (dotted line). Numbers 
represent mean fluorescence intensity from 5 different experiments.  
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Figure 4.2: Induction of partial activation of DCs by rFhGST-si and rFhCL1 is 
heat labile. DCs from C57BL/6 mice were cultured with culture medium, rFhCL1 or 
rFhGST-si (10 µg/ml) brought to room temperature of 1000C for 15 mins. 18h after the 
addition of antigens IL-6 and IL-12p40 were measured in the supernatants by sandwich 
ELISA. Data are the mean values of 3 individual wells (±SEM), and a representative of 
at least 2 individual experiments. ***, p ≤ 0.001 compared with positive untreated 
control. 
 
 
4.5.2. The partial activation of DCs by rFhCL1 and rFhGST-si is TLR4-
dependent 
Since previous reports have shown that helminth antigens can induce partial maturation 
in DCs through TLR4 activation (Jenkins et al., 2005, Goodridge et al., 2005), we went 
on to determine if the activation of DCs by rFhCL1 and rFhGST-si was dependent upon 
the TLR4 pathway. The secretion of IL-12p40 and IL-6 by rFhCL1 and rFhGST-si was 
significantly reduced in the absence of the TLR4 receptor (Fig. 4.3 A, B; p ≤ 0.001). 
While a low level of IL-6 secretion was measured in response to rFhCL1 in the TLR4 
deficient DCs, this was not significant compared to cells stimulated with culture 
medium. Similar to the cytokine results, rFhCL1, rFhGST-si and LPS failed to induce 
any alteration in CD40 expression in the absence of TLR4 (Fig. 4.3 C). As expected, 
TLR4 deficient DCs failed to respond to LPS.  
In addition, zymosan A, a TLR4-independent, TLR2 dependent agonist, induced 
the secretion of comparable quantities of IL-12p40 and IL-6 in both wild type and TLR4 
deficient strains of mice, confirming the integrity of TLR signalling in the knockout 
DCs.  
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Figure 4.3: The partial activation of DCs by rFhCL1 and rFhGST-si is TLR4 
dependent. DCs from C57BL/6 (wildtype background strain; WT) and TLR4 deficient 
(TLR4 KO) mice were cultured with medium (Med), rFhCL1 (10 µg/ml), rFhGST-si 
(10 µg/ml), zymosan (5 µg/ml) or LPS (100 ng/ml) for 24 h and the quantities of IL-
12p40 (A) and (B) IL-6 in supernatants determined by ELISA. Data are the mean values 
(±SEM) of at least 3 individual experiments. ***,  p ≤ 0.001 compared to control WT 
mice. (C) DCs were harvested and analysed by four-colour flow cytometry, gated on 
CD11c+ cells, for the expression of CD40. In each histogram, the stimulated cells are 
represented by the black line and the isotype control by the filled peak. Numbers 
represent mean fluorescence intensity from three separate experiments. 
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These results confirm that activation of DCs by rFhCL1 and rFhGST-si is dependent 
upon the presence of TLR4. To support this observation, the same analyses were 
repeated in C3H/HeN and C3H/HeJ mice which exhibit a point mutation in the TIR 
domain of TLR4 (Poltorak et al., 1998), so although they express the receptor, they fail 
to produce a response to LPS. DCs isolated from C3H/HeN mice gave similar results to 
DCs from C57BL/6 mice when stimulated with either rFhCL1 or rFhGST-si. DCs 
isolated from C3H/HeJ mice showed no increase in the expression of CD40 or secretion 
IL-6 or IL-12 p40 in response to rFhCL1, rFhGST-si or LPS (data not shown). 
 
4.5.3. rFhCL1 and rFhGST-si induce the secretion of chemokines from DCs  
Recently, it has been shown that Th1 promoting DCs selectively express elevated 
MIP1-α and promotes recruitment of Th1 cells (Gafa et al., 2007, Lebre et al., 2005) 
while MIP-2 a chemokine associated with helminth infection (Muller et al., 2003), 
promotes the recruitment of Th2 cells. Given the role played by these chemokines in the 
selective homing of immune cells, we sought to characterize the profile of MIP1-α 
(CCL3) and MIP-2 (CXCL2) chemokines produced by DCs following treatment with 
rFhCL1 and rFhGST-si. Results demonstrate that rFhCL1 or rFhGST-si induced both 
MIP1-α and MIP-2 from DCs (Fig. 4.4 A, B). However, these enzymes again showed a 
differential profile compared to LPS with both enzymes inducing significantly less 
MIP1-α than LPS but comparable levels of MIP-2. The polarised secretion of MIP-2 by 
these enzymes could influence a Th2 micro-environment by directly recruiting Th2 cells 
to the site of infection. The secretion of MIP1-α was TLR4 dependent since the 
production of this chemokine was absent in DCs isolated from TLR4 deficient mice. In 
contrast, the secretion of MIP-2 appeared to be partially dependent upon TLR4 (Fig. 4.4 
A, B; p ≤ 0.05) suggesting the involvement of a co-receptor. Further studies are required 
to identify this receptor and also characterise a role for MIP-2 in Fasciola infection.     
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Figure 4.4: Chemokine secretion is observed in DCs matured with rFhCL1 and 
rFhGST-si. DCs from C57B/6L (wildtype background strain; WT) and TLR4 deficient 
(TLR4 KO) mice were cultured with rFhCL1 (10 µg/ml), rFhGST-si (10 µg/ml) and 
LPS (100 ng/ml) for 24 hours, and the production of (A) MIP-1α and (B) MIP-2 in 
supernatants determined by ELISA. Data are the mean values of 3 individual wells 
(±SEM), and a representative of at least 3 individual experiments. *, p ≤ 0.05; ***, p ≤ 
0.001 compared to wildtype mice. 
 
4.5.4. rFhCL1 and rFhGST-si differentially activate MAPKs (p38, ERK and 
JNK), NF-κB and IRF5 in DCs compared to LPS 
Since the partial activation of DCs by rFhCL1 and rFhGST-si is mediated through 
TLR4, we investigated whether these antigens activated intracellular MAP Kinases 
associated with the TLR4 signalling pathway. To address this question, the level of 
phosphorylation of ERK, p38 and JNK in DCs following treatment with rFhCL1 and 
rFhGST-si was determined by western blot using LPS as a positive control. As 
expected, LPS caused the activation of all three signal transducers in comparison to 
medium with distinct kinetics similar to previously published data (Fig. 4.5 A, C) 
(Agrawal et al., 2003, Ardeshna et al., 2000, Arrighi et al., 2001). In contrast, only an 
increase in the activation of p38 was detected following treatment with rFhCL1. In 
addition, this was observed at a much later time point (60min) than that seen for LPS 
activation. Stimulation of DCs with rFhGST-si induced the phosphorylation of JNK and 
p38 but not ERK at most time points tested (Fig. 4.5 A, C). While the kinetic profile of 
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JNK and p38 activation was similar to that for LPS, peaking at 30min, the level of 
phosphorylation activated by rFhGST-si was significantly lower than LPS. 
The transcription factor NF-κB is primarily associated with TLR innate immune 
cell activation, typically DC maturation, and is involved in regulating the expression of 
a large number of inflammatory mediators. The phosphorylation of the DNA binding 
subunits, p65 is an indicator of NF-κB activation (Hayden and Ghosh, 2008). As 
expected, LPS stimulation of DCs led to an increase in the presence of phosphorylated 
NF-κBp65 (p-NF-κBp65) at 15, 30 and 60 minutes (Fig. 4.5 A, C). Similarly, rFhGST-
si induced a significant increase in the levels of p-NF-κBp65 15, 30 and 60 minutes. 
However, the extent of phosphorylation measured at 15 and 60 minutes was less than 
that seen for LPS (Fig. 4.5 C).  
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Figure 4.5: Differential activation of MAPKs, NF-κB and IRF5 in DCs is observed 
when treated with rFhCL1 and rFhGST-si compared to LPS. (A) DCs from C57B/6 
mice were cultured with culture medium, rFhGST-si (10 µg/ml), rFhCL1 (10 µg/ml) 
and LPS (100 ng/ml). At 15, 30, and 60 minutes, cells were lysed and total cellular 
protein was extracted. 10µg/sample of protein was separated on 10% SDS-PAGE gel, 
transferred onto a PVDF membrane and sequentially probed for phosphorylated- (p) 
JNK, p-p38, p-ERK, p-NF-κBp65 and IRF5. Representative blots are shown from three 
individual experiments. (B) Recombinant HEK-293 cells, functionally expressing TLR4 
protein linked to an NF-κB luciferase reporter gene, were stimulated with LPS, 
rFhGST-si (10 µg/ml) or rFhCL1 (10 µg/ml) for 24hrs. A HEK-293 cell line expressing 
the reporter gene only was used as a control (TLR-). (C) Densitometric analysis was 
performed on all immunoblots and values were expressed in arbitrary units as a 
percentage increase over the medium control group. *, p ≤ 0.05; ***, p ≤ 0.001 
compared with medium control group.  
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Activation of NF-κB p65 was not detected in DCs stimulated by rFhCL1 at any time 
point examined. To confirm these findings, human recombinant HEK-293 cells, 
functionally expressing TLR4 linked to an NF-κB reporter gene, were stimulated with 
rFhGST-si, rFhCL1 and LPS (Fig. 4.5 B). Consistent with the western blot analyses, 
data indicated that rFhGST-si but not rFhCL1 activated NF-κB and demonstrated that 
this was dependent upon TLR4.  
Since no phosphorylation of NF-κBp65 subunit was detected following 
treatment of DCs with rFhCL1, we investigated whether this enzyme activated the IRF5 
transcription factor. Following activation of TLR4, IRF5 directly interacts with the 
TLR4 adaptor protein MyD88 and functions as a key transcription factor for TLR4-
dependent induction of IL-6 and IL-12p40, independently of NF-κB and the MAPKs 
(Takaoka et al., 2005). Considering we have demonstrated that rFhCL1 induced 
secretion of IL-6 and IL-12p40 is dependent upon the presence of TLR4 (Fig. 4.3) we 
measured the levels of IRF5 by western blot in DCs activated with rFhCL1 and 
rFhGST-si (Fig 4.5 A, C). However, only rFhGST-si and not rFhCL1 significantly 
enhanced the activation of IRF5 compared to unstimulated cells at 15 and 30 minutes.  
 
4.5.5. rFhCL1 and rFhGST-si treated DCs do not phagocytose antigen 
As highlighted in section 3.2.5, DCs are considered professional phagocytes. The 
functional hallmark of ‘classical’ DC maturation is its ability to phagocytose antigen in 
combination with MHC II. Considering both enzymes failed to induce the expression of 
MHC II or to fully activate DCs, we investigated the ability of Fasciola enzyme 
activated DCs to phagocytose opsonised sheep erythrocytes. DCs treated with medium 
alone were used as a base control, while LPS was use as a positive activator of DC 
phagocytosis. DCs fully matured by LPS-stimulation, demonstrated an ability to 
efficiently phagocytose antigen with a significant increase (p ≤ 0.01) in the number of 
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engulfed erythrocytes compared with medium controls (Fig. 4.6). In contrast, rFhCL1- 
and rFhGST-si-treated DCs engulfed the same number of erythrocytes as immature 
unstimulated DCs, indicating an inability to phagocytose antigen (Fig. 4.6). 
 
 
Figure 4.6:  rFhCL1 and rFhGST-si treated DCs do not phagocytose antigen. DCs 
from C57BL/6 mice were cultured with medium, LPS (100 ng/ml), rFhCL1 or rFhGST-
si (10 µg/ml) for 2.5 h before the addition of opsonised sheep erythrocytes at a ratio of 
1:50. After 1 hour the extent of phagocytosis was assessed by measuring the number of 
engulfed erythrocytes using a colorimetric assay. Data are the mean values (±SEM) of 
at least 3 individual experiments. **, p ≤ 0.01 compared to untreated (Med) control 
group. 
 
4.5.6. rFhCL1 and rFhGST-si bias specific immune response by suppressing 
Th17 immune responses from OVA-specific T-cells 
Following phagocytosis, the role of fully matured DCs is to present antigen to T cells 
thus inducing antigen specific immune responses. We examined the ability of 
subcutaneously injected differentially activated DCs pulsed with OVA, to prime T 
helper cell responses in the skin draining lymph nodes (sdLN) of DO11.10 transgenic 
mice, a strain expressing a T cell receptor specific for OVA peptide (Jenkins et al., 
2005). 
sdLN cells isolated from mice which received DCs, secreted antigen-specific IL-
4, IL-10, IFN-γ and IL-17 (Fig. 4.7 A-D) in response to OVA peptide stimulation ex 
vivo. However, lymph node cells from mice that received DCs cultured with either 
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rFhCL1 or rFhGST-si and subsequently matured in the presence of OVA, had 
significantly reduced antigen-specific IL-17 production in response to stimulation with 
OVA peptide (Fig. 4.7 B; p ≤ 0.05 and p ≤ 0.001 respectively). No significant 
differences were observed in the antigen-specific production of IL-4, IL-10 and IFN-γ  
(Fig. 4.7 A, C, D) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: DCs activated with rFhCL1 and rFhGST-si suppress Th17 immune 
responses. DCs from DO11.10 mice were cultured with OVA (100 nM) following 
exposure to medium, rFhGST-si (10 µg/ml) or rFhCL1 (10 µg/ml) overnight at 37oC. 
(A-D) Stimulated DCs were subcutaneously injected over the sternum of naïve DO11.10 
mice. After 7 days, local sdLN (skin draining lymph nodes) were removed for re-
stimulation in vitro with OVA peptide (500 nM) or with PMA (25 ng/ml) and anti-CD3 
(1 µg/ml). After 72 h, supernatants were analysed by ELISA for the presence of IFN-γ, 
IL-17, IL-10 and IL-4. Data are the mean (± SEM) of three individual wells from four 
individual mice, and representative of three experiments. *, p ≤ 0.05; ***, p ≤ 0.001 
compared with OVA.   
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4.5.7. rFhGST-si and rFhCL1 suppress the ability of DCs to secrete IL-23 in 
response to LPS 
Since IL-23 from DCs is important in driving the secretion of IL-17 from CD4+ T cells 
(Aggarwal et al., 2003), we determined whether DCs exposed to rFhCL1 or rFhGST-si 
were less capable of producing IL-23. DCs were exposed to rFhCL1 and rFhGST-si 2.5 
hrs before activation with LPS. After 18h incubation in the presence of LPS, the 
quantity of IL-23 in the supernatant was measured. Concurrent with the ability to 
suppress IL-17 specific responses, treatment of DCs with rFhCL1 and rFhGST-si prior 
to LPS stimulation resulted in significant suppression of IL-23 production (Fig. 4.8; p ≤ 
0.001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: rFhGST-si and rFhCL1 suppress the ability of DCs to secrete IL-23 in 
response to LPS. DCs from C57BL/6 mice were cultured with culture medium, 
rFhCL1 or rFhGST-si (10 µg/ml) 2.5 h prior to LPS stimulation (100 ng/ml). 18h after 
the addition of LPS, IL-23 was measured in the supernatants by sandwich ELISA. Data 
are the mean values (±SEM) of at least 3 individual experiments. ***, p ≤ 0.001 
compared with LPS. 
 
4.6. Discussion 
Here we have selected recombinant forms of two major F. hepatica secreted molecules 
the protease rFhCL1 and anti-oxidant rFhGST-si, both of which are major components 
of the ES and examined their interactions with DCs. Both have the capacity to alter the 
function of innate immune cells and, consequently, the ensuing T-cell responses. 
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Despite enzymatic and functional differences between these antigens they both induced 
IL-6, IL-12p40 and MIP-2 secretion from DCs. This induction was mediated by TLR4 
but the subsequent intracellular signalling pathway induced by each antigen differed; 
while rFhCL1 signalled through p38, rFhGST-si mediated its effect via JNK, p38, p-
NF-κBp65 and IRF5. Neither rFhCL1 or rFhGST-si enhanced DC phagocytosis or 
induced Th2/Treg immune responses in vivo.  
Partial activation of DCs and the development of Th2 responses are typical of 
helminth infections (O'Neill et al., 2001), however, we found that DCs stimulated with 
either rFhCL1 or rFhGST-si were unable to induce the differentiation of Th2 or Treg 
cells. In contrast, DCs matured in the presence of either enzyme suppressed IL-17 
production from OVA-specific T-cells in vivo, inhibiting the development of a Th17 
immune response, independently of Th2 cells. This function has never previously 
described for a helminth-activated DC. Therefore, despite sharing some phenotypic 
characteristics of other helminth-antigen activated DCs (Jenkins and Mountford, 2005, 
Goodridge et al., 2005, Balic et al., 2004), the Fasciola antigen-activated DCs exhibit a 
different activation state and effector function. 
Regulation of IL-17 is critical to the control of inflammatory pathology 
associated with helminth infection, and has been particularly illustrated in the 
experimental model of S. mansoni where a strong correlation exists between the 
presence of Th1/Th17 immune responses and the development of severe inflammatory 
mediated pathology (Cheever et al., 1987, Rutitzky et al., 2008). Mice co-infected with 
S. mansoni and the intestinal hookworm Heligmosomoides polygyrus, showed reduced 
schistosome egg-induced hepatic immunopathology and a significant decrease in IL-17 
secretion from both granuloma cells and CD4 T-cells suggesting that the strong 
polarized Th2 environment promoted by H. polygyrus prevented the development of 
Th1 and Th17 immune responses (Bazzone et al., 2008).  
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This hypothesis links in with the observation that DCs exposed to either rFhCL1 
or rFhGST-si secreted reduced levels of IL-23, a cytokine known to be important in the 
expansion and survival of Th17 cells (Langrish et al., 2005). This is consistent with the 
studies of Shainheit et al (2008) showing that the in vitro differentiation of Th17 cells 
by schistosome-ligand activated DCs derived from CBA mice was dependent upon the 
secretion of IL-23 (Shainheit et al., 2008). The inhibition of Th17 development is 
clearly important for the success of F. hepatica infection considering that these two 
biochemically distinct enzymes perform this function via the modulation of DC 
activation. Moreover, rFhCL1 and rFhGST-si activated this suppressive population of 
DCs using different signalling pathways. While rFhCL1 activate p38 only amongst the 
transcription factors measured, rFhGST-si activated p38 and JNK, common MAPKs of 
the TLR4 pathway (Dowling et al., 2008), and the transcription factors NF-κB and 
IRF5.  
The activation of IRF-5 by a helminth parasite molecules has not been reported 
previously and thus it’s induction by rFhGST-si is of particular interest particularly 
because this transcription factor is expressed only in DC and B cells and is pivotally 
involved in the innate immune response (Honda and Taniguchi, 2006). IRF-5 was 
originally described as a transducer of virus-mediated signalling involved in the 
induction of anti-viral type 1 interferons (Barnes et al., 2002). However, despite 
functional similarity to the other IRFs, IRF5 appears to be induced in response to 
kinases activated by a range of TLR agonists rather than simply to viral antigens 
(O'Neill and Bowie, 2007). Therefore, while acting as an activator of type I interferon 
genes, IRF-5 also regulates the expression of proteins involved in cell growth regulation 
and immunomodulation (Barnes et al., 2003, Yasuda et al., 2007). While these 
functions are clearly important in host defence, there is also evidence that a deregulation 
   95 
of IRF5 impacts on the development of a range of Th17 mediated autoimmune diseases 
(Gutierrez-Roelens and Lauwerys, 2008).  
Activation of IRF5 by rFhGST-si may be required for the observed induction of 
IL-6 and IL-12p40 seen in stimulated DCs. In addition, the genes activated in response 
to IRF5 may be involved in the subsequent polarisation of T-cell responses by rFhGST-
si-activated DCs. The activation of NF-κB has been shown to be characteristic of Th2 
promoting DCs. S. mansoni LNFPIII induces rapid but transient NF-κB nuclear 
translocation and activity in the nucleus, in comparison with the persistent activation 
induced by Th1 promoting LPS (Thomas et al., 2005). Furthermore, studies suggest that 
the activation of NF-κB1 and not NF-κB2 is critical to the ability of DCs to prime Th2 
responses following exposure to SEA, LNFPIII-dextran or Trichuris muris (Perrigoue et 
al., 2008). Here we found that rFhGST-si induced a more persistent activation of NF-κB 
in DCs than that observed for LNFPIII which may explain the distinct capacity of these 
DCs to suppress Th17 rather than promote Th2 cells. Assessment of the relative 
contributions of NF-κB1 and NF-κB2 in response to rFhGST-si would further 
characterise this phenotype of DC.  
Studies suggest that ERK plays a central role in modulating the behaviour of 
DCs and promoting of Th2 responses, ERK deficient mice still retain the capacity to 
exhibit Th1 polarization but exhibit reduced Th2 immune responses (Agrawal et al., 
2006). We found that rFhGST-si induced the phosphorylation of p38 and JNK, but not 
ERK in DCs. This contrasts with SEA, which conditions DCs to induce strong Th2 
responses, induces the phosphorylation of ERK (for sustained periods) and p38 
(weakly) but not JNK (Aggarwal et al., 2003). Similarly, schistosome egg LNFPIII 
which induce Th2 immune responses also stimulates the phosphorylation of ERK 
(Thomas et al., 2003). The absence of ERK phosphorylation in DCs stimulated by 
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rFhGST-si, and rFhCL1, may contribute to their lack of ability to promote the 
differentiation of Th2 cells.  
Despite differences in the profile of transcription factors activated by rFhCL1 
and rFhGST-si, induction of both phenotypes of DC was dependent on the presence of 
TLR4 receptor, thus identifying these two enzymes as potentially novel helminth 
PAMPs. TLRs are implicated in the recognition of helminth parasite products by DCs, 
but since helminth-associated Th2 responses are not abrogated in the absence of TLRs 
(Kane et al., 2008) activation of DCs through these receptors may not be critical in the 
development of Th2 immune responses. On the other hand, TLR ligation by helminth-
derived antigens is recognized as a mechanism to limit the development of Th1 cytokine 
mediated inflammation. For example, the filarial nematode ES product, ES-62 interacts 
with TLR4 on DCs and results in the inhibition of IL-12 secretion in response to classic 
stimulators such as LPS/IFN-gamma (Goodridge et al., 2005).  
Similarly, both rFhCL1 and rFhGST-si reduced the ability of DCs to respond to 
LPS, significantly inhibiting the secretion of IL-23. Therefore products secreted by F. 
hepatica, like other helminths, induce, via interaction with TLR4, a phenotype of DC 
that is hyporesponsive to classical stimulation. However, unlike that found in other 
helminth studies, the consequence of this in Fasciola is a reduction in the development 
of inflammatory Th1/Th17 responses. Considering that a biochemically diverse range of 
helminth products are recognised by TLR4, it is perhaps not surprising that both 
rFhCL1 and rFhGST-si may utilised the same receptor.  
 However, the variation in transcriptional activation of DCs may reflect 
differences in their enzyme activity. FhCL1 is a protease and a member of papain-like 
family of cysteine proteases (Stack et al., 2007, Stack et al., 2008). Proteases of this 
family are secreted from a range of pathogenic organisms have been shown to have the 
capacity to degrade physiologically significant proteins such as immunoglobulins and 
   97 
collagen. rFhCL1 could feasibly digest peptides from the TLR4 receptor resulting in an 
altered conformational structure which could disrupt subsequent binding of co-
receptors, ultimately leading to the inactivation of signalling pathways. In the context of 
the current study it is also interesting to note that gingipain, a protease from Prevotella 
intermedia the causative agent of periodontis, and bromelein, a protease extracted from 
pineapple, both cleave CD14 from the surface of monocytes rendering the cells 
hyporesponsive to LPS (Deschner et al., 2003). However, no change in the level of 
surface expression of CD14 in response to rFhCL1 was observed (data not shown).  
Seven subclasses of GST have been identified in F. hepatica which can be 
distinguished from each other on the basis of substrate specificity and inhibitor 
sensitivity (Salvatore et al., 1995, Sheehan et al., 2001). In addition, the structure and 
binding interaction of the active site of sigma class-GST differs from that of the mu 
class (Sheehan et al., 2001). Therefore, fact the sigma class but not mu inhibited the 
activity of DCs would indicate that the modulatory effect is dependent on the specific 
enzymatic activity of the sigma class of GST. 
The demonstration that two biologically distinct molecules, using different 
pathways, activate DCs with the same capacity to modulate developing adaptive 
responses supports the view that helminth parasites induce a heterogeneous population 
of innate immune cells to control the outcome of infection. As stated earlier the majority 
of research helminth antigen-DC interactions have used preparations of parasite 
secretions which represent a composite of many different protein, lipids and sugars. A 
number of those molecules, including CL1 and GST, are universally expressed by all 
helminth parasites and suggest the existence of common mechanism(s) of modulation. 
Understanding how each individual antigen from helminth antigenic preparations affect 
DC maturation and function may shed light on the importance of discrete immune 
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modulatory mechanisms that collectively lead to the immune responses associated with 
helminth infection.  
There are a number of models put forward to define how DCs exposed to 
helminth antigens activate Th2/Treg immune responses associated with helminths 
(MacDonald and Maizels, 2008). In this study we have potentially identified two novel 
TLR PAMPs from the helminth F. hepatica which may give insights into a possible 
scenario for the induction of Th2/T regulatory responses cell associated with helminth 
infections. While they do not appear to promote a Th2/Treg immune response 
themselves, both rFhCL1 and rFhGST-si may promote an environment that is inductive 
to the generation of such a response by other secretory molecules. Overall the data 
suggests that helminth parasites secrete multiple molecules each possessing a unique 
mechanism of modulation, which can suppress inflammatory Th1/Th17 responses with 
redundancy thus permitting the uninhibited development of Th2/Treg by other secretory 
molecules. 
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Chapter 5: DCs stimulated with Ascaris lumbricoides extract induce a partially 
activated phenotype with Th2 inducing ability in vivo 
 
5.4. Introduction 
The human nematode parasite A. lumbricoides is of major medical importance and 
estimates put its prevalence at 1.5 billion people affected worldwide (Elliott et al., 
2007). Ascaris infection causes acute effects such as intestinal obstruction and chronic 
infection impacts upon growth, appetite, physical fitness, work capacity and cognitive 
development (Bradley and Jackson, 2004). These impacts are concentrated in those 
children who are also compromised by poor nutrition, and other educational and health 
disadvantages. Ascaris infection is characterised by a predominant Th2/Treg immune 
response and protection from A lumbricoides infection has been associated with high 
levels of the Th2 cytokines, IL-4 and IL-5 and low levels of Th1 cytokines (Cooper et 
al., 2000, Geiger et al., 2002).  
Antigens derived from A. lumbricoides and A. suum, which infect human and 
pigs respectively, have been of growing interest due to the potential immunosuppressive 
effects of ascarids on their hosts (Johnston et al., 2009). In both humans and animal 
studies, infection with parasitic nematodes such as A. lumbricoides has been associated 
with the protection from allergic and autoimmune disease (Harnett and Harnett, 2008). 
Previous studies have identified the ability of Ascaris derived antigens, mainly from A. 
Suum, to trigger in vitro nitric oxide from macrophage (Andrade et al., 2005), or alter 
expression of allegoric diseases (Rocha et al., 2008, Araujo et al., 2008, Lima et al., 
2002, Itami et al., 2005, Matera et al., 2008). 
While our understanding of the interaction of these Ascaris antigens on DCs 
function is limited, particularly those antigens derived from A. lumbricoides, a few 
studies have investigated the interaction of A. suum antigens and DCs (Table 1.1). Both 
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pseudocoelomic fluid (PCF) (McConchie et al., 2006) and high-molecular-weight 
components (PI) (Silva et al., 2006) of A. suum did not activate DCs. Pre-treatment of 
DC with PCF inhibited LPS-induced CD40 and CD86 as well as the production of IL-
12 in a dose-dependent manner (McConchie et al., 2006). PI suppressed costimulatory 
molecule expression of purified CD11c+ LN cells from OVA immunised mice. While 
compared to OVA immunised mice, purified CD11c+ from OVA+PI immnunised mice 
have a reduced proliferation of OVA specific T cells in vitro. Both were shown to be 
dependent on IL-10 as the suppreson was reversed in IL-10KO mice (Silva et al., 2006). 
Alternatively, the PC containing native glycophingolipid from A. suum have been 
shown to increase DC and macrophage costimulatory molecule expression and secretion 
of IL-12p40 and TNF-α. Pre-treatment could suppress LPS induced IL-12p70 in both 
cells (Kean et al., 2006).  
The focus of this chapter is to determine the interactions of native antigen 
preparation derived from the female form of A. lumbricoides since no previous studies 
have examined the effect of antigens upon DCs from this helminth. A. lumbricoides 
PCF antigens (AlPCF) was selected for use in this thesis because it is a metabolically 
active fluid which provides precursor molecules for membrane and cuticular synthesis 
(Kennedy and Qureshi, 1986). This makes it the closest possible approximation of 
FhTeg obtainable from A. lumbricoides for use as a comparison. Another factor for its 
selection is that AlPCF is easily obtained from the body cavity of adult worms. Other 
reasons for its use include results from studies that have shown PCF to contains a 
number of antigens that induce antibody responses in several different mammalian 
species, including mice (Kennedy and Qureshi, 1986, Urban et al., 1988). Some of these 
molecules are recognized as antigens by infected rabbits (Kennedy and Qureshi, 1986) 
and pigs (Urban et al., 1988). Notably, ABA-1 has been identified as a main protein 
constituent of PCF (Kennedy et al., 1991, Paterson et al., 2002), and is also the major 
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IgE-binding antigen in human patients that express resistance to ascariasis (Paterson et 
al., 2002).  
A thorough analysis of the effect of AlPCF on DC phenotype was measured by 
examining cytokine secretion and cell surface marker expression. The effect of Ascaris 
antigen on DC function was also determined by phagocytosis assay and T-cell-
polarizing function. Here we show that AlPCF extract can induce partial maturation of 
DCs as characterised by the increased production of IL-12 family related cytokines, and 
the chemokine MIP-2. No other inflammatory cytokines or maturation associated 
surface markers where induced. We also show that AlPCF-treated DCs can drive Th 
cells toward the Th2 pole. The present experiments shed further light on the DC 
activating properties of A. lumbricoides derived extracts. These results have generic 
implications for the understanding of DC-driven Th cell responses both directly on the 
host and the mechanisms of possible bystander effects.  
 
5.5. Results 
5.5.1. Ascaris antigen induces partial activation of murine BMDCs 
A. suum derived antigens have previously shown to have cytokine-inducing and 
immunosuppressive abilities on bone marrow derived macrophage and DCs (Kean et 
al., 2006, Deehan et al., 2002). To determine if the same was true for native A. 
lumbricoides derived antigens, BMDCs were cultured with native AlPCF (10 µg/ml) 
medium as a negative control, LPS as a positive control (100 ng/ml) for 24h and the 
supernatants analysed for cytokines responses. DCs stimulated with AlPCF stimulated 
significant levels of the cytokines IL-6, IL-12p40 and the chemokine MIP-2 (CXCL2). 
As expected, treatment of DCs with LPS induced “classical” maturation of DCs, evident 
by highly elevated levels of all cytokines and cell surface markers measured (Dowling 
et al., 2008).  
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Figure 5.1: AlPCF induces partial activation of DCs. A) DCs from C57B/6 mice 
were cultured with medium (Med), AlPCF (10 µg/ml) or LPS (100 ng/ml) for 24 hours, 
and the production of IL-12p70, IL-10, TNF-α, IL-12p40, IL-6, MIP-2 and PGE2 were 
measured using sandwich ELISA, and nitrite was measured using medium Griess 
reagent. Data are the mean values (±SEM) of at least 3 individual experiments. *, p ≤ 
0.05; **, p ≤ 0.01; ***, p ≤ 0.001 compared to Med. B) Cells were harvested and 
analysed by three-colour flow cytometry for CD14, CD40, CD80 and CD86. Mean 
fluorescent intensity (MFI); medium (left and grey line,), AlPCF (centre and dotted 
black line, 10 µg/ml), LPS (right and black line, 100 ng/ml) and Isotype (tinted). 
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The levels of cytokines induced by AlPCF were significantly higher than medium but 
less than those induced by the positive control, LPS (Fig. 5.1 A). We also measured IL-
12p70, NO, PGE2, TNF-α, IL-10, (Fig. 5.1 A), IL-23, MIP-1 and MCP (data not shown) 
and no up regulation of any of these cytokines was observed in response to AlPCF 
treatment. The ability of AlPCF to induce elevated expression of CD40, CD86 and 
CD80 and CD14 DCs was also investigated. Results demonstrated that AlPCF did not 
induce significant increased expression of any of the markers tested (Fig. 5.1 B) 
opposed to increased expression of all cell surface markers induced by the positive 
control LPS. AlPCF extracts used in these studies were deemed endotoxin free as 
assessed using the Pyrogene® endotoxin detection system (Cambrex) and did not effect 
DC viability Annexin V staining (data not shown). 
 
5.5.2. AlPCF induced cytokine production by DCs is dependent upon MAPKs  
To determine the possible signal transduction mechanism of AlPCF induced IL-6 and 
IL-12p40, we investigated whether it is targeting a common component of TLR 
pathways, such as the MAPKs. To address this question, DCs were pre-treated with 
MAPK inhibitors specific for ERK, p38 and JNK prior to AlPCF stimulation. As 
before, AlPCF induced IL-6 and IL-12p70 at significantly higher levels compared to 
untreated DCs. Pre-treatment with all three inhibitors resulted in a marked reducing in 
AlPCF-induced IL-6 (Fig. 5.2; p ≤ 0.001). Similarly, inhibition of all MAPKs resulted 
in marked reduction in AlPCF-induced IL-12p70 (Fig. 5.2; p ≤ 0.001). It should be 
noted that while pre-treatment of DCs with the JNK inhibitor significantly reduced 
AlPCF-induced IL-12p70, it was not totally abrogated to background control levels 
(untreated cells).  
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Figure 5.2: AlPCF induced cytokines expression is dependent upon MAPKs. IL-6 
and IL-12p40 induced by AlPCF are partially dependent on all MAPKs tested. DCs 
from C57B/6 mice were cultured with medium (Med), AlPCF (10 µg/ml) and LPS (100 
ng/ml) in the presence or absence of specific ERK (U0126; Sigma Aldrich), p38 (SB 
202190; Sigma Aldrich) or JNK inhibitors (JNK inhibitor I (L)-Form; Calbiochem) (all 
20 µM) which was added 1 h prior to antigen stimulation. Cells were incubated for a 
further 24 hours, and the production of IL-12p40 and IL-6 in supernatants determined 
by ELISA. Data are the mean values of 3 individual wells (±SEM), and a representative 
of at least 2 individual experiments. ***,  p ≤ 0.001 compared control mice.  
 
5.5.3. The partial activation of DCs induced by AlPCF is not TLR4 dependent 
Since TLRs has been shown to be important for helminth-derived antigen induction of 
IL-6 and IL-12 (Table 1.1), and that production of both cytokines is dependent on 
MAPK signalling pathways (Fig. 5.2), we went on to determine if the partial activation 
of DCs by AlPCF is dependent upon the TLR4. As expected, WT (wild type) DCs (on a 
C57BL background) produced significantly increased levels of IL-6, IL-12p40 and 
MIP-2 in response to LPS and zymosan compared with medium alone (Fig. 5.3; p ≤ 
0.001). Also as expected, TLR4KO DCs failed to respond to LPS, producing little or no 
IL-6, IL-12p40 and MIP-2, while stimulation with the TLR4-independent ligand 
zymosan, which signals through TLR2 (Gantner et al., 2003), remained unaffected. 
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AlPCF stimulated WT DCs produced increased levels of IL-6, IL-12p40 and MIP-2 as 
previously shown and no decrease was observed in TLR4KO DCs, which confirms that 
AlPCF partial activation of DCs is not TLR4 dependent. 
 
 
 
Figure 5.3: AlPCF induction of IL-6 and IL-12p40 and is not TLR4 dependent. 
DCs from C57BL/6 (wildtype background strain; WT) and TLR4 deficient (TLR4 KO) 
mice were cultured with medium only (Med), AlPCF (10 µg/ml), Zymosan (5 µg/ml) 
and LPS (100 ng/ml) for 24 hours, and the production of IL-12p40 and IL-6 in 
supernatants determined by ELISA. Data are the mean values (±SEM) of at least 3 
individual experiments. ***,  p ≤ 0.001 compared control mice.  
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5.5.4. AlPCF activates partial DCs phagocytosis 
The ability of DCs to phagocytose is a functional hallmark of their maturation. Both 
DCs and macrophages are considered professional phagocytes and are continuously 
sampling their environment for antigens. But DCs are distinguished in that their primary 
function is not to destroy phagocytised particles, but to process and express protein 
derived peptides on MHC class molecules leading to the initiation of adaptive immune 
responses (Savina and Amigorena, 2007). While maturation of DCs leads to the 
eventually down regulation of phagocytotic ability, studies have shown that 
phagocytosis is initially unregulated upon TLR stimulation (West et al., 2004). Here, 
DCs treated with medium alone were used as a base control, while LPS and zymosan 
treated DCs were use as positive activators of DC phagocytosis. DCs were cultured with 
AlPCF (10 µg/ml), LPS (100 ng/ml) or zymosan (5 µg/ml) for 2.5 hrs before the 
addition of opsonised sheep erythrocytes. After 1hr phagocytosis was stopped by the 
removal of supernatant and washing of cells with PBS to remove non-opsonised 
erythrocytes. Both LPS and zymosan stimulated DCs showed a significant increase (p ≤ 
0.01) in engulfed erythrocytes compared with untreated DCs (Fig. 5.4). AlPCF 
stimulated DCs showed increased phagocytosis of erythrocytes (p ≤ 0.01) to that of 
untreated DCs but less than those induced by either positive control. 
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Figure 5.4: AlPCF activates partial DC phagocytosis. DCs from C57BL/6 mice were 
cultured with AlPCF (10 µg/ml), LPS (100 ng/ml) or zymosan for 2.5 hrs before the 
addition of opsonised sheep erythrocytes to DCs at a ratio of 50:1. After 1 hr 
phagocytosis was stopped, cells washed to remove non-opsonised erythrocytes, lysed 
and amount of engulfed erythrocytes determined by colorimetric assay. Negative 
control cells were treated with 2 µM Cytochalasin D to block phagocytosis (data not 
shown). Data are the mean values (±SEM) of at least 3 individual experiments. **, p ≤ 
0.01 compared to AlPCF treated control group. 
 
 
5.5.5. AlPCF-stimulated DCs drive polarisation towards a Th2 phenotype in vivo 
Next we investigated the priming ability of AlPCF treated DCs to prime Th cell 
responses in the skin draining lymph nodes (sdLN) of DO11.10, after subcutaneously 
delivery. DO11.10 mice express a T cell receptor specific for OVA peptide. DCs were 
cultured with OVA (100 nM) in the presence or absence of AlPCF (10 µg/ml) and 
subcutaneously injected over the sternum of naïve D10.11 mice. After 7 days sdLN 
cells were re-stimulated in vitro with OVA, (0, 100, or 1000 ng/ml) for 72 hours, to 
determine the in-vivo Th-cell priming outcome. Antigen-specific levels of IFN-γ and 
IL-4 in supernatants was measured by ELISA.  
Analysis of the Th1 cytokine IFN-γ shown that sdLN cells from AlPCF DCs 
primed for increased production by sdLN cells (Fig. 5.5). This increase ranged from a 
7.4 – fold increase using 100 nM OVA, to a 2.4 – fold increase using 1000 nM OVA (p 
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≤ 0.01) compared to control unstimulated DCs. sdLN cells from mice inoculated with 
AlPCF DCs were also primed for increased production of the Th2 cytokine IL-4 (8.1- to 
5.6 – fold increase compared to medium control; p ≤ 0.001 and p ≤ 0.01, respectively). 
While IFN-γ and IL-4 were both stimulated by AlPCF primed DCs, IL-4 was induced at 
a much greater fold increase compared to that IFN-γ. 
 
 
 
 
Figure 5.5: DCs activated with AlPCF drive polarisation towards a Th2 phenotype 
in vivo. DCs from DO11.10 mice were cultured with OVA (100 nM) in the presence or 
absence of AlPCF (10 µg/ml) overnight at 37oC. DCs were washed and injected s.c. 
over the sternum of naïve DO11.10 mice. After 7 days, sdLN cells were removed for re-
stimulation in vitro with OVA (0 to 1000 nM) or PMA (25 ng/ml)/anti-CD3 (1 µg/ml). 
After 72 h, supernatants were analysed by ELISA for IFN-γ and IL-4. Data are the mean 
(± SEM) of three individual wells from four individual mice, and representative of two 
individual experiments. **, p ≤ 0.01; ***, p ≤ 0.001 compared with DC-Med.  
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5.6. Discussion 
DCs bridge the innate and adaptive arms of the immune response by detecting PAMPs 
from pathogens and activating naïve T cells (Kapsenberg, 2003). Studies investigating 
the effects of A. Lumbricoides derived antigens on these vital immune responders are 
limited. This study demonstrates that AlPCF extract can induce partial maturation of 
DCs as characterised by the increased production of IL-6, IL-12p40 and MIP-2. 
Although AlPCF stimulated DCs produce the above cytokines in significant amounts, 
little or no other cytokines associated with classically induced LPS maturation (IL-
12p70, TNF-α, NO, and IL-10 etc. (Dowling et al., 2008)) were observed. There is also 
a distinct lack maturation associated marker expression. This trait is also associated with 
FhTeg treated DCs. 
The activation state induced by AlPCF resembles the DC phenotype identified in 
studies investigating other helminth-derived antigens. Both Schistosoma larvae derived 
products (0-3hRP) (Jenkins and Mountford, 2005), and N. brasiliensis 
excretory/secretory antigens (NES) (Balic et al., 2004) have been shown to induce 
partial maturation of DCs characterised by IL-6, IL-12p40 and to have Th2 priming 
abilities. 0-3hRP could also stimulate IL-6, IL-10 and IL-12p40 from macrophages 
where the secretion of IL-12p40 and IL-10 are reduced in TLR4 knockout and mutant 
mice. However in that study the secretion of IL-6 was not dependent upon TLR4 
suggesting that other TLRs are involved (Jenkins et al., 2005). The filarial nematode 
phosphorylcholine (PC)-containing secreted product (ES-62), has been shown to be 
responsible for the immunomodulatory effect observed with native ES-62 (Goodridge et 
al., 2005). It induces the production of IL-12p40 and TNF-α in a TLR4 dependent 
manner. In contrast with these studies AlPCF antigen did not induce partial activation of 
costimulatory molecules or was it totally or partial dependent upon the TLR4 receptor.  
Most notably of all, apart from the lack of costimulatory marker activation, the DC 
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phenotype induced by AlPCF shows marked similarity to that of rFhGSTsi- and 
rFhCL1-stimulated DCs (Fig. 4.1).   
To date, much of the immunological processes resulting in DC activated Th1 
have been characterised (Kapsenberg, 2003). However, how Th2 responses are initiated 
is still poorly understood (MacDonald and Maizels, 2008). Our investigation into T 
helper cell priming capacity show that the DCs phenotype induced by AlPCF can prime 
for a mixed but Th2 polarised response in vivo. These observations would seem to 
support the DC maturation models, in which Th2 differentiation can occur through a 
default pathway, initiated by the absence of costimulatory molecule surface expression 
and strong to moderate cytokine production (MacDonald and Maizels, 2008). Also, 
AlPCF treated DCs could be seen to meet some of the criteria attributed to tolerogenic 
DCs (Morelli and Thomson, 2007), which while lacking archetypal maturation statues, 
remain immunogenic with Th2 polarising abilities (MacDonald et al., 2001, Whelan et 
al., 2000, Agrawal et al., 2003).  
Furthermore, under our experimental conditions the induction of cytokines by 
AlPCF is heavily dependent on MAPK signal transduction. Inhibition of ERK and p38 
lead to total reduction in IL-6 and IL-12p40. While inhibition of JNK results in total 
abrogation of IL-6, only partial reduction in IL-12p40 is observed. This inhibition 
profile differs from that that observed from LPS-matured DCs which shows an 
enhancement of IL-12p40 in the presence of each inhibitor (Dowling et al., 2008, 
Nakahara et al., 2006), indicating that MAPKs have varying roles in AlPCF-matured 
and LPS-matured DCs. Nonetheless, TLRs would seem to be the most likely PRR 
candidates for the detection of AlPCF. S. mansoni derived phosphatidylserine (PS) has 
been shown to have TLR2 activating capacity (van der Kleij et al., 2002). But while PS 
has been associated with inducing DC maturation (van Riet et al., 2009), limited data 
has been published on the effect PS has on DCs maturation statues. Our studies on 
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TLR4KO mice show that AlPCF is not dependent on TLR4 for the induction of 
cytokines, suggesting that other TLRs may be involved in the induction of the partial 
maturation statues. Kane et al. have shown that SEA can modulation both TLR-induced 
DC activation and induce Th2 responses in naïve mice independently of TLR2, TLR4, 
or MyD88 (Kane et al., 2008). Since the immunomodulatory characteristics of AlPCF 
differ from both PC and PS, further characterisation and qualification of both the ascaris 
extract and induced DC phenotype are needed. In summary we have shown the limited 
ability of AlPCF-treated DCs to phagocytose (Savina and Amigorena, 2007) and induce 
partial cytokine and chemokine production both of which may be an as yet undefined 
indicators of Th2 priming capacity, but further study on the effect of both functional 
capacities is warranted. 
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Chapter 6: Final Discussion 
6.2. Discussion 
Helminth parasites have evolved many mechanisms to suppress and/or modulate host 
immune responses. As a generalisation helminths induce a ‘modified’ Th2 immune 
response (Maizels et al., 2004). Experimental and epidemiological results also highlight 
the bystander effect of helminth infections on the outcome of co-current infections, in 
addition to atopic and autoimmune diseases (Elliott et al., 2007). But the mechanisms 
that induce these responses in the host are not fully understood. While much is known 
about how DCs respond to bacterial and viral pathogens that drive Th1/Th17 subsets, 
comparatively little is understood about how these cells respond to and influence the 
adaptive immune response to helminth parasites that drive Th2/Treg immune cells 
(Anthony et al., 2007).  
 Much of our knowledge on DC biology is based upon DCs exposed to LPS 
(Hoshino et al., 1999). DCs stimulated with LPS are said to drive a “classical” 
activation status which is defined as elevated expression of cell surface co-stimulatory 
markers (CD80, CD86, MHC II, CD40) and the production of pro-inflammatory 
cytokines (IL-6, IL-12 and TNF-α amongst others) (Kapsenberg, 2003, Dowling et al., 
2008). Activation of TLRs not only initiates the innate immune response but also trigger 
the development of adaptive-specific immune responses (Takeda et al., 2003, Pasare 
and Medzhitov, 2004). Therefore understanding the role and/or effect of helminth 
infections or helminth derived products on DCs might further our knowledge of how 
helminths drive modified Th2 responses and induce such powerful anti-inflammatory 
effects.  
 But, the effect of helminths and/or helminth-derived products on DC activation 
and functionality is limited. One reason for this is the fact that helminths are a diverse 
group of extracellular organises with various morphologies, multiple life stages and 
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occupy numerous niches within their hosts. A number of approaches must be used to 
overcome these various problems. Firstly, the access and use of a relatively easily 
reproducible model system is needed. In this case, a murine model of DCs induced from 
bone marrow is used (Lutz et al., 1999) as this model is well established and DCs are 
critical in driving adaptive immune responses. Secondly, the use of living parasites 
outside of their host niche is difficult and therefore native antigens were obtained from 
the parasites and used to mimic infectious conditions. In this study we used the 
tegumental coat of F. hepatica and the PCF of A. lumbricoides because these are 
immune dominant antigens that come into contact with host immune system, and that 
both are produced in cellular layers which provide metabolically active precursor 
molecules for membrane and cuticular synthesis. Thirdly, helminth products, mostly 
derived from preparation directly from the parasites are predominantly heterogeneous in 
nature (See Table 1.1), making it hard to attribute signal molecules to PRRs to signal 
transduction pathways. Recombinant antigens or purified native antigens of helminths 
origin may provide a solution. In this study we had access to two recombinant Fasciola 
antigens, rFhGST-si and rFhCL1 since these are the predominant antigens secreted in 
ES. Lastly, the question of which helminth parasite to obtain antigens from arises. We 
selected F. hepatica because it is of major agricultural importance while A. 
lumbricoides is of major human significance. Furthermore, they represent two of the 
three helminth groups (trematodes and nematodes) and current knowledge into the 
effect of both on DCs has not been previously investigated. 
We began with a comprehensive examination into the innate immune response 
to FhTeg by investigating its immune modulatory properties on bone marrow derived 
DCs. At the outset, a baseline of DC activation was needed from which the effect on F. 
hepatica antigens on DC function could be evaluated and compared. A comparative 
analysis of DC activation status matured against a panel of TLR ligands was used for 
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this purpose (Dowling et al., 2008). FhTeg alone could not induce any characteristic of 
a classical activated DC. But FhTeg could however down regulate the activation of DCs 
in response TLR and non-TLR ligands both prior to and following TLR and non-TLR 
stimulations. Our findings demonstrate FhTeg can act in an immunosuppressive manner 
on murine DCs in vitro. We then investigated the functional capacity of FhTeg treated 
DCs. When FhTeg-treated DCs were adoptively transferred into mice, mouse T cell 
responses were reduced and proliferation down when cultured ex vivo. T-cell priming 
studies demonstrated that FhTeg-primed DCs significantly suppressed local Th1 
immune responses in vivo, but did not appear to drive local Th2 responses. In addition, 
DC-FhTeg recipients stimulated with PMA/anti-CD3 produced significantly decreased 
levels of all cytokines and proliferated significantly less in response to OVA stimulation 
than cells from DC-Med recipients. The observed suppression of T-cell proliferation or 
cytokine production in DC-FhTeg recipient mice could not attributed to changes in the 
expression of T-cell surface markers. Whereas no uniform suppression of MAPK could 
be ascribed to FhTeg, the phosphorylation of the transcription factor NF-κBp65 was 
significantly reducing in LPS-stimulated DCs. 
 
Worm product Species of origin PRR(s) Activation status T helper 
Heterogeneous     
FhTeg Fasciola hepatica ND DC↔(Y) Th1  
AlPCF Ascaris lumbricoides ND DC Th2  
Defined     
rFhCL1 Fasciola hepatica TLR4 DC (Y) Th17  
rFhGST-si Fasciola hepatica TLR4 DC (Y) Th17  
 
Table 6.1: Helminth-derived products; a full list of helminth-derived products used in 
this thesis summarising their effect on DC phenotype and functionality. Abbreviations: 
ND, Not determined; TLR, Toll-like receptor; ; partial DC activation (Dowling et al., 
2008); ↔, no change; , induction; , suppression; (Y), suppression of secondary 
activation; DC, dendritic cell.  
 
In this study we also highlight the discovery of two potential TLR4 ligands derived 
from the helminth F. hepatica. Both rFhCL1 and rFhGST-si induce a partial activation 
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of DCs characterised by up regulation of IL-6, IL-12p40 and the cell surface marker 
CD40. In addition, DCs exposed to either antigen secreted reduced levels of IL-23. The 
partial activation of DCs by these molecules was dependant upon the presence of TLR4. 
Neither rFhCL1 nor rFhGST-si enhanced DC phagocytosis or induced Th2 immune 
responses in vivo. However, DCs matured in the presence of either enzyme attenuated 
IL-17 production from OVA-specific T-cells in vivo. Both rFhCL1 and rFhGST-si work 
through different signal transduction pathways. While rFhCL1 signalled through p38, 
rFhGST-si mediated its effect via JNK, p38, p-NF-κBp65 and IRF5.  
Finally, we investigated the effect of AlPCF antigens on DC activation and 
functions. Similar to both rFhCL1 and rFhGST-si, AlPCF induced a partially activated 
DC phenotype characterised by the cytokines IL-6 and IL-12p40. Unlike rFhCL1 and 
rFhGST-si, no enhancement of cell surface marker expression was induced and only the 
chemokine MIP-2 is induced by AlPCF. DCs treated with AlPCF partially activated DC 
phagocytosis and polarisation T-cell responses towards a Th2 phenotype in vivo. AlPCF 
induced cytokine expression is dependent upon MAPKs signal transduction pathways 
but is not TLR4 dependent. The PRR responsible for AlPCF detection is yet to be 
elucidated.  
 
Upon examining Table 1.1, a number of commonalities can be observed between the 
effects of various helminth-derived molecules on DCs. One such trend is that 
heterogeneous helminth derived-products, such as SEA, tend not to activate any signs of 
classical phenotypical DC activation. Therefore it is not unexpected that FhTeg alone 
does not activate DCs. Suppression of TLR-ligand induced DC activation by helminth 
products has also been an observed theme, with SEA (van Liempt et al., 2007) and 
HpES (Segura et al., 2007) being the best described examples. Our results show that 
FhTeg can also be grouped amongst these. However, it is unexpected that FhTeg does 
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not polarise modified Th2 responses, instead suppressing T-cell proliferation and 
cytokine production. The decrease in IL-10 observed was also not anticipated, since this 
cytokine is traditionally associated with an anti-inflammatory or regulatory response 
(Moore et al., 2001). But IL-10 may have a more versatile role in immune responses, 
with recent studies showing IL-10 production by Th1 cells (O'Garra and Vieira, 2007). 
Similarly, where DC activation was shown as with rFhGST-si, rFhCL1, is was 
not unexpected that activation observed was lower than that observed with ‘classical’ 
activation of DCs. There is a growing diversity of ligands that TLR4s can specify for 
and while further studies are needed, both rFhGST-si and rFhCL1 may potentially be 
added to that list in the future. However, it is a little unexpected that rFhGST-si but not 
rFhCL1 activates NF-κBp65 and both can still activate phenotypically similar DCs with 
the same capacity to modulate adaptive responses. Also, the activation of IRF-5 by 
rFhGST-si is the first reported induction of this IRF by a helminth parasite molecule, 
with further study needed to quantify importance of this observation.  It was however an 
unanticipated outcome that AlPCF does not induce co-stimulatory molecules while still 
inducing a cytokine secretion. While all three products induce a similar DC phenotype 
to that induced by Schistosoma larvae extracts (Jenkins and Mountford, 2005, Jenkins et 
al., 2005) or to a lesser extent ES-62 (Goodridge et al., 2005), only AlPCF-stimulated 
DCs could polarise a Th2 phenotype in vivo, while rFhGST-si and rFhCL1-stimulated 
DCs ameliorating Th17 responses. One major question to be answered from these 
studies is how AlPCF can induce polarised T helper responses in comparison to the 
suppression observed for FhGST-si and rFhCL1.  
The anti-inflammatory properties of FhTeg is in keeping with helminths need to 
suppress potentially harmful host processes (Goodridge et al., 2005). The suppression 
of the Th1 polarizing cytokine IL-12p70 is important in this context since Th1 
suppression has been observed during F. hepatica co-infections on a number of 
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occasions (Brady et al., 1999, Flynn et al., 2007). While the exact mechanism of FhTeg-
mediated suppression remains to be elucidated, FhTeg was able to suppress the effects 
of all TLR ligands tested. This included both MyD88-dependent and -independent 
pathways in addition to non-TLR ligands. Therefore it seems likely that FhTeg utilizes a 
pathway common to these receptors. We demonstrated that FhTeg can suppress the 
phosphorylation of NF-κBp65, and the suppression of this and other such NF-κB family 
transcription factors may explain the broad suppressive ability of FhTeg.  
When considering the various hypotheses put forward in the literature explaining 
the possible mechanisms of Th2 induction by DCs (MacDonald and Maizels, 2008), our 
results of the effect of FhTeg on DCs presented here correspond most closely to the 
inhibition model. These results suggested that FhTeg can maintain DCs in an immature 
state and the subsequent lack of cytokine production and costimulatory molecule 
expression can interfere with the function of DCs and their ability to prime naïve T cells. 
CTL receptors, which are important for the recognition of helminth products (van 
Kooyk and Rabinovich, 2008), have been highlighted as the most likely PRR to 
contribute to modulate TLR-ligand DC maturation. This study demonstrates a possible 
mechanism by which F. hepatica may use immunomodulatory products to its benefit by 
suppressing inflammatory cytokines.  
 Given that both rFhCL1 and rFhGST-si modulate DC activation resulting in the 
inhibition of the development of Th17 it is clear they play an important role in the 
survival of F. hepatica during infection. Furthermore, rFhCL1 and rFhGST-si activated 
this suppressive population of DCs utilising different signalling pathways. The 
persistent activation of NF-κB in rFhGST-si-stimulated DCs compared to that observed 
for other helminth-derived molecules such as LNFPIII may explain the distinct capacity 
of these DCs to suppress Th17 rather than promote Th2 cells. Alternatively, activation 
of IRF5 by rFhGST-si may be required for the observed induction of IL-6 and IL-12p40 
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seen in stimulated DCs. Assessment of the relative contributions of NF-κB1 and NF-
κB2 in response to rFhGST-si would further characterise this phenotype of DC. Also, 
two of the best studied helminth products SEA (Aggarwal et al., 2003) and LNFPIII 
(Thomas et al., 2003), are strong induces of the phosphorylation of ERK. Both also 
conditions DCs to induce strong Th2 responses. Therefore the absence of ERK 
phosphorylation in DCs stimulated by rFhGST-si and rFhCL1, may contribute to their 
lack of ability to promote the differentiation of Th2 cells.  
It could be argued that DCs stimulated by rFhGST-si or rFhCL1 may fit into 
either or both of the inhibition model or the alternative pathway model of induction of 
modified Th2 responses by helminth parasites (MacDonald and Maizels, 2008). While 
neither enzyme induced DCs capable of priming Th2 responses in vivo both suppress 
responses Th1 inducing ligands (i.e. LPS induced IL-23 from DCs). Conversely, both 
rFhGST-si and rFhCL1 may fit an alternative pathway model as both could be theorized 
to be neither Th1 nor Th2 stimuli, but rather a distinct set of PAMPs associated with the 
attenuation of Th17 responses which may then allow for the uninhibited induction of 
Th2/T regulatory responses cell associated with helminth infections. This theory 
supports broader observations that helminth parasites are in a continuous state of 
homeostasis with their hosts in an effort to enhance its rate of survival. Here we put 
forward one such mechanism were FhTeg may selectively suppress DC activation to 
other helminth products. For example, DCs exposed to FhTeg show suppression of IL-6 
and IL-12p40 induced by rFhGST-si (Fig. 6.1; p ≤ 0.001) but not rFhCL1. This may be 
part of an effectively effective system of helminths immunomodulation with a high 
level of redundancy.  
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Figure 6.1: FhTeg suppresses rFhGSTsi but not rFhCL1-induced IL-6 and IL-
12p40 production. DCs from C57BL/6 mice were cultured with FhTeg (10 µg/ml 2.5 h 
before) rFhCL1 or rFhGSTsi stimulation (10 µg/ml). Control DCs were treated with 
rFhCL1, rFhGST-si, LPS (100 ng/ml) or medium alone. After 18 h (A) IL-6 and (B) IL-
12p40 were measured in the supernatants by sandwich ELISA. Data are the mean values 
of 3 individual wells (±SEM), and a representative of at least 2 individual experiments. 
***, p ≤ 0.001 compared with rFhCL1 or rFhGST-si groups. 
 
Some TLRs, such as TLR4, recognizes ligand through accessory molecules like MD2 
and CD14 (Kim et al., 2007). These variations in transcriptional activation of DCs may 
reflect differences in their enzyme activity of rFhCL1 and rFhGST-si. Either enzyme 
could feasibly digest peptides from PRRs resulting in an altered conformational 
structure disrupting subsequent binding of co-receptors such as MD2. Preliminary 
results indicated that rFhGST-si phosphorylation of NF-κB may be dependent on the 
presence of TLR4 co-receptors. HEK cells transfected with TLR4 alone without the co-
receptors MD2 and CD14 exhibited reduced phosphorylation of NF-κB when treated 
with rFhGST-si compared to LPS stimulated cells in the same system (data not shown). 
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Further studies, including x-ray crystallography may be need to fully elucidate the 
specific binding mechanisms for each enzyme.  
Unlike the possible mechanisms for Th2 induction attributed to FhTeg, rFhCL1 
or rFhGST-si, AlPCF-stimulated DCs align most closely to the default mechanism. This 
model proposes that unless triggers for Th1 responses are received by the DC the T cell 
will automatically ‘default’ into a phenotype that will initial Th2 responses (Trinchieri, 
2003). This model also applies to the Th2 polarising abilities of DCs stimulated with 
Schistosoma larvae products (0-3hRP) (Jenkins and Mountford, 2005), which whom 
AlPCF-stimulated DCs share some similarities. Overall, a comparison of both AlPCF 
and FhTeg shows that while both induce some similarities in treated DCs, most notably 
a lack of and induction of maturation associated cell surface marker expression, they 
drive diverging adaptive responses. AlPCF-treated DCs induced a skewed Th2 response 
while FhTeg-treated DCs suppress Th induced responses.  
 
The firstly priority for future studies on FhTeg should be to identify any ligands 
contained within the tegument and the PRR used to detect them. Since FhTeg is a 
heterogeneous mix of molecules most likely compiled of proteins, lipids, carbohydrates 
and combinations of each, an extensive and systematic screening and identification 
process will need to be performed to detect the targets responsible for the results 
reported in this thesis. We have carried out a proteomic analysis on the FhTeg and have 
identified over 40 proteins. Initial fractionation using HPLC has identified a number of 
fractions and the proteomic analysis on each fraction is being performed to identify 
potential immune modulatory proteins. 
As initial results from the analysis of SEA have revealed (van Liempt et al., 
2007) multiple ligands may act in a synergistic fashion making such a process complex. 
It would also be interesting use confocal laser scanning techniques to track any 
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internalisation, compartmentalisation and subsequent presentation of any tegumental 
antigens. The effect FhTeg has on broader DC functions such as migration should also 
be studied. Extensive expression profiling of chemokine receptors (CCRs) following 
FhTeg exposure, particularly CCR5 and CCR7 which are down regulated and 
unregulated respectively during DC maturation (Luther and Cyster, 2001), would shed 
further light on broader effects on DC function.  
We have yet to determine whether FhTeg can suppress other members of the 
NF-κB family (such as the p50 subunit) or any other IRF transcription factors, such as 
IRF3, which are also activated following TLR-ligand stimulation. Similarity, gene 
expression profiling of DCs exposed to all helminth products tested in this thesis could 
give insights into their broader effects on DC. SEA was shown to induced remarkably 
few genes in treated DCs but when mixed with LPS, SEA significantly affects the 
expression of >100 LPS-regulated genes (Kane et al., 2004). It would to interesting to 
compare the effect of FhTeg on a similar system.  
When considering the results from chapters 4 and 5, the most obvious question 
to arise is how can AlPCF-stimulated DCs but not rFhCL1 or rFhGST-si-stimulated 
DCs lead to Th2 induction. Identifying the divergent characteristics of these DCs would 
be a priority. The use of helminth-derived immunomodulatory molecules which 
abrogate Th17 responses could lead to new therapeutic treatment for inflammatory 
disorders (Ruyssers et al., 2008). Studies have associated the abrogation of IL-23 to the 
reduction of IL-17 and ultimately attenuating the symptoms of experimental 
autoimmune uveitis (EAU) (Luger et al., 2008). It would be interesting to test rFhCL1 
and rFhGST-si in this model system and indeed in other systems where IL-17 has a 
critical role, including rheumatoid arthritis, asthma and inflammatory bowel disease 
(IBD) (Zhang et al., 2007). Recent studies have shown that IL-27 can antagonise Th17 
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cell development (McGeachy and Cua, 2008), and its possible induction by both 
rFhCL1 and rFhGST-si may link with these studies.  
While we have shown phosphorylation of one NF-κB family member by 
rFhGST-si it is possible that one or other member, such as the p50 subunit, many also 
be activated by AlPCF, rFhCL1 or rFhGST-si. The use of various transgenic mice, 
MyD88KO in the cases of rFhCL1 and rFhGST-si; TLR2KO mice in relation to AlPCF, 
would greatly enhance our understanding of the signal transduction pathways initiated 
by each ligand. If AlPCF is shown to contain a TLR2-activating ligand, mass 
spectrometry analysis would indicate the presence of phosphatidylserine (PS) which 
would be the most likely candidate.  
 In summary, we report that F. hepatica tegumental maintains DCs in an 
immature state, impairing their function and the subsequent development of adaptive 
immunity, although the precise immunological scenario is not completely understood. 
Given the powerful modulatory effect that FhTeg exhibits, understanding its exact 
mechanisms may lead to the development of novel immune therapeutics for the 
treatment of Th1-mediated inflammatory diseases (Elliott et al., 2003, Summers et al., 
2005). This study also demonstrates that another helminth-derived heterogeneous 
extract, A. lumbricoides PCF, can induce partial maturated of DCs as characterised by 
the increased production of IL-6, IL-12p40 and MIP-2 and that are capable of inducing 
Th2 responses. Lastly, two defined helminth enzymes have been shown to induce DCs 
capable of suppressing IL-17 secretion in vivo. Overall the data suggests that helminth 
parasites secrete multiple molecules each possessing a unique mechanism of 
modulation, which can either suppress inflammatory Th1/Th17 responses, or 
induce/permit the uninhibited development of modified Th2 responses.  
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